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Abstract 
 
Full thickness burns and trauma resulting in extensive full thickness skin loss or 
devitalisation gives rise to the need for skin replacement therapy. Cultured epithelial 
autologous keratinocytes application has been the main stay treatment over the last three 
decades. Different methods for cultured epithelial autologous keratinocytes delivery 
exist with thin epithelial sheet application and sprayed cell culture the most commonly 
used methods; each method has its advantages and drawbacks. 
Microcarrier beads for the culture of cells have been utilised in a number of different 
applications over the last forty years as they allow rapid cell culture and expansion in a 
controlled environment. More recently microcarrier commercially available gelatin 
microcarrier beads “Cultispher G®” have demonstrated the potential to support 
keratinocyte cell culture and proliferation in vitro.  
Wound contraction is a physiological component of wound healing and occurs within 
the proliferation phase of wound healing between 4 days to 3 weeks following the 
inflammatory phase. Wound contraction is a function of myofibroblasts leading to 
approximation of the wound margins and reduction in wound size. The migration of 
keratinocytes from the intact epithelium around the wound edges leads to epithelial 
closure and completes the process of wound healing. 
This study aimed to assess the use of microcarriers for supporting keratinocyte growth 
in vitro and evaluate the effect of keratinocyte delivery using microcarriers on wound 
contraction using a porcine wound model. In this study, in vitro assessment of 
keratinocyte expansion on microcarriers demonstrated sustainable expansion rates with 
data being comparable to traditional keratinocyte cell culture. Animal experiments 
utilising an in vivo porcine model have shown that keratinocytes delivered to the wound 
bed using gelatin microcarriers migrated off the beads and were shown to survive on the 
wound bed. 
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In the same animal model, autologous keratinocytes cultured on microcarrier beads 
reduced wound contraction when applied to full thickness wounds in combination with 
widely meshed autologous split skin graft compared with split thickness skin graft 
(STSG) alone or control wounds. 
The use of allogeneic cultured keratinocytes on microcarriers in combination with 
dermal regeneration template “Integra®” demonstrated a reduction in wound contraction 
compared with Integra® and STSG or Integra® alone. The use of autologous cultured 
keratinocytes and fibroblasts on microcarriers in combination with Integra® reduced 
wound contraction compared with Integra and cultured keratinocytes or Integra and 
STSG. The reduction in wound contraction maintained a large area of the original 
wound surface area, hence reducing the possibility of contracture formation. 
The use of microcarrier beads for culture and delivery of keratinocytes has the potential 
to overcome the disadvantages of the traditional methods of keratinocyte culture and 
delivery. It can also play a role in the reduction of wound contraction resulting in the 
retention of skin mobility and providing favourable functional and aesthetic outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
Table of Contents 
 
An investigation in the in vitro and in vivo use of microcarrier beads to support 
keratinocytes and the effect on wound contraction ........................................................... 1	  
Declaration ........................................................................................................................ 2	  
Abstract ............................................................................................................................. 3	  
Table of Contents .............................................................................................................. 5	  
List of figures .................................................................................................................... 8	  
List of tables .................................................................................................................... 10	  
Acknowledgement ........................................................................................................... 11	  
Chapter 1: Introduction ................................................................................................... 12	  
1.1 Anatomy and functions of human skin ................................................................. 12	  
1.2 Skin barrier breakdown or loss and its management ............................................ 18	  
1.3 Alternatives to skin grafting (Biological dressings) .............................................. 23	  
1.4. Microcarrier beads in tissue engineering ............................................................. 28	  
1.5. Microcarriers in keratinocyte cell culture ............................................................ 32	  
1.6. In vivo animal wound models .............................................................................. 35	  
Hypotheses for investigation ........................................................................................... 38	  
Experimental Aims .......................................................................................................... 39	  
Chapter 2: Materials and methods ................................................................................... 41	  
2.1 Materials ................................................................................................................ 41	  
2.1.1 Human keratinocytes cell culture ...................................................................... 41	  
Cell lines ..................................................................................................................... 41	  
Media and supplements .............................................................................................. 41	  
Reagents ..................................................................................................................... 42	  
Tissue culture consumables ........................................................................................ 42	  
2.1.2 Porcine keratinocyte and fibroblasts cell culture ............................................... 42	  
Porcine keratinocytes .................................................................................................. 42	  
Cell lines ..................................................................................................................... 43	  
Media and supplements .............................................................................................. 43	  
Reagents ..................................................................................................................... 44	  
Tissue culture consumables ........................................................................................ 44	  
2.1.3 Animal anaesthesia and theatre consumables .................................................... 44	  
Anaesthesia and per-operative drugs .......................................................................... 44	  
Theatre equipment and consumables .......................................................................... 45	  
2.1.4 Histology, immunohistochemistry and image analysis ..................................... 46	  
2.2 Methods ..................................................................................................................... 49	  
2.2.1 Human keratinocyte isolation ............................................................................ 49	  
2.2.2 Human keratinocyte culture media .................................................................... 49	  
2.2.3 Maintenance of 3T3 cells in human keratinocyte culture .................................. 50	  
2.2.4 Human keratinocyte cell culture ........................................................................ 51	  
2.2.5 Human keratinocyte cell culture maintenance ................................................... 52	  
2.2.6 Porcine keratinocyte transport and culture media .............................................. 53	  
2.2.7 Maintenance of 3T3 cells in porcine keratinocyte culture ................................. 53	  
2.2.8 Collagen coating of culture flasks ...................................................................... 53	  
2.2.9 Porcine keratinocyte isolation ............................................................................ 54	  
2.2.10 Porcine keratinocyte cell culture ...................................................................... 55	  
2.2.11 Porcine fibroblast isolation .............................................................................. 56	  
2.2.12 Porcine fibroblast cell culture .......................................................................... 56	  
2.2.13 Maintenance of the retroviral cell producer line .............................................. 57	  
2.2.14 Retroviral transduction of porcine keratinocytes with the GFP gene vectors .. 57	  
2.2.15 Calculation of transduction frequency ............................................................. 59	  
2.2.16 Keratinocyte cell seeding on microcarrier beads ............................................. 59	  
 6 
2.2.17 MTT staining of keratinocytes on microcarrier beads ..................................... 60	  
2.2.18 Acridine orange staining of keratinocytes on microcarrier beads .................... 60	  
2.2.19 Keratinocyte cell count using Trypan blue ...................................................... 61	  
2.2.20 Sample preparation for scanning electron microscopy (SEM) ........................ 61	  
2.2.21 MTT assay of porcine keratinocytes on microcarrier beads ............................ 62	  
2.2.22 RNA isolation from porcine keratinocytes on microcarrier beads ................... 63	  
2.2.23 Real-time quantitative PCR (qPCR) K14 mRNA from porcine keratinocytes 
on microcarrier beads .................................................................................................. 65	  
2.3 In vivo animal wound model ..................................................................................... 67	  
2.3.1 Animals .............................................................................................................. 67	  
2.3.2 Animal husbandry .............................................................................................. 67	  
2.3.3 Animal anaesthesia and euthanasia .................................................................... 68	  
2.3.4 Harvesting of split thickness skin grafts ............................................................ 69	  
2.3.5 Creation of full thickness wounds with PTFE chambers ................................... 69	  
2.3.6 Creation of square wounds for assessment of wound contraction ..................... 70	  
2.3.7 Measurement of wound surface area using Visitrak™ system ............................ 71	  
2.3.8 Tissue processing ............................................................................................... 71	  
2.4 Histology ................................................................................................................... 71	  
2.4.1 Haematoxylin and Eosin staining (H&E) .......................................................... 71	  
2.4.2 Immunohistochemistry ....................................................................................... 72	  
2.5 Data analysis ............................................................................................................. 74	  
2.5.1 Clinical analysis ................................................................................................. 74	  
2.5.2 Image analysis .................................................................................................... 74	  
2.5.3 Statistical analysis .............................................................................................. 74	  
Chapter 3: An investigation into in vitro keratinocyte cell culture on microcarrier beads
 ......................................................................................................................................... 75	  
3.1 Comparative analysis of two types of gelatin microcarrier beads for the culture of 
keratinocytes in vitro ................................................................................................... 75	  
3.1.1 Study objectives ................................................................................................ 75	  
3.1.2 Keratinocyte cell culture in cell rotator and magnetic stirrer ............................ 75	  
3.1.3 Viable keratinocyte cell count using Trypan blue ............................................. 78	  
3.1.4 Results ............................................................................................................... 78	  
3.2 Assessment of in vitro migration of porcine keratinocytes from microcarrier 
beads to monolayer tissue culture ............................................................................... 84	  
3.2.1 Study objectives ................................................................................................ 84	  
3.2.2 Porcine keratinocytes migration from microcarrier beads to tissue culture flasks
 .................................................................................................................................... 84	  
3.2.3 Results ............................................................................................................... 84	  
3.3 Assessment of porcine keratinocyte attachment on microcarrier beads using 
Scanning Electron Microscopy (SEM) ....................................................................... 87	  
3.3.1 Study objectives ................................................................................................ 87	  
3.3.2 Assessing porcine keratinocyte attachment on microcarrier beads using 
Scanning Electron Microscopy (SEM) ....................................................................... 87	  
3.3.3 Results ............................................................................................................... 88	  
3.4 Comparative analysis of porcine keratinocyte proliferation with/without feeder 
3T3 cells in stirred culture ........................................................................................... 90	  
3.4.1 Study objectives ................................................................................................ 90	  
3.4.2 Porcine keratinocyte proliferation with/without feeder 3T3 cells in stirred 
culture ......................................................................................................................... 91	  
3.4.3 Results ............................................................................................................... 91	  
3.5 Quantitative assessment of porcine keratinocyte proliferation on microcarrier 
beads (MTT assay, RNA isolation and real-time quantitative PCR) .......................... 95	  
3.5.1 Study objectives ................................................................................................ 95	  
3.5.2 MTT assay of porcine keratinocytes on microcarrier beads ............................. 95	  
 7 
3.5.3 RNA isolation from porcine keratinocytes on microcarrier beads .................... 95	  
3.5.4 Real-time quantitative PCR (qPCR) K14 mRNA from porcine keratinocytes on 
microcarrier beads ...................................................................................................... 96	  
3.5.5 Results ............................................................................................................... 96	  
3.6 Assessment of in vitro porcine keratinocytes and fibroblasts co-culture on 
microcarrier beads ..................................................................................................... 101	  
3.6.1 Study objectives .............................................................................................. 101	  
3.6.2 Porcine keratinocytes and fibroblasts co-culture on microcarrier beads ......... 101	  
3.6.3 Results ............................................................................................................. 101	  
Chapter 4: An investigation into the survival of retroviral GFP labelled porcine 
keratinocytes on microcarrier beads compared to sprayed keratinocytes in full thickness 
animal wound model ..................................................................................................... 106	  
4.1 Study objectives .................................................................................................. 106	  
4.2 Study design ........................................................................................................ 106	  
4.3 Results ................................................................................................................. 110	  
Chapter 5: Investigation of wound healing and contraction rate of autologous 
keratinocytes on microcarriers, sprayed keratinocytes and widely meshed skin graft . 116	  
5.1 Study objectives .................................................................................................. 116	  
5.2 Study design ........................................................................................................ 116	  
5.3 Results ................................................................................................................. 119	  
5.3.1 Macroscopic qualitative assessment ................................................................ 119	  
5.3.2 Histological and immunohistochemical analysis ............................................. 123	  
Chapter 6: Investigation of wound healing and contraction rate of allogeneic 
keratinocytes on microcarriers, sprayed keratinocytes and ultra-thin split skin graft on 
Integra® (Two stage dermal regeneration) ..................................................................... 127	  
6.1 Study objectives .................................................................................................. 127	  
6.2 Study design ........................................................................................................ 127	  
6.3 Results ................................................................................................................. 130	  
6.3.1 Macroscopic qualitative assessment ................................................................ 130	  
6.4.2 Histological and immunohistochemical analysis ............................................ 134	  
Chapter 7: Investigation of wound healing and contraction rate of autologous 
keratinocytes and fibroblasts on microcarriers and sprayed keratinocytes on Integra® 
(Two stage dermal regeneration) .................................................................................. 137	  
7.1 Study objectives .................................................................................................. 137	  
7.2 Study design ........................................................................................................ 137	  
7.3 Results ................................................................................................................. 140	  
7.3.1 Macroscopic qualitative assessment ................................................................ 140	  
7.3.2 Histological and immunohistochemical analysis ............................................ 143	  
Chapter 8: Discussion ................................................................................................... 148	  
8.1 Discussion of in vitro studies .............................................................................. 148	  
8.2 Discussion of in vivo studies ............................................................................... 161	  
8.3 Conclusion ........................................................................................................... 192	  
8.4 Assessment of hypotheses ................................................................................... 204	  
8.5 Future research .................................................................................................... 206	  
Publications and presentations from thesis: .................................................................. 208	  
9.1 Publications ......................................................................................................... 208	  
9.2 Presentations ....................................................................................................... 208	  
References ....................................................................... Error! Bookmark not defined.	  
 
 
 
 
 
 8 
List of figures 
 
Figure 1: Superficial dermal burn ................................................................................... 19	  
Figure 2: Deep dermal burn ............................................................................................ 20	  
Figure 3: Meshed skin graft 1:1 (left) compared to 5:1 (right) ....................................... 23	  
Figure 6: Standard curve for MTT assay against KC cell count ..................................... 63	  
Figure 7: Keratinocyte cell culture in a rotator ............................................................... 76	  
Figure 8: Keratinocyte cell culture in stirrer flask .......................................................... 76	  
Figure 9: MTT staining keratinocyte cell culture on microcarrier beads day 4 .............. 77	  
Figure 10: Acridine orange staining keratinocyte cell culture on microcarrier beads day 
4 ............................................................................................................................... 77	  
Figure 11: Cultispher G® & S® + cultured keratinocytes MTT staining days 4 and 18 . 79	  
Figure 12: Cultispher G® & S® + cultured keratinocytes acridine orange staining days 4 
and 18 ...................................................................................................................... 80	  
Figure 13: Alamar Blue® reduction keratinocyte cell culture on Cultispher G® & S® in 
cell rotator ............................................................................................................... 81	  
Figure 14: Acridine orange & MTT staining Cultispher G® + keratinocyte cell culture in 
magnetic stirrer flask D4 and D18 .......................................................................... 81	  
Figure 15: Alamar Blue® reduction keratinocyte cell culture on Cultispher G® in stirrer 
flask ......................................................................................................................... 82	  
Figure 16: Cell count using Trypan blue comparing keratinocytes in culture flasks vs. 
keratinocytes on microcarriers (Error bars refer to standard deviation) ................. 83	  
Figure 17: Cluster of microcarriers seeded with porcine keratinocytes in tissue culture 
flask (day 3) ............................................................................................................. 85	  
Figure 18: Microcarriers seeded with porcine keratinocytes in tissue culture flask (day 
6). ............................................................................................................................ 85	  
Figure 19: Microcarriers seeded with porcine keratinocytes in tissue culture flask (day 
9). ............................................................................................................................ 86	  
Figure 20: Cultispher G® microcarrier SEM ................................................................... 88	  
Figure 21: Cultispher G® seeded with porcine keratinocytes day 8 SEM ...................... 89	  
Figure 22: Cultispher G® surface seeded with porcine keratinocytes day 8 SEM .......... 89	  
Figure 23: AO staining day 3; keratinocytes + 3T3 (upper) & keratinocytes without 3T3 
(lower) ..................................................................................................................... 92	  
Figure 24: AO staining day 9; keratinocytes + 3T3 (upper) & keratinocytes without 3T3 
(lower) ..................................................................................................................... 92	  
Figure 25: MTT staining day 6; keratinocytes + 3T3 (upper) & keratinocytes without 
3T3 (lower) .............................................................................................................. 93	  
Figure 26: MTT staining day 12; keratinocytes + 3T3 (upper) & keratinocytes without 
3T3 (lower) .............................................................................................................. 93	  
Figure 27: Comparison between KC cell count +/- 3T3 at days 3, 6, 9, and 12 ............. 94	  
Figure 28: MTT assay vs. sample volumes Days 7, 14, and 21 ...................................... 96	  
Figure 29: Porcine keratinocyte cell count x 103/ml calculated using MTT assay results
 ................................................................................................................................. 97	  
Figure 30: Chart representation of RNA isolation measurements in standard and diluted 
samples porcine keratinocytes + keratinocytes day 10 ........................................... 98	  
Figure 31: Melting curve SYBR Green 2 qRT-PCR K14 ............................................. 100	  
Figure 32: qPCR K14 mRNA expression relative to GAPDH days 14 and 21 ............ 100	  
Figure 33: Porcine keratinocytes (GFP labelled) + porcine fibroblasts on microcarriers 
day 3 ...................................................................................................................... 102	  
Figure 34: Porcine keratinocytes (GFP labelled) + porcine fibroblasts on microcarriers 
day 9 ...................................................................................................................... 103	  
Figure 35: MTT assay results day 7 porcine keratinocytes and keratinocytes + 
fibroblasts .............................................................................................................. 103	  
 9 
Figure 36: MTT assay results day 14 porcine keratinocytes and keratinocytes + 
fibroblasts .............................................................................................................. 104	  
Figure 37: PTFE wound chamber ................................................................................. 106	  
Figure 38: Operating theatre NPIMR, Northwick Park, London .................................. 107	  
Figure 39: Zimmer® dermatome ready for use. ............................................................ 108	  
Figure 40: Diagrammatic representation of the site of the PTFE wound chambers on the 
flank of the animal ................................................................................................ 109	  
Figure 41: Wound chamber allocation Pig 1 (Exp 1.09) .............................................. 110	  
Figure 42: (A) Wound chambers post insertion (B) Dressings and foam jackets applied 
post procedure ....................................................................................................... 110	  
Figure 43: The 3 treatment groups Days 7 and 15 ........................................................ 111	  
Figure 44: Tracing of GFP labelled keratinocytes and Hx & E staining in 3 treatment 
groups after 2 weeks .............................................................................................. 112	  
Figure 45: (A) K14 and (B) Laminin immuno-staining for 3 treatment groups ........... 114	  
Figure 46: Wound allocation in one animal (Exp 2.10) ................................................ 117	  
Figure 47: Zimmer® mesher .......................................................................................... 118	  
Figure 48: (A) Visitrak™ tracing sheet (B) Visitrak™ device. ....................................... 119	  
Figure 49: The 3 treatment groups days 4 and 8 (Exp 2.10) ......................................... 120	  
Figure 50: The 3 treatment groups Days 15 and 21 (Exp 2.10) .................................... 121	  
Figure 51: Graphical representation of wound contraction in wound surface area ...... 122	  
Figure 52: Hx & E and K14 immuno-labelling of the 3 groups ................................... 125	  
Figure 53: Hx & E staining and Collagen VII immuno-labelling of the 3 groups ........ 125	  
Figure 54: Laminin immuno-labelling (using FITC) in the 3 groups ........................... 126	  
Figure 55: Wound allocation in one animal (Exp 3.10) ................................................ 129	  
Figure 56: The MCAlK treatment group (A to C Integra® alone, D to G post treatment) 
[Exp 3.10] .............................................................................................................. 131	  
Figure 57: Day 42 (Experiment termination) ................................................................ 132	  
Figure 58: Graph representation of wound contraction in wound surface area (Days 21 
and 42) ................................................................................................................... 133	  
Figure 59: Hx & E, Collagen VII and K14 immuno-labelling of the 3 groups ............ 135	  
Figure 60: Laminin and α SMA immuno-labelling of the 3 groups ............................. 136	  
Figure 61: Wound allocation in one animal (Exp 4.10) ................................................ 139	  
Figure 62: Wounds following Integra® inset D7 and D14 (Pre and Post-treatment) .... 141	  
Figure 63: Wounds in the 3 treatment groups Days 7, 14, and 21 (Exp 4.10) .............. 142	  
Figure 64: Graph representation of wound contraction in the 3 groups over 21 days .. 143	  
Figure 65: Hx & E and Collagen VII immuno-labelling of the 3 groups ..................... 144	  
Figure 66: K14 immuno-labelling of the 3 groups ........................................................ 145	  
Figure 67: Laminin immuno-labelling of the 3 groups ................................................. 146	  
Figure 68: α-SMA immuno-labelling of the 3 groups .................................................. 147	  
 
 
 
 
 
 
 
 
 
 
 
 10 
List of tables 
Table 1: Commercially and Non-commercially available types of microcarrier beads .. 30	  
Table 2: Preparation of cDNA synthesis mix ................................................................. 65	  
Table 3: Preparation of SYBR Green II®-Step 2 working mix ....................................... 66	  
Table 4: Thermal cycling SYBR Green II®-Step 2 programme ..................................... 67	  
Table 5: Cell count using Trypan blue comparing keratinocytes in culture flasks vs. 
keratinocytes on microcarriers ................................................................................ 83	  
Table 6: RNA isolation measurement microcarriers + porcine keratinocytes day 10 .... 97	  
Table 7: Mean and Standard deviation wound surface area in the 3 groups ................. 122	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11 
Acknowledgement 
 
I would like to thank my supervisors Justin Sharpe and Dr Paul Sibbons for their 
support and guidance during the course of this thesis. Very special thanks to Prof Tony 
Metcalfe (Director of research, Blond McIndoe Research Foundation) for all his time 
and effort in checking the final amendments of the thesis. 
In addition, I would also like to thank all the staff at Blond McIndoe research 
foundation for their help with 3T3 cells preparation, cell culture maintenance, and the 
histology of the animal experiments. 
My thanks go to all the staff at NPIMR (Northwick Park Institute for medical research) 
for all their help with the animal procedures. This work was generously funded by 
“SPARKS” charity for children’s health. 
Finally, I would like to thank my wife Sobia for her encouragement and support during 
the whole time of this project. 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
 
Chapter 1: Introduction 
1.1	  Anatomy	  and	  functions	  of	  human	  skin	  
 
The skin covers the entire interface between the human body and the outside 
environment. “The integument” is the term used to describe the skin and its appendages. 
These appendages include hair follicles, sebaceous glands, sweat glands, and the nail 
apparatus.  
The skin plays an important role in the interaction of the body with the outside 
environment. It covers an average surface area of more than 1.5 m2 in an adult making 
up in total about 6-8 % of total body weight (Slominski et al. 2008).  
The multiple functions of skin include acting as a barrier to physical, biological and 
chemical agents, as well as to ultraviolet (UV) radiation. The barrier function of skin 
prevents dehydration by controlling loss of fluid (Frodin and Skogh 1984). Other 
functions include sensory and thermoregulatory role through sweat secretion, vitamin D 
synthesis, and excretion of metabolic waste products through sweat glands (Sato et al. 
1989). Another important role of skin is the change in appearance produced by the 
action of underlying muscles controlled by the sympathetic nervous system and related 
to emotional expression (Roosterman et al. 2006).   
Two types of skin are found: non-hairy “glabrous” skin (covering the palms of the 
hands and soles of the feet) and hairy skin (covering the majority of the body surface 
area). The skin is formed of two distinctive layers: the outer epidermal layer and the 
inner dermal layer (Mackenzie 1969). 
The combined thickness of the epidermis and dermis is around 0.5 to 4 mm depending 
on the anatomical site and type of skin. Thick skin is found in the palms of the hand and 
soles of the feet (4 mm thick), while thin skin (0.5 mm thick) is found on the eyelids. 
The epidermis is firmly attached to the underlying dermis through the basement 
membrane. Epidermal projections into the dermis are formed known as ‘rete ridges’ or 
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‘pegs’. Complementary projections of the dermis into the epidermis are called dermal 
papillae. 
The epidermis is a stratified squamous epithelium, which includes several cell types. 
These cell types include keratinocytes, melanocytes-which produce melanin pigment-
Langerhans cells-which have an immune function-and Merkel cells which have a 
sensory function (Gottschaldt and Vahle-Hinz 1981). Keratinocytes, which are the 
predominant cells within the skin, make up at least 80% of the epidermis cellular 
population (Prunieras 1979).  
The epidermis is arranged into four distinct layers, each showing a pattern of 
keratinocyte proliferation, differentiation and maturation. The four main layers are: 
stratum basale (germinal layer), spinosum, granulosum and corneum. In glabrous skin, a 
fifth layer called the stratum lucidum is found between the granular and the cornified 
layers. These layers reflect the differentiation of keratinocytes as they are displaced 
from the basal layer to the outermost cornified layer. The process of terminal 
differentiation involves a series of biochemical and morphological changes, which 
result in the production of an anucleate cornified keratinocyte layer forming the stratum 
corneum. 
The stratum basale is a single layer of cuboidal basal cells attached to the basement 
membrane by hemi-desmosomes containing integrins. Adjacent cells are attached by 
desmosomes containing cadherins. The majority of the cells in this layer are mitotically 
active and their role in the renewal of the epidermis is through upward displacement, 
replacing the outermost superficial layer lost during normal epidermal turnover 
(Prunieras et al. 1976).   
Above the stratum basale is the stratum spinosum consisting of several layers of 
irregular, polyhedral shaped cells that display spiny projections. Cells from the previous 
layer lose contact with the basement membrane and are subsequently pushed up to form 
this layer (Ehrlich 2004). Cells become progressively flattened as they move up towards 
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the epithelial surface. Cells contain lamellar granules, which provide the epidermal 
lipids responsible for the barrier properties of the skin. 
Above the stratum spinosum is the stratum granulosum, which is comprised of three to 
five layers of flattened cells. In this layer, lamellar granules containing lipids and 
keratohyalin granules are present within the cells cytoplasm. The appearance of the 
keratohyalin granules signifies the loss of the nuclei and cytoplasm of keratinocytes 
(Prunieras 1979). The keratohyaline granules contain proteins that promote hydration 
and cross-linking of keratin, and along with the desmosomal connections help to form 
the waterproof barrier of the skin. 
The stratum corneum consists of several layers of flattened cells without nuclei or 
organelles, and a keratin rich cytoplasm. This cornified layer consists of anucleated and 
highly keratinised cells called “corneocytes” which are metabolically inactive.  
Type I and II intermediate filaments are two keratin subfamilies found predominantly in 
keratinocytes and epithelial cells. Their main function is to act as a structural frame for 
keratinocytes. Epithelial cells contain 20 types out of the total 30 different types of 
keratin polypeptides identified (Moll et al. 1982). Expression of keratin polypeptides is 
linked to cellular differentiation and its regulation is dependent on various intracellular 
and extracellular stimuli, and also pathological disease processes. 
Moll et al. (1982) established a numerical tagging system subdividing keratin 
polypeptides into acidic type (K10-K20 molecular weight 56.5-46 kilo Daltons-kD), 
and basic-neutral type (K1-K9 molecular weight 67-64 kD). Filaments within the cells 
are pairings of one acidic and one basic-neutral polypeptides of similar weight.  
Sun et al. (1983) introduced the theory of tissue-specific expression of keratins in pairs. 
Specific types of epithelium and stages of differentiation are characterised by specific 
pairings of Type I-Type II keratins. The variation is likely to be due to the different 
physiological role of various types of cells within the epithelium.  
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In the epidermis, all basal keratinocytes synthesise Keratins K5 and K14, while K15 and 
K17 are occasionally present. Throughout the process of keratinocyte differentiation, 
secondary keratins are expressed depending on cell type. In normal epidermis, K1 and 
K10 are expressed; K6 and K16 are expressed in keratinocytes within tissue culture and 
in the epidermis during wound healing. Keratinocytes within tissue culture may differ in 
their keratin expression from epidermal keratinocytes in normal skin (Wu et al. 1982). 
Keratin expression is dependant on the degree of differentiation achieved by cells 
during the culture process influenced by culture conditions such as the composition of 
the culture media and the presence of fibroblasts. 
Other types of cells within the epidermis include; melanocytes, which are pigment-
melanin-producing cells, which protect the body from ultraviolet radiation. Melanin 
pigment is found inside intracellular organelles ‘melanosomes’, their number and 
melanin content varies with different skin types (Ebanks et al. 2011). Melanocytes are 
present in variable ratios to keratinocytes (Pelle et al. 2005). Their ratio to basal 
keratinocytes is 1:36 on average across the total body surface area, in sun–exposed areas 
it is 1:5 and 1:20 on the trunk. 
Langerhans cells are dendritic cells, which play a role in the immune function of the 
skin barrier. Their role is mainly to induce immune response following infection, which 
is reduced following burn injuries and skin barrier damage (van den Berg et al. 2011). 
Other cells within the epidermis include Merkel cells, which are responsible for tactile 
sensation through tactile discs, which are amalgamated groups of Merkel cells attached 
to keratinocytes through desmosomes. 
The basement membrane (BM) zone lies at the interface between the epidermis and the 
dermis, also known as the “dermal-epidermal” junction. As the epidermis is mainly 
avascular, the basement membrane serves as a support for the avascular epidermis. The 
basement membrane zone is formed of four layers: the plasma membrane of the basal 
keratinocyte, lamina lucida, lamina densa, and lamina fibro-reticularis. 
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The lamina lucida contains laminin and anchoring filaments bridging the gap between 
the basal keratinocytes and the lamina densa underneath. The lamina lucida is electron 
lucent (i.e. appears transparent under electron microscopy) and has an absence of 
hemidesmosomes. The lamina densa contains collagen type IV and proteoglycans, and 
the lamina fibro-reticularis contains anchoring fibrils and collagen Type I, III, VI, and 
VII (Ko and Marinkovich 2010). 
The basement membrane is the natural barrier for nutrient delivery to keratinocytes, and 
a selective filter for plasma proteins, which influence the metabolism of keratinocytes 
within the basal layer of the epidermis (Prunieras et al. 1983). Dermal extracellular 
matrix (ECM) proteins also penetrate the basement membrane to reach epidermal 
keratinocytes. 
The dermis lies below the epidermis and acts as support and mould for the epidermis. 
Three distinctive layers form the dermis: the papillary dermis, the reticular dermis, and 
the hypodermis. The dermis is formed mainly of dermal cells and connective tissue 
matrix surrounding the skin appendages such as hair follicles, sweat glands, and 
sebaceous glands. Fibroblasts are the main cells in the dermis along with collagen and 
elastin fibres forming the extracellular matrix connective tissue. Other cells within the 
dermis include: monocytes, macrophages, and dendritic cells, which have an immune 
function similar to Langerhans cells within the epidermis (Warfel et al. 1993). 
The papillary dermis forms projections from the dermis into the epidermis and is highly 
vascular. Underneath the papillary dermis and above the reticular dermis lies the sub-
papillary plexus of blood vessels. This plexus is of significant importance as it 
represents the main blood supply to the avascular epidermis (Braverman and Keh-Yen 
1981). The structure of the collagen and elastin fibres changes from fine to coarse 
through the transition from the papillary to the reticular dermis. The hypodermis is the 
deepest layer of the dermis and it represents the integration of the dermis into the 
underlying adipose and subcutaneous tissue (Braverman and Keh-Yen 1981). 
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Collagen is the main component of the dermis and more than 20 types of collagen have 
been identified (Kadler et al. 1996). Fibroblasts produce procollagen molecules which 
are secreted into the extracellular matrix, where metalloproteinases modify the 
procollagen into collagen molecules (Kadler et al. 1996). Collagen molecules then 
become cross-linked and aligned into collagen fibrils and filaments having a high 
tensile strength. Types I, III and V collagens are the most common collagens of the 
human dermis, with type I contributing 90% of the dermis collagen content (Han et al. 
2008). The dermis ‘ground substance’ consists of glycoproteins, glucosaminoglycans 
and proteoglycans. The ground substance maintains the structure of the dermis and 
supports cellular attachment and migration within the dermis. The proteoglycans within 
the ‘ground substance’ influence tissue repair through binding of growth factors and 
cytokines, which in turn control cellular proliferation during wound healing (Pineau et 
al. 2008).  
Fibroblasts are the main cell type within the dermis and they produce dermal connective 
tissue matrix proteins. Fibroblasts have an important role in wound healing through 
interaction with keratinocytes resulting in stimulation of epithelialisation and epithelial 
differentiation (Tobin 2006). Following epithelial breakdown or loss, fibroblasts 
produce extracellular matrix proteins acting as scaffolds for cellular migration during 
wound healing. Hypertrophic scarring or keloid formation, are considered pathological 
end results of this process. During the wound healing process, the presence of 
mechanical tension due to epithelial disruption or loss leads to fibroblasts acquiring a 
characteristic phenotype. This phenotype is a α smooth muscle actin (α-SMA) 
expressing phenotype and at this stage fibroblasts are called myofibroblasts (Watsky et 
al. 2010). Wound contraction is primarily a function of myofibroblasts, which remain 
active until wound closure is achieved. Continuous proliferation of myofibroblasts 
beyond wound closure gives rise to hypertrophic scarring and keloid formation. 
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Other cells within the dermis include monocytes and macrophages, which play a role in 
the immunological functions of the skin. Their functions include phagocytosis of dermal 
cells, and they play a role in the inflammatory phase of wound healing. They produce 
cytokines and growth factors such as transforming growth factor β1 (TGF β1) and 
interleukin 1 and 6 (IL-1 & 6) during wound healing regulating both cellular activities 
and tissue remodelling (Powell et al. 1999). 
1.2	  Skin	  barrier	  breakdown	  or	  loss	  and	  its	  management	  
 
Skin loss or damage to the skin barrier function can result from different types of 
trauma including burns. Burn injuries affect 48 per 100 000 children and 18 per 100 000 
adults every year in England and Wales (Khan et al. 2007). In comparison to wartime, 
burn injuries represent around 5% of the total number of trauma casualties as in the Iraq 
conflict since 2003 (Foster et al. 2011, Kauvar et al. 2006). This is compared to less 
than 1% of trauma injuries in general population (Khan et al. 2007). Burn injuries can 
result from thermal, chemical, electrical or radiation injury. Burn injuries produce 
coagulative necrosis of the skin and possibly underlying tissues as well as systemic 
effects. The systemic effects of burn injuries, depending on the extent and depth of the 
injury, could be life threatening (Baron et al. 1994). 
The depth of the burn injury can be classified as: superficial epidermal, superficial 
dermal, deep dermal, and full thickness burns. 
In superficial epidermal burns, the epidermis is damaged and the underlying dermis 
remains intact, and epidermal regeneration occurs through keratinocyte migration. 
 19 
!  "! 5!cm!
 
Figure 1: Superficial dermal burn 
Area of erythema, which blanches on application of pressure involving anterior aspect of right knee and 
upper leg in an adult, blisters covering the anterior leg have been removed. Distance between arrows is 
5cm. 
 
In superficial dermal burns (figure 2), the epidermis is damaged along with the 
superficial layers of the dermis. These wounds are characterised by pain, blanching on 
pressure and blistering. Healing occurs through regeneration from the dermal 
appendages. In the absence of infection, superficial dermal burns will heal in around 
two weeks. If more than 10% of the total body surface area is involved, healing may 
take longer or surgical intervention is required. 
In deep dermal burns (figure 3), the majority of the dermis is involved in the injury. 
These wounds are usually painless injuries, where blistering is uncommon, and are 
characterised by ‘fixed-staining’ red colour resulting from capillary blood vessel 
damage. Deep dermal burns, if left to heal without intervention, can take more than 
three weeks to heal. This results in excessive scarring and contracture formation.  
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In full-thickness burns, all skin components are damaged to the level of subcutaneous 
fat or fascia. Full thickness burns require surgical intervention to allow healing due to 
the lack of keratinocyte source for regeneration. Small areas of full thickness burns (less 
than 2-3 cm in diameter) could possibly heal by keratinocyte migration from the wound 
edges. 
!"! 2.5!cm!
 
Figure 2: Deep dermal burn 
“Fixed staining” involving the left hand in an adult in a deep dermal burn injury. The burn is seen 
affecting the left hand and forearm with no blistering. 
“Fixed staining” refers to the red areas in the palm, which are red stained and do not blanch on 
application of pressure. Distance between arrows is 2.5cm. 
 
Jackson (1953) studied the extent of skin and surrounding tissue damage caused by burn 
injuries. He described three distinctive zones, which are: Zone of coagulation or 
‘necrosis’, zone of stasis, and zone of hyperaemia. The zone of coagulation is the 
central area of tissue destruction caused directly by the burn injury. The zone of stasis is 
the area surrounding the zone of coagulation; this area could convert to an area of 
necrosis or progress to recovery. Fluid resuscitation and early reversal of the 
physiological deficit resulting from the burn injury can prevent the progression to 
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necrosis. This effect can also be achieved using different types of early interventions 
reversing the local and systemic effects of the burn injury (Zawacki 1974, Battal et al. 
1996, Isik et al. 1998, Shupp et al. 2010). The zone of hyperaemia surrounds the zone 
of stasis. It represents the systemic reaction to the burn injury, which is dependent on 
the extent of body surface area involved. The zone of hyperaemia is localised in small 
burn injuries. In extensive burns involving more than 25% of total body surface area, 
the zone of hyperaemia extends to involve the whole of the body (Baxter 1993). 
Different toxins released from the zone of coagulation or ‘necrosis’ can lead to a 
systemic inflammatory response, which can progress to multiple organ failure 
depending on the burn total body surface area. Therefore, the aim of burn management 
is to prevent infection, promote healing in the zone of necrosis, and prevent conversion 
of the zone of stasis to necrosis and the inflammatory response in the zone of 
hyperaemia. 
The management of burn injuries has changed as the understanding of the dynamics of 
the injury evolves. Sir Archibald McIndoe (1900-1960) introduced saline (0.9-1.8% 
sodium chloride) wound irrigation for burns after noticing the increased likelihood of 
survival of RAF pilots who sustained severe burns, but fell into the sea before their 
rescue in World War II. Seawater, which contains 3.5% sodium chloride acted as a 
cleaning agent for the burns and provided a cooling effect. Baxter and Shires (1968) 
introduced fluid resuscitation based on the understanding of fluid loss and hypovolemia 
following burns. The need to prevent infections and use anti-microbial topical 
applications such as silver nitrate were later introduced (Ross and Hulbert 1940, Clowes 
et al. 1943). Since these early efforts, advances are made everyday in the types of 
topical agents and dressings used in burns management. Further understanding of the 
metabolic requirements of the burn victims and the need for nutritional support 
improved burns survival. Advances in the anaesthetic care and rehabilitation support, 
has also led to improved survival rates in recent years. 
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Burn tissue or ‘eschar’ consists of purulent exudate produced by the immigrating 
inflammatory cells and organisms, dried blood and denatured skin proteins. The 
‘eschar’ is quickly colonised by endogenous bacteria derived from skin appendages. 
Therefore, rapid excision of the dead tissue leaving behind viable tissue only followed 
by early wound coverage, are the fundamental factors in the reconstruction of severe 
burns injuries.   
Early excision of burn eschar is known to improve survival in full thickness burns 
(Farmer et al. 1955, Macmillan and Artz 1957, Macmillan 1958). One of the significant 
improvements to burns management in recent times has been the introduction of 
tangential excision of burn tissue (Janzekovic 1970). Tangential excision, which is the 
repeated use of the skin graft knife to shave the burn eschar down to viable tissue, 
reversed the zone of stasis and reduced the inflammatory response in the zone of 
hyperaemia. Early excision and skin grafting reduces mortality and hospital stay in 
extensive burn injuries involving more than 20% total body surface area (Ong et al. 
2006). However, early excision of burns presented a different challenge in extensive 
burns covering more than 50% of the total body surface area.  
Early excision of burn eschar requires simultaneous skin coverage in the form of skin 
grafting. In extensive burns, the lack of suitable areas for skin graft harvesting results in 
a delay in treatment, which can seriously affect the outcome. Also donor sites from skin 
graft harvesting add to the total area of skin loss. Local and potential systemic 
complications during wound healing of donor sites can add to the already existing 
challenges of burn injuries management. The time needed for re-epithelialisation of the 
donor site prolongs hospital stay and extends the time intervals between grafting 
sessions (Andreassi et al. 2005).  
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1.3	  Alternatives	  to	  skin	  grafting	  (Biological	  dressings)	  
 
Skin loss following burn injuries, ideally requires replacement of the lost skin with skin 
harvested from another anatomical area. Therefore skin grafting continues to be the 
standard treatment following deep dermal or full thickness burn injuries.  
Tanner et al. (1964) introduced meshing of skin grafts i.e. passing the skin graft sheet 
through a ‘mesher’ to punch holes within the graft sheet to expand the coverage surface 
area (figure 4). The meshing ratio is controlled by the size of the roller in the mesher, as 
size increases, a proportionate increase in the meshing ration is seen (figure 4). 
 
Figure 3: Meshed skin graft 1:1 (left) compared to 5:1 (right) 
Wider meshing ration allows expansion of the skin graft size as shown to allow coverage of a larger 
surface area 
http://www.gatewaymed.com/products.aspx?productId=17 
 
This is done in fixed ratios ranging from 1:1.5 (also known as mini-meshing) up to 1:6 
depending on donor site availability and wound area treated (figure 5). Progressive 
keratinocyte migration from the skin graft islands into the mesh defects leads to wound 
healing. Nevertheless, the wider the meshing ratio, more keratinocyte migration and 
wound contraction are needed to achieve healing and close the gaps within the meshing 
pattern. This can lead to delayed wound healing and possibly secondary breakdown and 
extensive scarring (Gangemi et al. 2008).    
Based on the fact that in extensive burns, the surface area of intact skin available for 
skin graft harvesting is limited, the development of skin alternatives became a priority. 
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The idea of developing skin alternatives became a necessity for patient survival in 
extensive burns when there is minimal donor site area available for skin grafting.  
Skin alternatives or ‘Biological dressings’ would be able to provide temporary or 
permanent cover in extensive cases of skin loss following burns or trauma. Girdner 
(1881) first described the use of cadaveric human skin as a biological dressing. The 
wide spread use of skin grafts of variable thickness was popularised by Thiersch in 
1886 (Thiersch 1886)  and Schone in 1906 (Schone 1906) (Leon-Villapalos et al. 2010, 
Schone 1906). 
Further research in the 1950s and 1960s led to the foundations of the current use of 
allograft as a biological skin treatment for major burns (Mowlem 1952, Jackson 1953, 
Zaroff et al. 1966). Allografts are harvested from deceased donors in longitudinal sheets 
and used as fresh, or cryopreserved at -80°C for up to six months (Pianigiani et al. 
2005).  The allografts can be lyophilised using dry freezing or glycerol to prolong their 
shelf life to around 6 months. 
The use of deceased donor allograft skin for burns has very clear advantages and 
disadvantages (Leon-Villapalos et al. 2010). The advantages include allograft skin 
providing temporary cover of the burn wound when autograft is not available in both 
partial thickness and full thickness burns; in addition, it can be used as a cover layer for 
widely meshed grafts (Alexander et al. 1981). Other applications include exfoliative 
skin loss disorders such as; toxic epidermal necrolysis and staphylococcal scalded skin 
syndrome, and as temporary cover following burn excision prior to autografting. The 
use of deceased donor allograft has been shown to improve wound healing and reduce 
heat and ﬂuid loss (Brychta et al. 2002).  
The disadvantages of using allografts include their eventual rejection due to 
immunogenic rejection and the possibility of transmission of blood born infection.  
The need to establish an adequate and successful method to preserve allograft skin led 
to the development of preservation by refrigeration over variable periods of time as 
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performed by Wentscher in 1903. This was followed by the addition of glycerol as a 
cryopreservant (Billingham et al. 1955). The same authors also described the 
phenomenon of “second-set” rejection of allogeneic tissue because of the presence of 
humoral antibodies from prior exposure to the same allogeneic source.  
The pathological immunosupression present in the early stages of a severe burn injury 
protects allografts from rejection during the early period following their application.   
Clearly the role of allografts as a biological replacement is temporary, and their use is 
limited to the early phase of skin loss injuries. 
Spurred by the limitations of the use of allografts, the need for skin replacement 
products has become a priority over the last fifty years. The idea of developing a skin 
substitute has been a focus of many researchers with variable degrees of success. 
Biological skin substitutes are products that are capable of replacing the damaged skin 
barrier either on a temporary or permanent basis. All biological skin substitutes ideally 
should have the following criteria: be clinically safe, replace the skin barrier, easy 
handling and application. 
MacNeil (2007) reviewed the ideal properties for biological skin replacements, they 
should not be immunogenic, toxic, activate an inflammatory response or transmit 
disease. The skin replacement should also be biodegradable, support the regeneration of 
normal skin, and prevent fluid and heat loss from the wound surface. 
Currently, there is no available skin replacement fulfilling all of the above-mentioned 
criteria. However, there are few bioengineered skin replacement products in the market, 
which can address some of the complications following the loss of the skin barrier. 
The materials currently available include; Xenografts (Porcine skin), allogeneic cells 
combined with synthetic/xenogenic scaffold such as Apligraf® (Novartis, Switzerland), 
TransCyte® (Advanced BioHealing, California, USA), and “Recell®” (Avita Medical, 
Cambridge, UK) freshly harvested keratinocytes sprayed on burn wounds. Occlusive 
dressings temporarily restoring the skin barrier function in partial thickness burns and 
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providing wound cover in full thickness burns include; Biobrane® (Smiths and Nephew, 
Hull, UK) and Duoderm® (ConvaTec, Middlesex, UK). 
Over the last three decades, recent advances have produced dermal replacement 
products such as Integra® (Integra Life Science, New Jersey, USA) and Matriderm® 
(Eurosurgical Limited, Surrey, UK). Dermal replacement therapies, as the name 
implies, provide a dermal substitute which following successful re-vascularisation 
would still require epidermal cover. The only procedure available until the emerging of 
keratinocyte cell culture has been a split skin graft. The possibility of isolating 
epidermal keratinocytes and expanding them in vitro opened the door for a new era in 
the management of burns and skin loss injuries. 
The efforts of Rheinwald and Green (1975a) provided the breakthrough with the 
introduction of keratinocyte cell culture in vitro. They were able to isolate epidermal 
keratinocytes and expand the cells in culture using 3T3 cells (lethally-irradiated Swiss 
mouse fibroblasts). Further efforts through the addition of epidermal growth factor led 
to successful repeated expansion of keratinocytes in vitro (Rheinwald and Green 1977).  
Further additions to the culture medium, such as Cholera endotoxin (Green 1978), 
hydrocortisone, and insulin (Tsao et al. 1982) led to the use of defined medium and the 
optimisation of culture conditions. Following repeated expansion over a period of 3-4 
weeks, keratinocyte colonies form thin confluent sheets, which can be re-applied to the 
wound (Boyce and Hansbrough 1988). 
The early applications of cultured keratinocytes included the treatment of venous leg 
ulcers (Leigh et al. 1987, Marcusson et al. 1992) and severe burn injuries (Bettex-
Galland et al. 1988, Ronfard et al. 1991). In cases using cultured keratinocytes to treat 
severe burns’ injuries, variable success rates were reported (Williamson et al. 1995, 
Caruso et al. 1996, Caruso et al. 1999). The success rate was measured against different 
variables; including re-epithelialisation, wound healing and patient survival. The most 
commonly reported outcome measure is the percentage of take of the cultured 
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keratinocyte sheet graft to the wound bed. The percentage of take reported in literature 
varies from 15% (Blight et al. 1991) to 95% (Compton 1992). The variation arises from 
patient factors, wound bed preparation; different methods of graft application, dressings, 
and post-operative wound care protocols. 
Fraulin et al. (1998) introduced the use of freshly harvested sprayed keratinocytes in a 
pig model to promote wound healing. This method was adopted as an alternative to the 
use of cultured epithelial sheet grafts in the treatment of skin loss. The use of sprayed 
cultured keratinocytes in combination with fibrin glue was reported to successfully 
promote re-epithelisation (Currie et al. 2003). Although cultured keratinocytes appear to 
be the ideal alternative to skin grafting (Boyce 1996, Boyce 2001, Boyce et al. 2006a), 
particularly in extensive cases of skin loss when no donor sites are available for skin 
graft harvesting, they have clear disadvantages.  
The disadvantages include the lack of dermal cellular support, as the epithelial sheets 
are mainly keratinocytes lacking any dermal components. The absence of dermal cells, 
mainly fibroblasts, contributes to the fragility of the epithelial cell sheets (Boyce and 
Hansbrough 1988), early wound breakdown post-operatively, and unpredictable 
scarring in the long-term (Desai et al. 1991). Other factors contributing to the fragility 
of the epithelial sheets include the repeated use of trypsin to harvest keratinocytes 
during the in vitro expansion process (LaFrance and Armstrong 1999). Repeated 
trypsinisation can affect keratinocyte cell-to-cell adhesion in vivo and leads to the 
formation of fragile epithelium (LaFrance and Armstrong 1999). 
Efforts to address the fragility of epithelial sheet grafts include the use of in vitro tissue 
constructs such as collagen (Boyce 1998, Boyce et al. 1988) and de-cellularised dermis 
(Atiyeh and Costagliola 2007). Also synthetic membranes were used to support the 
grafts during transfer and wound application including polyurethrane (Rennekampff et 
al. 1996) and silicone (Hernon et al. 2006). The use of support membranes allows easy 
handling of the fragile sheets. 
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The length of time required for the culture process is another disadvantage; patients 
with extensive burns are usually critically ill facing a life threatening injury. Early 
wound coverage following burn excision has been shown to improve survival. This is 
difficult to achieve as the cycle of keratinocyte culture and expansion takes around 3-4 
weeks, which could be crucial time lost before the cultured cells are available for wound 
application. The use of lethally irradiated mouse fibroblasts (3T3) in keratinocyte cell 
culture is also another disadvantage. The use of xenogenic cells raises theoretical 
concerns about the possibility of disease transmission from mice. 
1.4.	  Microcarrier	  beads	  in	  tissue	  engineering	  
 
Researchers over the last 20 years have explored various methods to improve the 
process of keratinocyte cell culture. Improvements were required to reduce the time 
needed to reach cell confluence, fragility of the epithelial cell sheets, delivery methods 
and dermal-alternatives to support the cultured epithelial sheet graft. 
Van Wezel (1967) introduced the use of microcarriers “small particles with diameters 
ranging between 100 and 400 µm in tissue culture. He described the use of the beaded 
ion exchange medium DEAE (Diethylaminoethyl) Sephadex™A-50 as a microcarrier to 
facilitate the growth of mammalian cells. He further developed the system for large-
scale viral vaccine production (van Wezel 1976). 
Four decades later, microcarriers are available from a variety of materials including; 
cellulose, chitosan, collagen, dextran, gelatin, glass, polyethylene, and polystyrene.  
The use of microcarriers in tissue engineering has many advantages; cell expansion can 
be rapidly achieved using bioreactors, and using microcarriers allows close monitoring 
and modification of culture conditions. Also, cells expanded on microcarriers can be 
transplanted in vivo and their ability to regenerate lost or damaged tissue assessed 
experimentally and clinically (Martin et al. 2011).  
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The applications of microcarriers depend on cellular attachment, and many factors 
influence the attachment of cells to the surface of microcarriers. These factors include; 
the chemical composition of the microcarriers, surface structure, degree of porosity, and 
charge density of the particle. In addition, the number of cells that can attach to the 
microcarrier depends on the particle diameter and the resulting surface area. 
The advantages of the use of microcarriers in cell culture include the large surface area 
provided by microcarriers in a relatively small volume. This large surface area allows 
cell culture and culture conditions assessment within confined space in a bioreactor-type 
environment. For example, 1 g of Cytodex™1 microcarriers provides a surface area of 
4400 cm2, the surface area approximately equivalent to 58 “75 cm2 culture ﬂasks” 
(Martin et al. 2011). This clearly demonstrates that using microcarriers for tissue culture 
is space saving and cost effective, as well as less time and labour intensive than 
standard culture methods.  
A review of the literature published in PubMed, Embase®, and Cochrane reviews 
database revealed numerous applications for the use of microcarriers in tissue 
engineering, some of these applications are referred to in the table 1. The examples of 
application represent a summary of common applications and are not inclusive. 
In addition, cell culture on microcarriers allows adjustment of culture conditions such as 
medium and culture composition, and mechanical forces in stirred culture. The use of 
culture medium additives and adjusting the rotation of stirred culture can be achieved 
due to the versatile attachment of cells to the microcarriers’ surface compared to normal 
culture. Other advantages are that serial culture samples can be analyzed from the 
culture and thus cell differentiation can be regulated in large scale bio-reactor models 
(Freed et al. 1993). 
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Table 1: Commercially and Non-commercially available types of microcarrier beads  
(Martin et al. 2011). The examples of application represent a summary of common applications and are 
not inclusive. 
 
Microcarriers can also be used as cell delivery systems, as cells on microcarriers can 
either be directly applied to a specific anatomical site or biological background, or 
incorporated into a larger scaffold and subsequently transplanted. The potential for 
using microcarriers for tissue engineering applications is extensive (table 1), and 
successful culture methods have been reported for a range of different cell lineages. 
Bone-forming osteoblasts have been shown to proliferate on a range of microcarriers 
and have been used in both in vitro and in vivo investigations (Howard et al. 1983, 
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Shima et al. 1988). In recent years, various types of microcarriers have been 
investigated for bone tissue engineering such as polycaprolactone microcarriers seeded 
with rat bone marrow-derived stem cells (Hong et al. 2009) and gelatin microcarriers 
seeded with mouse embryonic stem cells (ESCs) or dermal ﬁbroblasts (Sommar et al. 
2010).  
New developments in cartilage tissue engineering involve the seeding of chondrocytes 
on biomaterials such as collagen membranes (Vinatier et al. 2009, van Osch et al. 
2009). Chondrocytes have been shown to alter their phenotype to fibroblasts in 
monoculture, along with a change in collagen production from type II to type I 
(Frondoza et al. 1996, Freed et al. 1993). Microcarriers with surface modiﬁcations to 
enhance cell attachment have recently been reported. These included poly (L-lactide) 
(PLLA) with chitosan surface coating (Lao et al. 2008),  poly(D/L-lactide-co-glycolide) 
(PLGA) microcarrier with positive charge surface modiﬁcation (Chun et al. 2004),  and 
PLLA microcarrier with RGD (arginine-glycine-aspartic acid) surface modiﬁcation 
(Chen et al. 2006). All of these microcarriers were shown to support the growth and 
proliferation of chondrocytes.  
The use of microcarriers for endothelial cell culture helped to identify endothelial cell 
growth dynamics, and factors involved in capillary network formation. Endothelial cell 
attachment to microcarriers within a fibrin matrix led to the development of a three-
dimensional angiogenesis model (Wissemann and Jacobson 1985).  
Another area of tissue engineering where microcarrier culture has expanded is 
Parkinson’s disease treatment, which may be aided by the use of microcarriers. Rats 
with hemi-parkinsonism were treated with adrenal chromafﬁn cells on Cytodex™ 
microcarriers (Cherksey et al. 1996, Saporta et al. 1997, Borlongan et al. 1998). 
The use of microcarriers for the expansion of Adipose-derived stem cells (ADSCs) has 
been under investigation in recent years (Choi et al. 2008, Chung and Park 2009, Serra 
et al. 2009). Recent animal work utilised rabbit bone marrow-derived mesenchymal 
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stem cells (MSCs) transfected with green ﬂuorescent protein (GFP). The MSCs were 
attached to PLGA microcarriers following differentiation then injected into the cervical 
region of mice. Four weeks post-transplantation, newly formed fat pads containing 
GFP-positive cells were observed.  
Another frontier where the use of microcarriers for cell culture is promising is 
hepatocyte cell culture. The culture of adult rat hepatocytes on microcarriers was 
initially used to investigate hormone metabolism in vitro (Athari et al. 1988). Further in 
vivo studies demonstrated metabolic improvements over a period of 30 days following 
the injection of hepatocytes cultured on microcarriers into rats with a defective bilirubin 
or albumin metabolism (Demetriou et al. 1986a, Demetriou et al. 1986b). 
Further reports showed a signiﬁcant increase in survival rate in rats with partial 
hepatectomy which received hepatocytes transplanted on microcarriers when compared 
with control groups (Demetriou et al. 1988). As an alternative to transplantation into the 
liver, hepatocytes cultured on microcarriers can be used in extra-corporal bio-artiﬁcial 
liver devices. 
1.5.	  Microcarriers	  in	  keratinocyte	  cell	  culture	  
 
Cultured keratinocytes are most frequently used in the form of conﬂuent epidermal 
sheets or sprayed single-cell suspensions are harvested from culture flasks using trypsin 
prior to application to the wound bed. 
The use of trypsin to harvest keratinocytes from culture flasks has been reported to 
damage anchoring basement membrane proteins. Such damage results in mechanical 
instability and deficient dermal–epidermal adhesion at the level of the basement 
membrane (Desai et al. 1991).  
The use of microcarriers for keratinocyte cell culture does not require the application of 
trypsin for cell harvest, as keratinocytes are cultured on biodegradable microcarriers that 
can be applied directly to the wound. Furthermore, the utilisation of microcarriers in 
keratinocyte culture reduces culture time and costs (Atiyeh and Costagliola 2007).  
 33 
Voigt et al. (1999) first reported the use of microcarriers for skin cell culture, where 
human keratinocytes were shown to proliferate on Cytodex™ 3 dextran microcarriers. 
Microcarriers and keratinocytes were cryopreserved and remained viable following 
thawing. In a mouse wound model, new epithelium was observed following application 
of microcarriers and keratinocytes. Dextran beads were incorporated in the scar tissue, 
and elicited an inﬂammatory reaction, as the microcarriers were not biodegradable.  
LaFrance and Armstrong (1999) expanded porcine fibroblasts and keratinocytes on 
biodegradable PLLA microcarriers in separate cultures. A mixture of both microcarriers 
was applied to a pig wound model and migration of cells from the microcarriers as well 
as re-establishment of dermal and epidermal elements were observed. 
Kim et al. (2005) reported similar results using keratinocytes expanded on PLGA 
microcarriers in an athymic mouse model. However, PLGA microcarriers were reported 
to produce a mild foreign body reaction. In both studies, no estimate of the percentage 
of keratinocytes’ survival in vivo was available as no biomarker was used to trace the 
cultured keratinocytes.  
The concept of using biodegradable gelatin-based microcarriers for keratinocyte culture 
has become more popular as the drawbacks of using non-biodegardable microcarriers 
are overcome. Cultispher® microcarriers (gelatin-based) have been investigated for 
supporting keratinocyte culture and results have shown that they are capable of 
supporting the growth of keratinocytes and ﬁbroblasts (Gustafson et al. 2007, Seland et 
al. 2011, Liu et al. 2006, Borg et al. 2009). These studies focused on optimising 
conditions for supporting effective growth of keratinocytes on microcarriers including: 
preconditioning of culture media and the use of defined media. 
Conventional keratinocyte cell culture relies on the presence of a layer of lethally 
irradiated mouse 3T3 fibroblasts. Theoretically, the xenogenic origin of the 3T3 cells 
could pose a risk of cross-species disease transmission following clinical application.  
Liu et al. (2006) seeded Cultispher® microcarriers with dermal autologous fibroblasts, 
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the cells were later removed using freezing in liquid nitrogen while preserving 
extracellular matrix and other growth factors secreted by fibroblasts. The modiﬁed 
microcarriers were then inoculated with keratinocytes, which showed an increase in 
proliferation and viability when compared with keratinocytes grown on unmodiﬁed 
microcarriers. In addition, the keratinocytes remained viable at room temperature and 
upon refrigeration, indicating the possibility of this bioreactor system being suitable for 
future clinical application. 
In another study, keratinocytes grown on Cultispher® microcarriers in deﬁned media 
were applied to full-thickness wounds in mice, and contributed to the development of a 
neo-epidermis. The microcarriers degraded in 2-3 weeks time, and the epidermis was 
thicker compared to the epidermis developing following single-cell suspension 
treatment (Seland et al. 2011). 
Borg et al. (2009) demonstrated that in an in vitro skin equivalent model, keratinocytes 
grown on Cultispher® in standard media without the addition of feeder cells were able 
to form an epidermis.  Zhang et al. (2009) reported that ﬁbroblasts grew on porcine 
acellular dermal matrix microcarriers. The dermal matrix material was under 
investigation as a dermal substitute in full thickness wound treatment. Application of 
these microcarriers in a full-thickness wound mouse model demonstrated a higher rate 
of wound healing when compared with mice receiving no treatment following wound 
formation. 
In a small clinical study, autologous human keratinocytes cultured on Cultispher® 
microcarriers were used to treat chronic venous leg ulcers (Liu et al. 2004). Partial or 
full re-epithelialisation was observed in all wounds treated with either single or serial 
applications of microcarriers plus keratinocytes. No inﬂammatory response was noted 
following the degradation of the microcarriers over a period of 2-3 weeks. Based on this 
evidence microcarriers used for autologous keratinocyte culture could be used to treat 
skin defects such as chronic non-healing wounds or full-thickness skin loss. 
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In microcarrier culture, cells grow as monolayers on the surface of the small spheres or 
as multi-layers in the pores of macro-porous spheres which are usually suspended in 
media using a gentle stirring action. This allows maximisation of the culture surface 
area and reduces space and culture cost. In traditional keratinocyte culture, epidermal 
sheet grafts are required to cover extensive areas of skin loss, in case of severe burns 
with tens of plastic culture flasks being used to produce these sheet grafts. A bioreactor 
model utilising microcarriers and occupying a considerable smaller volume could 
substitute for a large number of tissue culture flasks. The use of microcarriers in cell 
culture generally has many advantages; such as improved control of culture media, 
increasing the production capacity of the culture and protection against physical stress 
(Giard et al. 1977, Mered et al. 1980). The risk of contamination in cell culture is 
related to the number of handling steps required to produce a given quantity of cells or 
products, microcarrier cell culture reduces the number of handling steps (Meignier 
1979). There is a much reduced risk of infection in cell culture using microcarriers 
compared to traditional methods (Meignier 1979).  
Hence, microcarriers could represent an improved culture and delivery method for 
autologous keratinocytes when compared with traditional cell culture. Microcarriers 
clearly have great potential in keratinocyte cell culture and this potential could be 
extended to clinical applications. Clinically, microcarriers and cultured keratinocytes 
could be used as an effective treatment to full-thickness skin loss in the future. 
1.6.	  In	  vivo	  animal	  wound	  models	  
 
Any biological or chemical products intended for clinical use have to undergo extensive 
investigations for safety, efficacy, and adverse effects. Serial clinical trials in multiple 
phases (Phase I-IV) are designed to investigate all these aspects. Phase I and II are 
usually in healthy volunteers to assess biocompatibility, safety and adverse reactions. 
Phase III and IV involve studies in patients to assess therapeutic effects on specific 
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diseases or disorders. An important stage prior to the start of clinical trials is the pre-
clinical testing in a relevant animal model. 
An in vivo animal model is essential for an accurate assessment of the biological 
integration and performance of any skin replacement treatment. Animal models used to 
assess skin substitutes or similar products can help to predict biocompatibility, efficacy, 
and the immune reaction of the biomaterials when applied in humans. Therefore, the 
choice of such an animal model is very important to reflect enough similarities in 
treatment outcomes when compared to humans.  
Sullivan et al. (2001) provided evidence in support of the use of pig animal model for 
skin substitutes and wound healing research. Similarities in anatomy, structure, 
physiology and immunological properties of human and pig skin support the use of a 
pig wound model (Sullivan et al. 2001). Small animals e.g. mice, rats, and guinea pigs 
are often used for in vivo biomedical studies because of the reduced housing 
requirements, and the low cost overall compared to larger animals. The use of small 
animals is useful for specific studies, where immune-compromised or transgenic mice 
are used to demonstrate wound healing concepts.  The data obtained is often limited and 
can only serve to prove or disprove a hypothesis. The limitation is related to the 
fundamental difference in the wound healing process of small animals.  Thin epidermis, 
dermis, and a “panniculosus carnosus” layer (thin muscle) promote wound healing 
through contraction, rather than keratinocyte migratory activity (Wong et al. 2011).  
In comparison, pig skin in general and the dermis in particular are very similar to 
human skin. The human epidermis thickness is between 50 µm-120 µm comparable to 
porcine epidermis thickness of 30-140 µm. Both types of epidermis have a similar 
turnover period of 28-30 days (Vardaxis et al. 1997). Both the porcine and human 
dermis have similar structure, with the dermis being clearly differentiated into papillary 
and reticular layers (Vardaxis et al. 1997). The porcine reticular dermis has reduced 
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elastin fibre content compared to human dermis and the porcine dermis contains 
apocrine glands as opposed to eccrine sweat glands in humans.  
The immunological and enzymatic properties of human and porcine skin, cytokeratin 
distribution and basement membrane components are very similar (Sullivan et al. 2001).  
The pig is the only animal which has a comparable number of skin hair follicles to 
humans (Vardaxis et al. 1997). This is of significant value in wound healing research, as 
re-epithelialisation can progress from hair follicle remnants following partial skin loss 
in humans, and re-epithelialisation occurs in a similar fashion in porcine skin. Taking 
into consideration the similarities between porcine and human skin, porcine models are 
considered the most appropriate and relevant animal model for skin wound healing 
studies (Vodicka et al. 2005) 
In conclusion, the pig animal model appears to be the best available tool for 
experimental studies for human skin regeneration and wound healing. The pig wound 
model allows the reproduction of consistent experimental results, which can assist in 
future clinical applications. It can also reduce the time required for the introduction of 
new treatments for skin loss and wound healing to clinical practice, with a recognisable 
benefit to all patients. 
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Hypotheses for investigation 
 
 
Human and pig keratinocytes will attach to microcarrier beads in vitro and proliferate 
under in vitro culture conditions 
 
Cultured autologous pig keratinocytes on microcarrier beads will migrate from the 
microcarrier beads and integrate into neo-epithelium when applied to porcine full 
thickness wounds 
 
Green fluorescent protein is a long-term retroviral genetic marker in cultured pig 
keratinocytes on microcarrier beads when applied to full thickness wounds 
 
Cultured autologous pig keratinocytes on microcarrier beads will form permanent 
epithelium when applied to full thickness wounds 
 
Cultured autologous pig keratinocytes on microcarrier beads will reduce wound 
contracture when applied to full thickness wounds in combination with widely meshed 
split skin graft  
 
Cultured allogeneic pig keratinocytes on microcarrier beads in combination with two-
stage artificial dermal regeneration template and artificial skin replacement will produce 
epithelial closure when applied to full thickness wounds 
 
Cultured allogeneic pig keratinocytes on microcarrier beads in combination with two-
stage artificial dermal regeneration template and artificial skin replacement will reduce 
wound contracture when applied to full thickness wounds  
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Cultured autologous pig keratinocytes and fibroblasts on microcarrier beads in 
combination with two-stage artificial dermal regeneration template will form a 
permanent functional epithelium when applied to full thickness wounds 
 
Cultured autologous pig keratinocytes and fibroblasts on microcarrier beads in 
combination with two-stage artificial dermal regeneration template will reduce wound 
contraction in full thickness wounds. 
 
Experimental Aims 
 
To assess the proliferation of human keratinocytes on microcarrier beads in vitro 
compared with conventional culture (Chapter 3) 
 
To compare different types of gelatin microcarrier beads to support the growth and 
proliferation of human keratinocytes in vitro (Chapter 3) 
 
To assess the proliferation of porcine keratinocytes on microcarrier beads in vitro 
compared with conventional culture (Chapter 3) 
 
To compare the application of cultured autologous keratinocytes on microcarrier beads 
with cultured sprayed keratinocytes on re-epithelisation of full thickness wounds 
(Chapter 4) 
 
To compare the use of Green Fluorescent Protein as a marker of cultured keratinocytes 
on microcarrier beads with cultured sprayed keratinocytes in full thickness wounds 
(Chapter 4)  
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To compare the effect of cultured keratinocytes on microcarrier beads and sprayed 
keratinocytes in reducing the rate of wound contraction in full thickness wounds 
(Chapter 5) 
 
To compare the effect of allogeneic cultured keratinocytes on microcarrier beads and 
allogeneic cultured sprayed keratinocytes in combination with artificial dermal 
regeneration template in reducing the rate of wound contraction in full thickness 
wounds (Chapter 6) 
 
To compare autologous cultured keratinocytes on microcarrier beads alone or in 
combination with autologous cultured fibroblasts on microcarrier beads in reducing the 
rate of wound contraction in full thickness wounds (Chapter 7) 
 
To compare cultured allogeneic and autologous keratinocytes on microcarrier beads 
with cultured allogeneic and autologous sprayed keratinocytes in combination with two-
stage artificial dermal regeneration template in re-epithelisation of full thickness 
wounds (Chapter 6-7) 
 
To compare cultured autologous keratinocytes on microcarrier beads with cultured 
autologous keratinocytes and fibroblasts in combination with two-stage artificial dermal 
regeneration template in re-epithelisation of full thickness wounds (Chapter 7) 
 
To compare cultured autologous keratinocytes and fibroblasts on microcarriers with 
cultured autologous sprayed keratinocytes in combination with two-stage artificial 
dermal regeneration template in re-epithelisation of full thickness wounds (Chapter 7) 
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Chapter 2: Materials and methods  
2.1	  Materials	  	  
2.1.1	  Human	  keratinocytes	  cell	  culture	  	  
Cell	  lines	  	  
Swiss 3T3 mouse embryo fibroblasts, passage number 24 (The Imperial cancer research 
fund (ICRF), London, UK) 
Media	  and	  supplements	  	  
Source: GIBCO BRL, Life technologies, Paisley, Scotland  
⇒ Dulbecco’s Modified Eagle’s Media (DMEM) with 1000 mg/l D-glucose 
⇒  Hanks Balanced Salt Solution (HBSS)  
⇒ Penicillin/ Streptomycin 5000 units ml-1/5000 µg ml-1 
⇒ F12 + GlutaMAX™ Nutrient Medium  
Source: Sigma-Aldrich Ltd., Dorset, UK 
⇒ Hydrocortisone (Cortisol, 17-Hydrocorticosterone)   
⇒ Cholera Toxin  
Source: Austral Biologicals, USA 
⇒ Human recombinant EGF 50 µg/ml stock  
Source: Imperial Laboratories Ltd, West Portway, Andover, England  
⇒ Foetal bovine serum (Foetal calf serum)  
Source: Sigma-Aldrich Ltd., Dorset, UK for Percell Biolytica, Sweden 
⇒ Cultispher S® microcarriers 
⇒ Cultispher G® microcarriers 
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Reagents	  	  
Source: Boehringer Mannheim, Lewes, Sussex, England  
⇒ Dispase® 
 Source: Difco Laboratories, Detroit, Michigan, USA  
⇒ Trypsin (0.25%)  
Source: GIBCO BRL, Life Technologies, Paisley, Scotland  
⇒ Trypsin 0.05%/ EDTA 0.02%  
Tissue	  culture	  consumables	  	  
Source: Greiner Bio-One Ltd, Gloucestershire, England  
⇒ 175 cm2 canted neck filter cap tissue culture flasks 
⇒  75 cm2 canted neck filter cap tissue culture flasks 
⇒  30 ml sterile universal tubes  
Source: Becton Dickinson Labware, NJ, USA supplied by Marathon Laboratory 
Supplies, Park Royal, London, England  
⇒ Falcon® 5 ml, 10 ml, 25 ml, and 50 ml sterile tubes  
⇒ 20 ml sterile universal tubes 
⇒  Sterile Petri dishes 90 x 15 mm (D x H) 
⇒ 200 ml sterile pots  
Source: Fisher Scientific UK, England 
⇒ Manually programmable cell rotator 
⇒ Pre-plugged and non-plugged glass Pasteur pipettes 
2.1.2	  Porcine	  keratinocyte	  and	  fibroblasts	  cell	  culture	  
Porcine	  keratinocytes	  
In vitro studies: Isolated from skin grafts harvested from white pigs donated by 
Plumpton College, near Lewes, East Sussex, UK.  
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In vivo studies: Isolated from skin grafts from white pigs used in experimental work 
(Northwick Park Institute Medical Research (NPIMR), Harrow, London) 
Cell	  lines	  	  
⇒ Swiss 3T3 mouse embryo fibroblasts, passage number 24 (The Imperial Cancer 
Research Fund (ICRF), London, UK) 
⇒ PT67 retroviral producer cell line PT67pFB-hrGFP A2 clone from PT67 
packaging cell line (BD Biosciences Clontech, Oxford, UK) and ViraPort™ 
retroviral reporter vector (Stratagene, La Jolla, California, USA) supplied by 
Agilent Technologies UK Ltd., Cheshire, UK. 
Media	  and	  supplements	  	  
Source: GIBCO BRL, Life Technologies, Paisley, Scotland  
⇒ Dulbecco’s Modified Eagle’s Media (DMEM) with 1000 mg/l D-glucose 
⇒  Opti-MEM®(calcium-free) reduced serum media with GlutaMAX® 
⇒ Hanks Balanced Salt Solution (HBSS)  
⇒ Penicillin/ Streptomycin 5000 units ml-1/5000 µg ml-1 
⇒ Amphotericin B 250 µg ml-1 (to prevent fungal infection and no effect on 
keratinocytes expansion was noted following the addition of Amphotericin B) 
⇒ Calcium chloride (0.1M)  
⇒ Lipofectamine Plus™ reagent for PT67 cell line 
 Source: Sigma Alddrich Co Ltd, Poole, Dorset, England  
⇒ Rat Tail Collagen (type 1)  
 Source: Imperial Laboratories Ltd, West Portway, Andover, England  
⇒ Foetal bovine serum (Foetal calf serum)  
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Reagents	  	  
Source: Boehringer Mannheim, Lewes, Sussex, England  
⇒ Dispase® 
Source: Difco Laboratories, Detroit, Michigan, USA  
⇒ Trypsin (0.25%)  
Source: GIBCO BRL, Life Technologies, Paisley, Scotland  
⇒ Trypsin 0.05%/ EDTA 0.02%  
Tissue	  culture	  consumables	  	  
Source: Greiner Bio-One Ltd., Gloucestershire, England  
⇒ 75 cm2 canted neck filter cap tissue culture flasks 
⇒ 175 cm2 canted neck filter cap tissue culture flasks 
⇒ 30 ml sterile universal tubes  
Source: IBS Integra Biosciences, Switzerland 
⇒ Cellspin™ magnetic stirrer  
⇒ Cellspin™ magnetic stirrer flasks (100 ml and 250 ml) 
2.1.3	  Animal	  anaesthesia	  and	  theatre	  consumables	  	  
Anaesthesia	  and	  per-­‐operative	  drugs	  	  
Source: Parke-Davies Veterinary Ltd, Pontypool, Gwent, Wales  
⇒ Ketamine (Vetalar®)  
Source: Bayer UK Ltd, St Edmunds, Suffolk, England 
⇒ Xylazine (Rompun®)  
Source: Zeneca Ltd, Macclesfield, Cheshire, England 
⇒ Halothane (Fluothane®)  
Source: BOC Ltd, Guilford, Surrey, England 
⇒ Nitrous Oxide 
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⇒ Oxygen  
Source: Astra Pharmaceuticals Ltd, Kings Langley, Hert’s, England 
⇒ Bupivicaine (Marcaine®)  
Source: Biorex Laboratories Ltd., Enfield, UK   
⇒ Lignocaine Gel B.P. 2%  
Source: Smith Kline Beecham Animal Health, Surrey, England 
⇒ Ampicillin “Ampifen LA™” (long acting penicillin)  
Source: Veterinary Products, Grampian Pharmaceuticals, Lancashire, England 
⇒ Caprofen® 
Theatre	  equipment	  and	  consumables	  	  
Source: Depuy Healthcare Ltd, Leeds, England 
⇒ Chlorhexidine (4%) (Hydrex®)  
Source: Steripak Ltd, Rancorn, Cheshire, England 
⇒ Normal Saline (sodium chloride 0.9%)  
⇒ Sterile alcohol (70%)  
Source: Seton Healthcare, Oldham, Lancashire, England 
⇒ 10% povidine iodine in aqueous solution (Betadine®)  
Source: Northwick Park Hospital Pharmacy, Harrow, England 
⇒ Liquid Paraffin  
Source: Swann Morton®, Sheffield, England  
⇒ Scalpel Blades size 10 and size 15 
⇒ Silvers™ skin graft knife and blades 
Source: Smith and Nephew, Hull, England 
⇒ Elastoplast® adhesive roll bandages  
⇒ Paraffin Gauze dressings “Jelonet®” 
⇒ VISITRAK™ Digital, digital wound measuring device  
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⇒ VISITRAK™ Grid, single use 3 layer tracing grid  
Source: Johnson & Johnson, Ascot, Berkshire, England 
⇒ Velband® wool bandage  
Source: Ethicon Ltd, Edinburgh, Scotland 
⇒ 2/0 and 3/0 silk sutures  
Source: Zimmer Ltd., South Marston Park, Swindon, England 
⇒ Zimmer® Air Dermatome  
⇒ Disposable dermatome blades 
⇒ Skin graft adjustable mesher 
⇒ Plastic skin graft holders 1:3 and 1:6 
Source: 3M United Kingdom plc, Bracknell, England 
⇒ 3M Vista™ skin stapler 
Source: The Bioengineering Department, Northwick Park Institute for Medical 
Research, Harrow, England 
⇒ Percutaneous poly-tetrafluroethylene (PTFE) wound isolation chambers  
Source: Promedics Ltd, Blackburn, Lancashire, England 
⇒ Protective pig thermoplastic jackets secured with Velcro® straps  
Source: Southern Foam, Crawley, Sussex, England 
⇒ Foam support for protective pig jackets  
⇒ Foam adhesive  
Source: Kendall Healthcare part of Covidien Ltd., Fareham, Hampshire, UK  
⇒ Telfa Clear™ Non-adherent wound dressing  
2.1.4	  Histology,	  immunohistochemistry	  and	  image	  analysis	  
 
Source: GIBCO BRL, Life Technologies, Paisley, Scotland   
⇒ MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) for 
staining and cell assay 
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⇒ Acridine orange dye 
Source: QIAGEN UK, Manchester, UK 
⇒   RNeasy™ universal kit 
⇒ Oligotex™ mini RNA kit 
⇒ SYBR green™ Real Time-PCR kit 
⇒ Qubit® 2.0 Fluorometer 
⇒ Step One Plus™ Real Time PCR System 
Source: Digitron, Torquay, Devon, UK  
⇒ Pneumatic actuator controller 
⇒ Pneumatic piston  
Source: Surgipath Europe Ltd., Poole, Peterborough, England 
⇒  Microtome blades 
Source: Raymond A Lamb Ltd., England 
⇒ Menzel-Glaser® Microscope slides 
⇒ Twin Frost Microscope slides 
⇒ Microscope Glass cover slips 
Source: BOC gases, Shoreham-by-Sea, West Sussex, UK  
⇒ Compressed nitrogen  
Source: BDH laboratory supplies, Poole, Dorset, England 
⇒ Formaldehyde 
⇒ Gluteraldehyde 
⇒ Haematoxylin (Gill’s/Harris’) 
⇒ Eosin 
⇒ DPX mountant  
⇒ Xylene 
⇒ Methanol 
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Source: Vector Laboratories Ltd, Peterborough, England 
⇒ VECTABOND® reagent  
⇒ VECTASTAIN® ABC Standard Kit 
⇒ VectaMount® permanent mounting medium 
⇒ D.A.P.I (4', 6-diamidino-2-phenylindole) fluorescent stain 
⇒ Dylight™ staining kit (FITC, flourescine isothiocyanate) 
Source: abcam, Cambridge, UK 
⇒  K14, Laminin, and α smooth muscle actin secondary antibodies 
Source: BMRF Histopathology Lab, Queen Victoria Hospital, East Grinstead, 
England.  
⇒ Trypan blue  
⇒ Sodium Chloride 
⇒  Sodium Acetate Anhydrous 
⇒  Triton X 100 
⇒  Acetic Acid  
⇒ Diaminobenzidine Tetrachloride dihydrate  
Source: Genta Medical, York, UK.  
⇒ I.M.S. (Industrial Methylated Spirit) 
Source: Sakura Finetek Europe, The Netherlands   
⇒ Tissue-Tek® OCT (Optimal cutting temperature) compound, embedding medium 
for frozen tissue specimens  
Source: Canon UK Inc., Reigate, Surrey, UK 
⇒ Canon EOS 300D digital camera  
Source: Carl Zeiss Ltd., Welwyn Garden City, Hertfordshire, UK 
⇒  Zeiss Axioscope microscope 
⇒ Axiovision® software for image analysis 
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2.2 Methods  
Human keratinocyte cell culture handling was performed in class II microbiology safety 
cabinet (Jouan LC2.12, Thermoscientific, NY, United States) and the human 
keratinocyte were kept in a humidified incubator (LEEC research® CO2 incubator, 
LEEC, Nottingham, UK) at 37°C, relative humidity 98% and 5% CO2 in a separate 
laboratory from the porcine cell culture. 
Porcine keratinocyte and fibroblast cell culture handling was performed in class II 
microbiology safety cabinet (Jouan LC2.12) and all porcine cell cultures were kept in a 
humidified incubator (LEEC research® CO2 incubator) at 37°C, relative humidity 98% 
and 5% CO2.  
2.2.1	  Human	  keratinocyte	  isolation	  	  
Split thickness skin grafts were obtained from skin samples from discarded tissue (e.g. 
following breast reduction or abdominoplasty) from the Plastic Surgery Department, 
Queen Victoria Hospital, East Grinstead with patients’ consent for skin use in vitro. 
The surface of skin samples were prepped using the antimicrobials “Betadine®” and 
“Hydrex®” prior to harvesting a small split skin graft under sterile conditions using 
either mini Zimmer® electric dermatome with large specimens or Silvers™ skin graft 
knife (Swann Morton®, Sheffield, England) with small specimens. Both methods of skin 
graft harvest produce the same thickness of skin graft so no difference was noted in 
culture following the use of either method for skin graft harvest. 
2.2.2	  Human	  keratinocyte	  culture	  media	  
Human skin graft transport solution 
 
⇒ Hanks Balanced Salt Solution (HBSS) 
⇒ Penicillin/Streptomycin 100 units ml-1/100 µg ml-1  
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Human keratinocyte culture medium with Cholera Toxin 
 
• DMEM with GlutaMAX™1000 mg/l D-glucose 
• Foetal calf serum 20% 
• Hydrocortisone 0.4 µg/ml  
• Nutrient F 12 Medium 20% 
•  Human Recombinant Epidermal Growth Factor 10 µg/ml 
•  Cholera Toxin 10-10 M 
• Penicillin/Streptomycin 100 units ml-1/100 µg ml-1 
3T3 growth medium 
 
• DMEM with GlutaMAX™ 1000 mg/l D-glucose 
•  Foetal calf serum 10%   
2.2.3	  Maintenance	  of	  3T3	  cells	  in	  human	  keratinocyte	  culture	  
Swiss 3T3 fibroblasts irradiated with 60 Gray from a Caesium-137 source (Blond 
McIndoe research foundation, East Grinstead, West Sussex, UK) were cultured in 75 
cm2 flasks using 10 ml of 3T3 growth medium. The medium was aspirated and the cells 
washed in 10 ml of HBBS solution when the flasks were 75% confluent. The HBSS 
solution was aspirated and the cells were dispersed using 2.5 ml 0.05% trypsin / 0.02% 
EDTA incubated for 5 minutes at 37°C. 2.5 ml of 3T3 growth medium were used to 
neutralize the trypsin.  
Then the cells were centrifuged at 1000 rpm for 5 minutes and the supernatant 
discarded. The cells were re-suspended in 5 ml of 3T3 growth medium and a 
haemocytometer (Neubauer haemocytometer, Camlab, Cambridge, UK) used to 
perform a cell count. The cells were either re-seeded in a ratio 1:10 into 75 cm2 flasks 
for 3T3 cell culture or used in human or porcine keratinocyte cell culture.  
A layer of fibroblasts is essential for keratinocyte cell culture (Human or porcine), as 
the fibroblasts produce growth factors essential to support keratinocytes. Fibroblasts are 
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pre-irradiated with a sub-lethal dose of irradiation to suppress their growth within the 
culture, whilst allowing them to continue to produce growth factors.  
2.2.4	  Human	  keratinocyte	  cell	  culture	  	  
In the class II safety cabinet, a sterile petri dish (90 x 15 mm, D x H) was opened and 
the skin sample was placed on the inside using sterilised forceps. In between each use 
the forceps were stored in a 20 ml universal container containing sterile alcohol. The 
forceps were left to air dry before further use.  
The skin was washed three times in separate 50 ml Falcon® tubes each containing 25 ml 
of Hanks buffered saline with Penicillin/Streptomycin 100 units ml-1/100 µgml-1. 
The skin was then placed into a 50 ml Falcon® tube containing 20 ml of 2 mg/ml 
Dispase®, sealed and transferred to an orbital shaker at 37°C/30 rpm. The skin was 
incubated for about 1 hour then the Falcon® tube was cleaned with sterile alcohol and 
placed back in the safety cabinet. Dispase® was used to separate the epidermis from the 
dermis and trypsin was used to breakdown the epidermis. The skin was placed onto a 
clean petri dish and the epidermis was gently peeled off the dermis using two pairs of 
forceps. The epidermis was then placed into a 50 ml Falcon® with 25 ml of trypsin, and 
placed in the orbital shaker at 37°C/30 rpm. The epidermis was incubated for another 
hour and the tube cleaned with sterile alcohol and placed back in the safety cabinet.  
10 ml of human keratinocyte culture medium was added to the Falcon® tube and gently 
shaken. The epidermis was then removed and placed onto a clean petri dish with the skin 
surface facing down. The cells on the inferior surface of the epithelium were gently 
scraped using the back of a pair of curved forceps. 5 ml of human keratinocyte culture 
medium were trickled over the scraped surface of the skin twice, aspirated and added to 
the Falcon® tube. The Falcon® tube was then centrifuged at 400g for 4 minutes. The 
supernatant was removed and the cells re-suspended in 10 ml of fresh human 
keratinocyte culture medium. A cell count was undertaken using a haemocytometer and 
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the keratinocytes were seeded at a density of 4 x 106 with 2 x106 freshly harvested 
irradiated 3T3 cells as described in 2.2.3 into each 75 cm2 flask. The flasks were then 
incubated at 37°C with 98% humidity and 5% CO2.  
2.2.5	  Human	  keratinocyte	  cell	  culture	  maintenance	  	  
The flasks were removed from the incubator to the safety cabinet, gently shaken to 
remove the dead cells and human keratinocyte culture medium was added to the flasks 
10 ml/ 75 cm2 flask. Freshly irradiated 3T3 calls were added (1 x 106/75 ml flask) 3 
times/week. When the colonies were 80-90% confluent they were split into new flasks.  
The medium was removed and the cells washed with HBSS three times to remove traces 
of foetal calf serum and non-viable cells. Trypsin was added to the flasks (2 ml/ 75 cm2) 
and the flasks placed back in the incubator at 37° C with 5% CO2 for 10 minutes. The 
flasks were then removed from the incubator and gently tapped on the side to release the 
cells. The flask was held upright for 5 minutes to allow the cells to settle down to the 
bottom of the flask. Human keratinocyte culture medium was added to the flask (8 ml/ 
75 cm2) and the contents pipetted gently for a minute to form an even solution. The 
solution was re-seeded into new flasks (from one 75 cm2 flask, 2 ml was aliquoted into 
each of 4 new 75 cm2 flasks). Fresh irradiated 3T3 cells were added to each flask (2 x106 
3T3/ 75 cm2 flask) and further human keratinocyte culture medium (10 ml/ 75 cm2 
flask). A “T” number is allocated to each flask to indicate the number of times the cells 
were trypsinised i.e. T1 indicating the first passage. 
The cells were harvested between the T2 and T4 stage in a sub-confluent density. In the 
2-3 days prior to harvesting, no 3T3 cells were added to the culture flasks to avoid 
difficulties in removing them prior to keratinocyte harvest. The medium change was 
carried out every 48 hours. 
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2.2.6	  Porcine	  keratinocyte	  transport	  and	  culture	  media	  	  
Porcine keratinocyte growth medium 
 
• Opti MEM 1 with GlutaMAX™ 
• Foetal calf serum 10%  
• Penicillin/Streptomycin 100 units ml-1/100 µg ml-1 
• Final [Ca2+] 0.5 mM  
Porcine keratinocyte transport solution 
 
• Hanks Balanced Salt Solution (HBSS)  
• Amphotericin B 1.25 µg/ml  
• Penicillin/Streptomycin 200 units ml-1/200 µg ml-1 
3T3 growth medium 
 
• DMEM with GlutaMAX™ 1000 mg/l D-glucose 
• Foetal calf serum 10% 
PT67 growth medium 
 
• DMEM with GlutaMAX™ 4500 mg/l D-glucose 
• Foetal calf serum 10% 
• Penicillin/Streptomycin 100 units ml-1/100 µg ml-1   
2.2.7	  Maintenance	  of	  3T3	  cells	  in	  porcine	  keratinocyte	  culture	  
3T3 cells for porcine keratinocyte culture were maintained as previously described in 
section 2.2.3 maintenance of 3T3 cells for human keratinocyte culture but in a different 
laboratory.  
2.2.8	  Collagen	  coating	  of	  culture	  flasks	  	  
Pig keratinocytes were grown in vitro in culture flasks coated with rat tail collagen type 
I. A stock solution of rat tail collagen was made by dissolving 10 mg of rat tail collagen 
type I in 40 ml of 0.1 M acetic acid and left on a stirrer for 2 hours.  
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160 ml of tissue culture grade distilled water were added to make 200 ml in total. 
Chloroform was then used to sterilise the solution by dripping the chloroform liquid on 
a glass rod touching the bottom of the container, and this was left overnight at 4°C. In 
the morning, the sterile rat tail type I collagen solution was pipetted from underneath the 
chloroform.  
75 cm2 tissue culture flasks were coated by contact with 10 ml of collagen solution for 2 
hours. The collagen solution was aspirated and the flasks were allowed to dry with the 
caps off for 4 hours. 
The flasks could be stored at room temperature for up to one month and the collagen 
solution could be used up to 3 times before discarding. Immediately prior to use the 
culture flasks were rinsed with 10 ml of Hanks Balanced Salt Solution (HBSS).  
2.2.9	  Porcine	  keratinocyte	  isolation	  	  
A different isolation protocol was used for porcine keratinocyte isolation to address the 
higher risk of contamination and culture infection in porcine keratinocyte culture. 
Porcine split thickness skin grafts were wrapped in a sterile gauze swab and placed into 
a 50 ml Falcon® tube containing 20 ml of porcine keratinocyte transport solution. 
Following transport to the laboratory, the skin was divided into small pieces measuring 
about 3 x 3 cm using a sterile disposable size 15 scalpel in a sterile petri dish. The skin 
samples were washed 5 times using transport solution in 5 different 50 ml Falcon® 
tubes, each tube is placed on a shaker for 1 minute at 200 rpm. Once removed the skin 
was placed into a solution of 20 ml of 2 mg/ml filtered Dispase® containing 200 
units/ml Penicillin, 200 µg/ml Streptomycin and 1.25 µg/ml Amphotericin at 4°C 
overnight.  
The following day at room temperature, a further 5 ml of Dispase® were added and the 
tube placed in an orbital shaker at 37°C for one hour at 30 rpm. The epidermis was then 
separated gently from the dermis. The epidermis was then washed using the transport 
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solution and placed into 10 ml of 0.25% trypsin solution containing 200 units/ml 
Penicillin, 200 µg/ml Streptomycin. This was left in the orbital shaker at 37°C for one 
hour. The epidermis was removed from the trypsin solution and the inferior surface 
abraded using sterile curved forceps to remove the keratinocytes. The trypsin was 
inactivated using 10 ml Optimem® and 10% foetal calf serum and centrifuged for 5 
minutes at 400g. The supernatant was aspirated and the cell pellet re-suspended in 
porcine keratinocyte growth medium and a cell count performed using a 
haemocytometer.  
2.2.10	  Porcine	  keratinocyte	  cell	  culture	  	  
The 75 cm2 flasks previously coated with rat tail collagen were washed with HBSS and 
seeded with 2 x106 irradiated 3T3 cells in porcine keratinocyte culture medium. The 
flasks were incubated for 2 hours at 37°C prior to isolating the pig keratinocytes. The 
pig keratinocytes were seeded at a density of 4 x106 per 75 cm2 flask in 10 ml of growth 
medium. The medium was replaced every 48 hours and 90% confluence was reached 
after one week. Confluence was estimated by the size of newly formed colonies within 
10 fields (x5) magnification in each flask. 
When 90% confluence was reached, the keratinocytes were passaged using 0.05% 
trypsin / 0.02% EDTA. The flasks were washed three times with HBSS and then HBSS 
was aspirated. 5 ml of trypsin were added to each 75 cm2 flask and the flasks incubated 
at 37°C for 10 minutes. The trypsin was neutralized with 5 ml growth medium and a 
cell count performed using a haemocytometer. The keratinocytes were then sub-cultured 
in a ratio of 1:4 into rat tail collagen coated flasks pre-seeded with irradiated 3T3 cells 2 
hours before the addition of porcine keratinocytes. These secondary cultures reached 
90% confluence in 3-4 days. Over a period of 3 weeks, after the cultures are passaged 
for about 4 times, the keratinocytes were harvested at 50% confluence the day prior to 
application to reduce the effect of contact inhibition on proliferation post application. 
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For cell spray suspension preparation, a cell count was performed using a 
haemocytometer and the keratinocytes re-suspended in growth medium (without foetal 
calf serum) at a concentration of 107 cells/ml.  
2.2.11	  Porcine	  fibroblast	  isolation	  
Pig skin samples were harvested, transported and stored overnight as described in 2.2.9 
Porcine keratinocyte isolation. 
The following day at room temperature, a further 5 ml of Dispase® were added and the 
tube placed in an orbital shaker at 37°C for one hour at 30 rpm. The epidermis was then 
separated gently from the dermis. The dermis was then washed using the transport 
solution and placed into 5 ml of collagenase (defrosted just before use). This was left in 
the orbital shaker at 37°C for 2 hours. 5 ml of 3T3 growth medium were added to 
dermis and collagenase and pipetted through a cell strainer into a Falcon® tube 
containing further 5 ml of 3T3 growth medium. Another 10 ml of 3T3 growth medium 
were added and the tube centrifuged for 5 minutes at 400g. The supernatant was 
aspirated and the cell pellet re-suspended in 10 ml of 3T3 growth medium and a cell 
count performed using a haemocytometer. The fibroblasts were seeded 1 x 106 cells/75 
cm2 flask and incubated at 37°C 5% CO2. 
2.2.12	  Porcine	  fibroblast	  cell	  culture	  
The 3T3 growth medium was replaced after the first 24 hours and then every 48 hours 
and 90% confluence was reached after 4-5 days.  
When 90% confluence was reached, the fibroblasts were passaged using 0.05% 
trypsin/0.02% EDTA. The flasks were washed three times with HBSS and then HBSS 
was aspirated. 5 ml of trypsin were added to each 75 cm2 flask and the flasks incubated 
at 37°C for 5 minutes. The trypsin was neutralized with 5 ml 3T3 growth medium and a 
cell count performed using a haemocytometer. The fibroblasts were then sub-cultured in 
a ratio of 1:10 into 75 cm2 flasks. These secondary cultures reached 90% confluence in 
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3-4 days. The fibroblasts were harvested at 50% confluence the day prior to application. 
For cell spray suspension preparation, a cell count was performed using a 
haemocytometer and the fibroblasts re-suspended in 3T3 growth medium. 
2.2.13	  Maintenance	  of	  the	  retroviral	  cell	  producer	  line	  	  
The retroviral producer cell line PT67pFB-hrGFP A2 clone cell line was maintained as 
the Swiss mouse 3T3 fibroblasts in section 2.2.3 using PT67 growth medium. 
	  2.2.14	   Retroviral	   transduction	   of	   porcine	   keratinocytes	   with	   the	   GFP	  
gene	  vectors	  
The ViraPort™ retroviral vector pFB-HrGFP (Stratagene), containing the humanised 
form of the green fluorescent protein (GFP) from the “sea pansy Renilla Reniformis”,  
was used to transfect a RetroPack PT67 packaging cell line (Clontech) according to the 
manufacturer’s instructions using Lipofectamine Plus™ reagent.  
Cells were cultured under selective pressure in DMEM with GlutaMAX™, sodium 
pyruvate, 4.5 gm/l glucose, and 10% foetal calf serum. Fluorescent colonies were 
isolated, expanded and screened for production of the virus containing the hrGFP 
protein. Screening was done using fluorescent microscopy by inspection of 10 fields 
(x20) magnification and counting fluorescent colonies. The PT67pFB-hrGFPClone A2 
cell line was maintained as described in section 2.2.113. The cells were stored in liquid 
nitrogen and then thawed one week prior to the start of the porcine keratinocyte cell 
culture. 
Following the PT67pFB-hrGFPClone A2 cell harvest as described in section 2.2.3 
maintenance of 3T3 cell culture, a cell count was performed using a haemocytometer. 
The medium was then removed and DMSO (Dimethyl Sulphoxide) 10% v/v added to 
give a final concentration of 3 x 106/ml. DMSO was used to reduce intracellular 
metabolism prior to freezing, and to act as “antifreeze” to protect cells from ice crystals 
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formation during freezing or thawing. 1 ml of the cell suspension was added to each 
freezing vial. The vials were labeled with cell line, number of passage, cell count, 
project number, and date. The freezing vials were placed in a beaker containing ice then 
in a freezing plastic vessel (BiCell® freezing vessel, Osaka, Japan) at freezing rate of 
approximately -1°C per minute prior to storage in a -70°C freezer overnight. The next 
day the freezing vials were transferred to a liquid nitrogen storage tank. 
When required, the PT67pFB-hrGFPClone A2 cells were thawed after removal from 
liquid nitrogen tank to around 37°C in a warm water beaker, taking care the cells did not 
touch the cap of the vial. The cells were pipetted from each vial and placed in a 
universal tube. 10 ml cold DMEM were slowly dripped on the cells. The total volume 
was topped to 20 ml using cold DMEM and the cells spun at 400g for 4 minutes. The 
medium was aspirated from above the cells, and the cell pellet re-suspended in 20 ml 
DMEM and 10% foetal calf serum. The cells were again spun at 400g for 4 minutes, 
medium aspirated, and the cell pellet re-suspended in warm PT67 growth medium. A 
cell count was performed using a haemocytometer and the PT67pFB-hrGFPClone A2 
cell density seeding in the flasks was; 1 x 106 in 75 cm2 flask and 2.5 x 106 in 175 cm2 
flask. PT67 growth medium was added; 10 ml in 75 cm2 flask and 30 ml in 175 cm2 
flask. The flasks were incubated at 37°C humidity 98% and 5% CO2. 
Once the porcine keratinocytes had undergone their first passage, the medium in the 
PT67pFB-hrGFPClone A2 flask was changed to the porcine keratinocyte growth 
medium and placed into an incubator at 37°C and 5% CO2 for 2 hours. The flask was 
then transferred to a 32°C incubator for 48 hours. The medium was removed from the 
flasks and spun down at 3600 rpm for 10 minutes. The supernatant was then removed 
and pooled.  
The medium in the porcine keratinocytes flasks was then removed and replaced with the 
pooled medium. These flasks were placed back into the 37°C incubator and 5% CO2 for 
2 hours. They were then transferred to a 32°C incubator for 48 hours. Following this the 
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flasks were rinsed with HBSS twice and fresh porcine keratinocyte growth medium and 
3T3 cells were added. The porcine keratinocyte cell culture continued as described in 
section 2.2.10. The transduction frequency was then calculated as in section 2.2.15, and 
the process repeated following the next passage prior to keratinocyte cell harvest for in 
vivo application.  
2.2.15	  Calculation	  of	  transduction	  frequency	  
 
The flasks containing the transduced keratinocytes were examined using the inverted 
fluorescent microscope. The keratinocytes expressing Green Fluorescent protein (GFP) 
in each flask were counted in ten areas (field width 2 mm) at x40 magnification. This 
was compared with the total number of keratinocytes in similar ten areas (field width 2 
mm) using the same magnification; a percentage was calculated to give an estimate of 
the transduction rate. 
Following keratinocyte harvest for in vivo application, after the cell count was 
performed, a second cell count was performed using the inverted fluorescent 
microscope to again confirm the transduction frequency. Transduction frequency was 
found to be around 75% prior to in vivo application.  
2.2.16	  Keratinocyte	  cell	  seeding	  on	  microcarrier	  beads	  
 
2 g of Cultispher G® microcarrier beads were reconstituted in 100 ml PBS for one hour 
and sterilised in autoclave. The beads were stored at 4°C refrigerator for up to two 
weeks. 
Prior to use, the microcarriers were washed three times, twice in PBS and once using 
keratinocyte growth medium. When cultured keratinocytes reached 80–90% confluence, 
the cells were harvested from culture flasks using 0.05% trypsin. 
The keratinocytes were transferred to a 100 ml Cellspin™ magnetic stirrer flask at a 
seeding density of 5 x 106 cells per 5 ml of microcarrier stock solution in a total volume 
of 40 ml keratinocyte growth medium. No 3T3 cells were added to the culture flask. As 
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described by Borg et al. (2009) cultures were left static for 24 hours, and then stirred at 
45 rpm for 5 minutes with 40 minute static intervals. 50% of the growth medium was 
replaced three times per week after stopping the stirrer and allowing the beads to settle 
in the bottom of the flask. At day 7, the total volume was increased to 100 ml and the 
speed to 50 rpm with continuous stirring. 
2.2.17	  MTT	  staining	  of	  keratinocytes	  on	  microcarrier	  beads	  
 
1 ml was pipetted from the culture vessel (either Falcon® tube or stirrer flask) 
containing keratinocytes on microcarrier beads. MTT was dissolved in Ca++ and Mg++ 
free PBS to a final concentration of 5 mg/ml. MTT was then added to the 100 µl culture 
aspirate 1:10 to a final concentration of 0.5 mg/ml, followed by incubation at 37°C for 
45 minutes.  
The medium was then removed from the beads and replaced with HBSS. The viable 
cells attached to the microcarrier beads were visible using phase-contrast microscopy. 
Enzymes within viable keratinocytes reduce MTT to formazan, which has a distinctive 
blue colour. 
2.2.18	  Acridine	  orange	  staining	  of	  keratinocytes	  on	  microcarrier	  beads	  
 
Acridine orange is a nitrogen heterocyclic chromophore containing the acridine nucleus, 
which binds to DNA and RNA by intercalation between successive base pairs to 
produce a broad emission band in the green to red wavelength region (Kimmel et al. 
1986). Acridine orange is excited by blue-green laser light (488 nm) or by ultraviolet, 
violet, and blue interference filters coupled to an arc-discharge lamp (mercury or 
xenon). 
1 ml was pipetted from the culture vessel (either Falcon® tube or stirrer flask) containing 
keratinocytes on microcarrier beads. Acridine orange was dissolved in distilled water to 
a final concentration of 1 mg/ml. Acridine orange was then added to the 1 ml culture 
aspirate 1:10 to a final concentration of 0.1 mg/ml, followed by incubation at 37°C for 
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15 minutes. The medium was then removed from the beads and replaced with HBSS. 
The cells attached to the microcarrier beads were visible using ultraviolet microscope. 
Acridine orange is excited by blue-green laser light (488 nm) or by ultraviolet, violet, 
and blue interference filters coupled to an arc-discharge lamp (mercury or xenon). 
Excitation maximum shifts to 460 nm (blue), and the emission maximum shifts to 650 
nm (red). RNA staining within keratinocytes produced an orange colour.  
2.2.19	  Keratinocyte	  cell	  count	  using	  Trypan	  blue	  
 
Trypan blue chromophore penetrates the damaged wall of non-viable cells staining the 
cells blue. A cell count using a haemocytometer was done following Trypan blue 
application.  
The magnetic stirrer was switched off and the flask carefully moved to the safety 
cabinet. 1 ml of keratinocyte cell suspension was aspirated from the stirrer flask after 
gentle pipetting to avoid the microcarriers settling down the stirrer flask. The 1 ml 
suspension was placed in a screw cap tube and spun for 4 minutes at 1500 rpm. The 
microcarriers were dissolved and the cells dissociated using 0.25 ml trypsin and 
incubated at 37°C for 10 minutes. After 10 minutes, all the beads were dissolved as 
observed visually and the keratinocytes were preserved. 1 ml of keratinocyte growth 
medium was added and the tube re-spun for 2 minutes at 1500 rpm. The medium is 
aspirated and the cell pellet re-suspended in 100 µl of keratinocyte growth medium prior 
to the addition of 0.25 ml Trypan blue. A haemocytometer was used for cell count using 
the microscope, where both stained and non-stained (i.e. viable) cells were counted. 
Each cell count was repeated 3 times and an average cell count calculated. 
2.2.20	  Sample	  preparation	  for	  Scanning	  Electron	  Microscopy	  (SEM)	  
Porcine keratinocytes were isolated as described in 2.2.9, cultured as described in 
2.2.10, and seeded on microcarrier beads as described in 2.2.16.  
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On day 8, the stirred culture was switched to static for 15 minutes and the microcarriers 
allowed to settle down the stirrer flask. Inside the safety cabinet, 2 ml of microcarriers 
and keratinocytes were pipetted from the bottom of the flask. The microcarriers and 
keratinocytes were washed twice using PBS and fixed with 2.5% glutaraldehyde in 
0.1M Cacodylate buffer (pH 7.2-7.4) for 40 minutes at 4ºC. 
The microcarriers and keratinocytes were rinsed using 0.1M Cacodylate buffer twice. 
This was followed by dehydration with graded series (increasing concentration) of 
ethanol for 5 minutes each; 25%, 50%, 75%, 90%, and 100% (twice). The microcarriers 
and keratinocytes were dried using Hexamethyldisilasane (HMDS). The samples were 
immersed in HMDS for 3 minutes, left to air dry in a fume cupboard overnigh. The next 
morning, the samples were mounted on SEM aluminium stubs (Agar scientific, 
Stansted, Essex, UK). 
The samples were sputter coated to ensure a conductive pathway for the electron beam 
through the non-conductive specimens using Leit-C conductive carbon cement (Agar 
scientific, Stansted, Essex, UK). Then the samples were coated a very thin coating of 
palladium metal using a sputter coater (Polaron SC7640, Quorum Technologies Ltd., 
Lewes, East Sussex, UK). The samples were viewed using SEM (JEOL JSM-6310 with 
spatial resolution 1-2.5 nm), University of Brighton, East Sussex, UK. 
2.2.21	  MTT	  assay	  of	  porcine	  keratinocytes	  on	  microcarrier	  beads	  
 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) reduction assay 
was used to quantify porcine keratinocyte proliferation.  
Porcine keratinocytes were isolated as described in 2.2.9, and cultured as described in 
2.2.10. The keratinocytes were seeded on microcarrier beads in stirred culture as 
described in 2.2.16. The magnetic stirrer was stopped and microcarriers left to settle at 
the bottom of the flask. The flask was placed inside the safety cabinet.  
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500 µl samples containing microcarriers and cells in duplicates were aspirated from the 
stirrer flask. The medium was replaced with fresh medium containing 10% MTT. 
Samples were incubated for 4 hours at 37°C and washed with PBS to remove unbound 
MTT. The resulting formazan crystals were dissolved using vortex spinner in 1 ml of 
dimethyl sulfoxide. 100 µl of each sample was plated in triplicates in 96-well plates, 
followed by reading the absorbance at 590 nm (Reference ﬁlter 620 nm, Sunrise plate 
reader, Tecan® group, Switzerland). Absorbance readings were plotted against a 
standard curve obtained using a serial dilution of porcine keratinocytes. 
 
Figure 4: Standard curve for MTT assay against KC cell count 
MTT assay results used to calculate KC cell count, a linear relationship between MTT assay readings and 
the KC cell count within stirred culture was seen 
 
 
Keratinocyte cell count was calculated using MTT assay readings from serial porcine 
keratinocyte cell counts isolated from stirred microcarrier culture previously. The 
readings showed a linear relationship up to sample count of 10 000 cells (figure 6).  
Using a standard equation (Tecan® product information) in Microsoft Excel® sheet 
using the assay reading for the sample, the cell count within the sample was calculated. 
2.2.22	  RNA	  isolation	  from	  porcine	  keratinocytes	  on	  microcarrier	  beads	  
 
Porcine keratinocytes were isolated as described in 2.2.9, cultured as described in 
2.2.10, and seeded on microcarriers in stirred culture as described in 2.2.16. 
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On day 10, the magnetic stirrer was stopped and the microcarriers allowed settling for 
15 minutes prior to aspiration of 10 ml of microcarriers and keratinocytes. The beads 
were incubated with 0.25 ml trypsin at 37°C for 10-15 minutes to dissolve the beads and 
dissociate the keratinocytes. Trypan blue cell count was performed and the total number 
of keratinocytes/ml calculated. The medium was gently aspirated using pipette. 5 ml 
HBSS were added to wash beads, left to settle and aspirated as before. 
The beads were covered with 5 ml 0.5% trypsin/HBSS solution and left for 10-15 
minutes at 37°C until the beads were dissolved. 5 ml culture medium were added and 
centrifuged at 1500 rpm for 4 minutes. The culture medium was aspirated and fresh 5 
ml medium added, final cell count confirmed, and centrifuged at 1500 rpm for 4 
minutes. The culture medium is then aspirated and 350 µl Buffer RLT® (proprietary 
name) were added and homogenised by pipetting up and down.  
Qiagen RNeasy mini kit® was used and buffers were adjusted according to cell count. 
The lysate was homogenised by centrifuging for 2 minutes at 1500 rpm then 350 µl of 
75% ethanol were added and homogenised by pipetting up and down. The 700 µl 
sample was transferred to a collection tube and the tube was labelled on the side and the 
top. The tube was spun in a mini-centrifuge at 10 000 rpm for 15 seconds (The 15 
seconds were counted after 8000 rpm). The flow-through was aspirated and discarded 
and 350 µl of Buffer RLT® (proprietary name) added. The tube was spun again at 10 
000 rpm for 15 seconds, and the flow-through aspirated and discarded. 350 µl wash 
Buffer RWI® (proprietary name) were added and the sample spun at 10 000 rpm for 15 
seconds, the flow-through aspirated and discarded. 500 µl of Buffer RPE® (proprietary 
name) were added and sample was spun at 10 000 rpm for 15 seconds, the flow-through 
aspirated and discarded. 500 µl of Buffer RPE® were added and the sample spun at 10 
000 rpm for 2 minutes, the flow-through aspirated and discarded. The sample was 
transferred to a new tube and 30 µl RNase® free water were added, and sample was 
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spun at 10 000 rpm for 1 minute. Another 30 µl RNase® free water were added and 
sample was spun at 10 000 rpm for 1 minute. 
SYBR Green II gel kit® was used to ensure purity of RNA sample initially then Quant-
iT RNA assay kit® was used to quantify RNA concentration. Two 200 µl of working 
solutions were prepared (1 µl RNA reagent: 199 µl RNA buffer) for each standard and 
each sample. Two RNA standards were prepared each in 190 µl working solution: 10 µl 
standard. The samples were prepared in 199 µl working solution: 1 µl sample. RNA 
measurement was done using Qubit® Flurometer measuring 2 x standards followed by 
measurement of RNA in each sample. 
2.2.23	  Real-­‐time	  quantitative	  PCR	  (qPCR)	  K14	  mRNA	  from	  porcine	  
keratinocytes	  on	  microcarrier	  beads	  
 
Porcine keratinocytes were isolated as described in 2.2.9, and cultured as described in 
2.2.10. The keratinocytes were seeded on microcarrier beads in stirred culture as 
described in 2.2.16. On day 10, the samples were prepared for RNA isolation as 
described in 2.2.19. SYBR Green II kit® was used for generating full-length cDNA 
from RNA and K14 mRNA measurement using QuantiTect SYBR Green PCR Kit®. 
cDNA synthesis reactions were performed in duplicates and then used as a template for 
thermal cycling. cDNA synthesis mix was prepared for 1 reaction in a total volume of 
20 µl as shown below (table 2): 
Component Volume 
Enzyme mix 1 ul 
5x cDNA synthesis buffer 4 ul 
RNA primer (Mouse K14 F & R) 1 ul 
dNTP mix (Promega: U1511) 2 ul 
Water 11 ul 
Template 1 ul 
Total 20 ul  
 
Table 2: Preparation of cDNA synthesis mix 
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The volumes of the components were added to a pre-chilled sterile vial, which was kept 
on ice at all times. Following mixing 20 µl of each reaction was transferred to two 
empty replicate wells and the tubes sealed. The tubes were incubated at 42°C for 30 
minutes followed by reverse transcription (RT) inactivation at 95°C for 2 minutes (pre-
programmed in SYBR Green II®-Step 1 programme). The duplicates were pooled 
together to produce 40 µl of cDNA sample. The concentration of the sample was 
measured using Quant-iT ssDNA assay kit® for use with Qubit® Flurometer. 
For SYBR Green II®-Step 2, working mixes were prepared in triplicates for each cDNA 
dilution and non-template control (NTC). The volume of each component for 1 reaction 
was 25 µl; 24 µl were prepared as shown below: 
Component Volume 
QPCR Master Mix 12.5 ul 
Primer Forward (Mouse K14-F) 2.5  ul 
Primer Reverse (Mouse K14-R) 2.5 ul 
Water 6.5 ul 
Total 24 ul 
 
Table 3: Preparation of SYBR Green II®-Step 2 working mix 
 
Optimisation of SYBR Green II® qPCR reactions was performed as per manufacturers’ 
instructions to exhibit good amplification efficiency over a broad dynamic range. The 
optimal annealing temperature was identified for each assay through running pre-assay 
samples on agarose gel. 24 µl of working mix were added to each well of PCR plate, 1 
µl of template was added to each set of triplicates and 1 µl of water to each set of NTC. 
The plate was sealed using heat seal and centrifuged briefly to ensure reaction mix in 
the bottom of each well. The plate was then placed in the Bio-Rad Cycler. 
For thermal cycling, the following conditions were pre-programmed in the SYBR Green 
II®-Step 2 programme: 
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Cycle Step Temperature Duration 
Cycle 1 (1x) 
Step 1 (activation 
step) 95°C  15 mins 
Cycle 2 (50x) Step 1 (denaturation) 95°C  15 secs 
 Step 2 (annealing) 60°C  20 secs 
 Step 3 (extension) 72°C  20 secs 
Data collection and real-time analysis 
Cycle 3 (1x) Step 1 95°C  30 secs 
Cycle 4 (1x) Step 1 55°C  30 secs 
Cycle 5 (80x) Step 1 55°C  10 secs 
Increase set point temperature after cycle 4 by 0.5˚C 
Melt Curve data collection 
 
Table 4: Thermal cycling SYBR Green II®-Step 2 programme 
 
Relative expression of the target gene was calculated using the 2 ΔCT method described 
by Livak and Schmittgen (2001). Relative K14 mRNA expression was assessed on days 
14 and 21 of microcarriers culture. 
2.3 In vivo animal wound model 
2.3.1	  Animals	  	  
Female out-bred white pigs aged 4-5 weeks and weighing 20-25 kg, were supplied by 
Bury Farm, Edgware, England.  
2.3.2	  Animal	  husbandry	  
Animal experiments were carried out under the UK Home Office project license 
PPL80/2215 and personal license PIL80/11190 in accordance with the Animals 
(Scientific Procedures) Act 1986. The animal studies were performed at Northwick Park 
Institute for Medical Research (NPIMR), Harrow, London.  
The pigs were delivered 7-10 days prior to the first operative procedure to allow the 
animals to become familiar with their surroundings according to the rules of good 
husbandry. The animals were initially housed during the acclimatization period in pens 
accommodating up to 6 pigs at a time.  
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Following the first procedure (skin graft harvesting), the animals were placed in 
individual pens in order to avoid trauma to the wounds and disruption of dressings.  
At the start of each procedure the animals weighed between 20-30 kg. Animals were 
kept starved pre-operatively overnight as with standard general anaesthesia. There were 
no unplanned animal deaths during the in vivo studies. 
2.3.3	  Animal	  anaesthesia	  and	  euthanasia	  	  
All in vivo procedures were performed under general anaesthesia. Animals were enticed 
into a mobile covered container where they were pre-medicated with an intramuscular 
injection of Xylazine® 1 mg/kg and Ketamine® 5 mg/kg. The animals were then 
transported to the operating theatre and given inhalation anaesthesia using an animal 
specific face mask. This was a combination of 2-5% halothane and 3-5 l/min of nitrous 
oxide and oxygen (1:1) and this was used to maintain anaesthesia during the procedure. 
Pressure points (flexed knee joints of all four limbs) were protected throughout the 
procedure with appropriate cotton wool padding.  
Antibiotic prophylaxis was given on induction for all procedures including dressing 
changes by a single intramuscular injection of Ampicillin® 25mg/kg. Postoperative 
analgesia included the application of topical 2% Lignocaine® gel to skin graft donor 
sites, and a subcutaneous injection of Carprofen (Xenecarp®) 4 mg/kg once daily for 2-3 
days after the procedure. An anti-parasitic “Ivermectin” (Ivomec®, Merial Animal 
Health Ltd) 1 ml subcutaneous injection into the neck was given after the first 
procedure only. 
Euthanasia was carried out after wounds excision for histological analysis; the animal 
was put under general anaesthesia followed by an intramuscular injection of 140 mg/kg 
Pentobarbitone (Expirol®).  
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2.3.4	  Harvesting	  of	  split	  thickness	  skin	  grafts	  	  
Spilt thickness skin grafts were harvested either for harvesting porcine keratinocytes for 
cell cultures or for application alone or in combination with other treatments as part of 
the in vivo experiments. 
The para-vertebral area on the animal back was shaved and cleaned with a scrubbing 
brush using chlorhexidine 4% scrub (Hydrex®). Then, the skin was prepared using 0.5% 
chlorhexidine in alcohol; normal saline (sodium chloride 0.9%) was used to wash it off. 
Then a further prep with povidine iodine 10% in aqueous solution (Betadine®) was 
done. This was left for five minutes and then washed off with sterile alcohol 70% and 
allowed to evaporate. The animal was then draped with sterile surgical drapes.  
The skin was then coated in sterile liquid paraffin to allow easy glide of the dermatome. 
A single skin graft sheet (8 x 8 cm) was harvested from each animal using the Zimmer® 
air dermatome at a standard setting to achieve thickness of 600 µm. 
The skin graft for harvesting keratinocytes was wrapped in sterile gauze, placed into a 
sterile container soaked in the transport medium.  
The donor site was then dressed with topical 2% Lignocaine® gel, paraffin gauze 
dressing (Jelonet®) and Betadine® soaked gauze. The donor site was healed in 2-3 
weeks time and could be harvested again if required. 
2.3.5	  Creation	  of	  full	  thickness	  wounds	  with	  PTFE	  chambers	  
Six full thickness wounds were made on each pig, three on each flank. Skin grafts were 
harvested previously from each animal, and the wounds were sited away from the donor 
site for skin graft harvesting. The flanks of each animal were prepared first by shaving 
with an electric clipper and then a hand held razor and then prepared as described in 
section 2.3.3. The animal was draped with sterile surgical towels.  
Full thickness wounds were made on the flanks using a sterile cardboard template (4 cm 
in diameter) and cut out using a size 10 scalpel. The wounds were made through the 
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epidermis, dermis, subcutaneous fat and the “panniculus carnosus” layer; hence the 
fascia overlying the muscle was the wound bed.  
In order to prevent wound healing from the edges and keratinocyte migration from the 
wound edges, Polytetrafluoroethylene (PTFE) chambers were inserted into the wounds. 
To allow the insertion of the wound chambers, the wound edges were undermined by 
1cm and a 1 cm incision was made in the edge of the wound at the 3 o’clock margin. A 
preset hole in the chamber edge at the 3 o’clock margin was used to secure it in position 
using 2/0 silk sutures. The wounds either had cultured keratinocytes on microcarrier 
beads or as cell spray with/without meshed split skin graft applied or were left untreated 
a control group. The wounds were dressed with Telfa clear™ and covered with Jelonet® 
and lightly packed gauze. The outermost gauze was soaked with Betadine® and gauze 
soaked in Betadine® was wrapped around the outside of the chamber. The flanks were 
wrapped in Velband® cotton wool bandage and secured with Elastoplast® and Mefix® 
adhesive tape. Custom-made foam jackets were applied and secured using Velcro® tape.  
Throughout the in vivo animal experiments, the foam jackets remained secured in place, 
and there was no incidence of the animals removing them between dressing changes. 
2.3.6	  Creation	  of	  square	  wounds	  for	  assessment	  of	  wound	  contraction	  
The animals were anaesthetised as described in 2.3.3. Three square-shaped wounds 
were created on the flank of each animal measuring 4 x 4 cm using a sterile plastic 
template. STSG was harvested from one flank (not previously used for STSG harvesting 
for keratinocyte culture) using Zimmer® air dermatome (800 µm thick) and meshed 6:1 
using carriers and Zimmer® mesher. The STSG was applied to the wounds and inset 
using 3M™ skin staples and treatments applied according to a preoperative randomised 
allocation. 
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2.3.7	  Measurement	  of	  wound	  surface	  area	  using	  Visitrak™	  system	  
For the assessment of wound contraction in square wounds, the surface area of each 
wound was directly traced using Visitrak™ transparent sheet, and the surface area 
measured on Visitrak™ device at each dressing change. 
The sheet was held in place by an assistant to trace the wound on the animal’s back 
maintaining contact with the wound edges during the process. For each wound, the 
tracing was repeated 3 times and an average calculated at each time point. 
2.3.8	  Tissue	  processing	  	  
A whole wound excision biopsy after removal of the PTFE chamber was performed 
following termination of the animals, at fixed time periods throughout the study. After 
terminal anaesthesia with a lethal dose of barbiturates the PTFE chamber was removed 
and whole wounds were excised. The time between initiation of anaesthesia and wound 
excision did not exceed one hour. The wound biopsy was then divided into four 
quadrants. Each of these sections was placed into folded aluminum foils, with the 
relevant sectioning face marked. The folded aluminum foils were filled with optimal 
cutting temperature compound (OCT) and frozen by immersing in liquid nitrogen.  
The sections were stored at -40°C. 15µm thick frozen sections were cut using a 
cryotome in an insulated cabinet at -20°C. 
2.4 Histology 
2.4.1	  Haematoxylin	  and	  Eosin	  staining	  (H&E)	  	  
 Haematoxylin and Eosin (H&E) staining was performed for basic assessment of re-
epithelialisation in vivo. Slides were air dried overnight then stained in haematoxylin for 
1 minute, washed in running tap water for 5 minutes. The slides were then stained in 
0.5% aqueous eosin for 5 minutes and dehydrated in ascending concentrations of 
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alcohol (30%, 70%, and absolute by volume). The slides were immersed in xylene and 
agitated for 2 minutes then immersed for further 4 minutes in static xylene. The slides 
were mounted in Distyrene Plasticiser and Xylene (DPX). OCT allowed a greater 
surface area for the section to stick and provided a slight temperature difference 
between the slide and the section to improve adherence. The sections were sealed with 
50mm coverslips and left to air-dry flat overnight.  
2.4.2	  Immunohistochemistry	  	  
Immunohistochemistry was performed using nickel enhancement of the avidin-biotin 
complex (ABC) method. This was used to visualise specific cell structure within the 
tissue sections. The primary antibody attaches to the targeted protein, the secondary 
antibody couples to the primary antibody and is then visualised under standard 
microscopy. 
Immunohistochemistry was used to visualise cytokeratin 14 (K14), a marker for basal 
keratinocytes (Abcam, UK, 1:250), laminin, an early marker of basement membrane 
formation (Abcam, UK, 1:250), collagen VII, a late marker of the basement membrane 
(Abcam, UK, 1:200), and alpha-smooth muscle actin (α  SMA) (Sigma, UK, 1:200), a 
marker for myofibroblasts. Positive controls were prepared from pig skin specimens 
away from the experiment wounds. Negative controls were prepared from muscle fascia 
underneath the skin specimens used for positive controls. 
Optimal antibody concentration was judged as being the concentration at which the 
greatest contrast was seen in the expected structures or areas of the cell or tissue. The 
final concentration was selected after producing positive staining in more than 5 out of 
10 positive control sections, while no staining was noted in the negative sections.  
Collagen VII was detected using ABC staining kit, K14, laminin and alpha-smooth 
muscle actin were detected using DyLight secondary antibodies and mounted in 
Vectamount with DAPI.  
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Prepared sections 12 - 15 µm-thick as described in section 2.3.6, and 200 µl of 
serum/antibody solution were required to cover each slide. The tissue sections were 
fixed in acetone/methanol (1:1) for 20 minutes at room temperature, rinsed in phosphate 
buffered saline (PBS) 3 times for 3 minutes each time. The sections were then placed 
into a humidified chamber and incubated for 30 minutes at 20°C (room temperature) 
with normal serum of the species used for secondary antibody preparation (Serum 
diluted 1:30 with PBS). After incubation, serum was blotted off without rinsing and the 
primary antibody, one of listed earlier, was applied at optimal dilution (1:200 or 1:250). 
Slides were incubated with primary antibody in a dark humidified chamber at 20°C for 
one hour. After incubation, the tissue sections were rinsed in PBS for 5 minutes. The 
secondary antibody was applied (ABC 1:100 and Dylight 1:150) then the sections 
incubated at 20°C for one hour. The secondary antibodies were optimized previously 
using serial dilutions (1:50, 1:100, 1:150, 1:200 and 1:250) followed by comparing the 
quality of staining. The sections were rinsed in PBS for 5 minutes and 3,3'-
Diaminobenzidine (DAB) substrate added and then further incubated for 10 minutes at 
room temperature until suitable staining developed. 
The DAB substrate (Vector labs, Ca, USA) was prepared as per manufacturer’s 
instructions using standard dropper (supplied with DAB kit, drop = 0.25 ml) by adding 
2 drops of buffer stock solution to 5 drops distilled water and mixed well. Then 4 drops 
of DAB stock solution were added and mixed well followed by adding 2 drops of 
hydrogen peroxide solution and mixed well. Since grey-black stain was desired, 2 drops 
of nickel solution were added and mixed well. The tissue sections were dehydrated in 
70% industrial methylated spirit (IMS) for 30 seconds then 100% IMS twice for 2 
minutes, then the sections were immersed in xylene and agitated for 2 minutes, then 
immersed for further 4 minutes in static xylene. The slides were mounted in DPX or 
DAPI (4',6-diamidino-2-phenylindole) anti-fade mountant (for immunofluorescence), 
and sealed with 50 mm coverslips and left to air-dry flat overnight. 
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2.5 Data analysis 
2.5.1	  Clinical	  analysis	   
During each in vivo experiment, wounds were macroscopically assessed for infection, 
epithelialisation, graft take, granulation tissue formation or any other complications.   
Wound photographs were taken with a Canon EOS 300D digital camera during dressing 
changes to document wound appearance for qualitative assessment.   
2.5.2	  Image	  analysis	   
Digital photographs of histological sections for image analysis were taken with a Spot 
1.1.0 (Diagnostic Instruments Inc., USA) and Olympus DP71 microscope-mounted 
camera (Olympus UK Ltd., UK) using standard settings from positive controls (standard 
settings for light intensity, gain, exposure time and offset were used in all experiments). 
Images were analysed using ImageJ® (National Institute of Health, USA) to detect the 
GFP-positive area in five random standard areas per section. For statistical analysis, 
multiple measurements were compared between different treatment groups using 
ANOVA (all pair-wise comparison).  
	  2.5.3	  Statistical	  analysis	   
Statistical analysis of data was performed and graphically represented using SigmaStat® 
3.5 (Systat Software UK Ltd., UK) and Microsoft Office Excel® 2003 (Microsoft 
Corporation, USA) software packages. Experimental groups were analysed using one-
way analysis of variance (ANOVA) and mixed model analysis of variance (t-test, 
Kruskal-Wallis test, and Holm-Sidak post hoc test) using Sigmastat® (Systat Software 
Inc., California, USA). 
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Chapter 3: An investigation into in vitro keratinocyte 
cell culture on microcarrier beads 
 
3.1	  Comparative	  analysis	  of	   two	  types	  of	  gelatin	  microcarrier	  beads	   for	  
the	  culture	  of	  keratinocytes	  in	  vitro	  
3.1.1	  Study	  objectives	  
The aim of this study was to establish a consistent and reliable method for keratinocyte 
cell culture in vitro on microcarrier beads. The use of biodegradable microcarriers 
would negate the need for trypsinisation prior to keratinocyte transferral to the wound 
bed. Trypan blue was used to compare keratinocyte cell count in vitro on microcarrier 
beads with standard culture.  
3.1.2	  Keratinocyte	  cell	  culture	  in	  cell	  rotator	  and	  magnetic	  stirrer	  	  
Keratinocytes were isolated from the skin samples as described in 2.2.4, and the 
keratinocyte cell cultures were maintained as described in 2.2.5.  
Following primary expansion for 7-10 days, keratinocytes were isolated from tissue 
culture flasks and seeded onto either Cultispher G® or Cultispher S® in static culture in 
15 ml Falcon® tubes; 1.25 x 105 cells, 2.5 ml of medium and 2.5 ml of microcarriers. 
Tubes were incubated at 37°C in 5% CO2 in a rotator (Fisher Scientific UK Ltd., 
Loughborough, UK) (figure 7) programmed to rotate full 360° 32 times in 24 hours 
(minimum rotation setting in 24 hours).  
Cultispher G® was used for keratinocyte culture in Cellspin™ magnetic stirrer flasks 
(figure 8). The seeding density was 1 x 106 cells/5 ml of microcarrier beads solution (2 
gm/100 ml) in a total of 40 ml of culture medium as described in 2.2.16. 
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Figure 5: Keratinocyte cell culture in Falcon®  tubes in a rotator.  
The rotator was kept in an incubator and set at the minimum setting for rotation in 24 hours to minimise 
culture agitation 
 
 
Figure 6: Keratinocyte cell culture in stirrer flask on a magnetic stirring unit.  
The stirrer flask and the stirring unit were kept in an incubator during the period of the experiment 
 
On Days 4, 8, 12, 18, 24 and 30, 100 µL of beads were removed using a sterile pipette, 
the beads were then added to 1:10 of either MTT as described in 2.2.17 (figure 9), or 
acridine orange as described in 2.2.18 (figure 10). MTT was used to detect 
metabolically active cells and acridine orange for general cell visualisation. 
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Figure 7: MTT staining keratinocyte cell culture on microcarrier beads day 4 
Dark stained keratinocytes following MTT staining seen attached to the surface of Cultispher G® 
microcarriers (x40 magnification, field width 0.9 mm) 
 
 
Figure 8: Acridine orange staining keratinocyte cell culture on microcarrier beads day 4 
Orange stained keratinocytes following Acridine orange staining seen attached to the surface of 
Cultispher G® microcarrier (x40 magnification, field width 0.9 mm) 
 
Alamar Blue® can successfully evaluate cellular health and is an indicator of cell 
viability. Alamar Blue® was added to 0.1 ml of keratinocytes and microcarrier beads 
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(1:10) then incubated at 37°C for 3 hours. 100 µl of each sample was plated in 
triplicates in 96-well plates, followed by reading the absorbance at 570 and 600 nm 
(Sunrise plate reader, Tecan® group, Switzerland). Negative control 96-well plate 
containing culture medium and microcarriers only was used initially to confirm zero 
absorbance in absence of keratinocytes. The reading was proportional to the number of 
viable cells and corresponded to the cellular metabolic activity. Finally, results were 
analysed by plotting fluorescence intensity (or absorbance) at different time points as 
percentage of Alamar Blue® reduction (fluorescence intensity) above control reading.  
	  3.1.3	  Viable	  keratinocyte	  cell	  count	  using	  Trypan	  blue	  
Keratinocytes were isolated from the skin samples and cultured as described in 2.2.1 
and 2.2.4, and maintained as described in 2.2.5.  
Following primary expansion for 7-10 days, keratinocytes were isolated from tissue 
culture flasks and seeded onto microcarriers as described in 2.2.16. Two tissue culture 
flasks were maintained as described before to compare cell counts with stirred culture. 
Cell count was performed at the following time points: day 6, day 10 and day 14.  
3.1.4	  Results	  
 
Standardisation of microscopy was performed as per Blond Mcindoe Research 
Foundation standard operating procedure using the same microscope with identical 
settings. Cultispher G® and S® supported Keratinocyte cell culture in cell rotator as 
demonstrated by MTT and acridine Orange staining. Figure 11 shows Cultishper G® 
and S® MTT staining at days 4 and 18. Clusters of dark stained keratinocytes were 
observed attached to the microcarriers indicating cellular attachment. 
Figure 12 shows similar findings as keratinocytes are seen attached to Cultispher G® 
and S® following staining with Acridine Orange at days 4 and 18. The orange colour of 
stained RNA within keratinocytes is seen attached to the surface of the microcarriers 
with increasing density from day 4 to day 18.  
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 Day 4     Day 18    
 
Cultispher G® + keratinocyte cell culture in cell rotator D4 and D18 
Dark stained keratinocytes on microcarriers surface showing increase in cell attachment and distribution 
across beads’ surface from day 4 to day 8 (x20 magnification, field width 1.8 mm)  
 
 Day 4     Day 18 
 
 
 
Cultispher S® + keratinocyte cell culture in cell rotator D4 and D18 
Dark stained keratinocytes on microcarriers showing increase in cell numbers and distribution on beads’ 
surface (left x40 and right x20 magnification, field width 0.9 mm and 1.8 mm respectively) 
 
Figure 9: Cultispher G® & S® + cultured keratinocytes MTT staining days 4 and  
 Day 4      Day 18    
 
 
Cultispher G® + keratinocyte cell culture in cell rotator D4 and D18 
Orange stained RNA within keratinocytes attached to the surface of microcarriers showing increase in 
cells attachment and distribution on beads’ surface from day 4 to day 18 (left x40 and right x20 
magnification, field width 0.9 mm and 1.8 mm respectively) 
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 Day 4      Day 18 
 
 
Cultispher S® + keratinocyte cell culture in cell rotator D4 and D18 
Orange stained RNA within keratinocytes attached to the surface of microcarriers showing increased cell 
attachment and distribution on beads’ surface from day 4 to day 18 (x20 magnification, field width 1.8 
mm) 
 
Figure 10: Cultispher G® & S® + cultured keratinocytes acridine orange staining days 4 and 18 
 
Successful keratinocytes attachment to both types of microcarrier beads started from as 
early as day 4 and continued throughout the following time points up to day 30. 
Alamar Blue® is a cell viability indicator that uses the natural reducing power of living 
cells to convert resazurin to the fluorescent molecule, resorufin. The active ingredient of 
Alamar Blue® (resazurin) is a nontoxic, cell permeable compound that is blue in colour 
and virtually non-fluorescent.  Upon entering cells, resazurin is reduced to resorufin, 
which produces bright red fluorescence. Viable cells continuously convert resazurin to 
resorufin, hence generating a quantitative measure of viability. 
Alamar Blue® reduction as percentage of increased reading compared to similar 
volumes of culture medium and microcarriers without keratinocytes indicated 
progressive increase in viable cells (figure 13).  
Around day 18 to day 20, a decrease in keratinocyte population was observed followed 
by an increase (figure 13). The reduction in viable keratinocytes could be explained by 
the turnover of keratinocytes within the culture, which occurs around 21 days. 
Based on the initial qualitative and quantitative data, no significant difference was 
shown between the two types of Cultispher® microcarriers.  
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Figure 11: Alamar Blue® reduction keratinocyte cell culture on Cultispher G® & S® in cell rotator 
(Error bars refer to standard deviation). 
 
 Day 4      Day 18    
 
Cultispher G® + keratinocyte cell culture in magnetic stirrer (AO staining) D4 and D18 
Orange stained RNA within keratinocytes attached to the surface of microcarriers showing increased cell 
attachment and distribution on beads from day 4 to day 18 (x20 magnification, field width 1.8 mm) 
 
Day 4      Day 18  
 
 
 
Cultispher G® + keratinocyte cell culture in magnetic stirrer (MTT staining) D4 and D18 
Dark stained keratinocytes on microcarriers surface showing increased cell attachment and distribution on 
beads’ surface from day 4 to day 18 (x20 magnification, field width 1.8 mm) 
 
Figure 12: Acridine orange & MTT staining Cultispher G® + keratinocyte cell culture in magnetic 
stirrer flask D4 and D18 
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Since according to the manufacturer’s information sheet, Cultispher G® microcarriers 
have more uniform pores and more suitable for anchorage dependent cells, Cultispher 
G® was chosen for keratinocyte culture in a magnetic stirrer flask.  
Using the magnetic stirrer culture, MTT and Acridine orange staining demonstrated 
keratinocyte attachment and distribution across Cultispher G® microcarriers surface 
throughout different time points in stirred culture as shown in figure 14. 
Alamar Blue® assay was performed as described previously, with samples in triplicates 
compared to readings from negative controls of culture medium and microcarriers only. 
Alamar Blue® assay demonstrated increased reduction percentage in comparison with 
rotator culture throughout the culture period. A slight decrease in proliferation was 
noticed at day 18, which was followed an increase at later time points as shown in 
figure 15. As previously observed with the rotator culture, this could be possibly 
explained by the keratinocytes turnover within the culture around day 21. 
 
Figure 13: Alamar Blue® reduction keratinocyte cell culture on Cultispher G® in stirrer flask  
(Error bars refer to standard deviation) 
 
Quantitative and qualitative data demonstrated keratinocytes attachment to 
microcarriers and an increase in viable cell populations within both static and stirred 
culture over different time points. Viable keratinocyte cell count doubled at consecutive 
 83 
time points (day 6 and 10). By day 14, keratinocyte cell number was comparable to 
similar cell populations obtained from tissue culture flasks (table 5). Cell counts were 
repeated 3 times for each time point and an average calculated. 
The presence of microcarrier beads within the stirred culture provided a large surface 
area for keratinocyte attachment. This compensates for the change in culture conditions 
compared to the traditional keratinocyte cell culture in tissue flasks. Keratinocytes in 
culture flasks showed an increased cell count of around 1 x 106 between days 10 to 14. 
 
Time point Human KC in Culture flasks Human KC on Microcarriers 
Day 0 5* 5 
Day 6 15.9* 15.5 
Day 10 41.2* 40.1 
Day 14 63.4* 62.2 
* Cell count from tissue culture flasks (175 cm2). All counts x 106 
 
Table 5: Cell count using Trypan blue comparing keratinocytes in culture flasks vs. keratinocytes 
on microcarriers 
 
 
 
 
 
Figure 14: Cell count using Trypan blue comparing keratinocytes in culture flasks vs. keratinocytes 
on microcarriers (Error bars refer to standard deviation) 
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3.2	   Assessment	   of	   in	   vitro	   migration	   of	   porcine	   keratinocytes	   from	  
microcarrier	  beads	  to	  monolayer	  tissue	  culture	  
3.2.1	  Study	  objectives	  
The aim of this study was to assess the ability of porcine keratinocytes to migrate off 
the microcarriers’ surface while retaining their ability to proliferate in culture 
conditions. The biodegradation of the microcarriers can be assessed in static culture 
conditions as an indicator for future application on wounds in vivo. 
3.2.2	   Porcine	   keratinocytes	   migration	   from	   microcarrier	   beads	   to	   tissue	  
culture	  flasks	  
 
Porcine keratinocytes were isolated from the porcine skin samples as described in 2.2.9 
and maintained as described in 2.2.10. Porcine keratinocytes were seeded on 
microcarrier beads in stirred culture as described in 2.2.16. 
On Day 8 of the stirred culture, the continuous stirring was stopped for 10 minutes and 
the microcarrier beads allowed to settle in the lower half of the flask. 1 ml of 
microcarrier beads was pipetted from the flask inside a safety cabinet. This was seeded 
into 75 ml tissue culture flask as described before and maintained as in 2.2.10. 
Images were taken at days 3, 6, and 10 to assess keratinocytes migration, colony 
formation, and confluence. 
3.2.3	  Results	  
Microcarrier beads seeded with porcine keratinocytes transferred to tissue culture flasks 
biodegraded without causing infection within the culture. The presence of the 
microcarrier beads did not influence the migration of the keratinocytes from the beads 
to the tissue culture flasks’ surface.  
The ability of porcine keratinocytes to form colonies in culture flasks and further 
confluence demonstrated cell migration from microcarriers to the surface of the culture 
flasks.  
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Figure 15: Cluster of microcarriers seeded with porcine keratinocytes in tissue culture flask (day 3) 
Microcarrier bead (red arrow) with keratinocytes attached to the surface surrounded by 3T3 cells attached 
to the surface of the culture flask day 3 (x40 magnification, field width 0.9 mm) 
 
 
 
 
Figure 16: Microcarriers seeded with porcine keratinocytes in tissue culture flask (day 6). 
Keratinocyte colony (blue arrow) and 3T3 cells (red arrow) attached to the surface of the culture flask, 
remnants of microcarrier bead seen surrounding the keratinocytes colony day 6 (x40 magnification, field 
width 0.9 mm) 
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Figure 17: Microcarriers seeded with porcine keratinocytes in tissue culture flask (day 9). 
Keratinocytes colony (red arrow) and remnants of microcarrier beads seen surrounding the keratinocytes 
colony day 9 (x40 magnification, field width 0.9 mm) 
 
These observational findings were limited in outlining the effect of microcarriers on the 
migration of keratinocytes in static culture. Further studies are required to thoroughly 
investigate the effect of microcarriers on keratinocyte migration in vitro. 
As seen in figure 17, the microcarrier bead was seen surrounded by 3T3 cells and no 
porcine keratinocyte colonies on day 3. In figure 18, by day 6, microcarrier beads 
started to dissolve, and a porcine keratinocyte colony was seen surrounded by the 
remnants of the microcarrier beads. In figure 19, by day 9, the keratinocytes were 80-
90% confluent following the beads dissolution having migrated successfully from the 
surface of the beads to the tissue culture flask. Representative images in the previous 
figures were selected which were typical of the cell behaviour observed. 
There was no evidence available to describe the exact number of keratinocytes, which 
migrated from the microcarriers’ surface to the culture flask. From the observational 
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findings, sufficient numbers of keratinocytes expanded in the culture flasks, survived 
the migration process, and formed confluent colonies (figure 19). 
Cultispher G® gelatin microcarrier beads can be biologically inert as they safely 
dissolved in static culture allowing keratinocyte migration to the surface of the culture 
flask. The expansion of keratinocytes in culture was maintained and keratinocytes were 
able to achieve early signs of confluence. 
3.3	   Assessment	   of	   porcine	   keratinocyte	   attachment	   on	   microcarrier	  
beads	  using	  Scanning	  Electron	  Microscopy	  (SEM)	  
3.3.1	  Study	  objectives	  
The aim of this study was qualitative assessment of cellular attachment of porcine 
keratinocytes to the porous surface of the gelatin microcarriers. The study would 
provide an examination of the relationship between keratinocytes, which are anchorage 
dependent cells, in cell culture and the surface of microcarriers in stirred culture. 
3.3.2	  Assessing	  porcine	  keratinocyte	  attachment	  on	  microcarrier	  beads	  using	  
Scanning	  Electron	  Microscopy	  (SEM)	  
 
Porcine keratinocytes were isolated as described in 2.2.9, cultured as described in 
2.2.10, and seeded on microcarrier beads as described in 2.2.16.  
The samples were prepared as described in 2.2.20, and viewed using SEM (JEOL JSM-
6310 with spatial resolution 1-2.5 nm), University of Brighton, East Sussex, UK. The 
resolution of the SEM depends on the size of the electron spot, which in turn depends 
on both the wavelength of the electrons and the electron-optical system that produces 
the scanning beam. 
Image is generated by an electron beam focused by one or two condenser lenses to a 
spot about 1-2.5 nm in diameter. The beam passes through pairs of scanning coils or 
pairs of deflector plates in the electron column, typically in the final lens, which deflect 
the beam in the x and y axes scanning over a rectangular area of the sample surface.  
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The energy exchange between the electron beam and the sample results in the reflection 
of high-energy electrons by elastic scattering, emission of secondary electrons by 
inelastic scattering and the emission of electromagnetic radiation, each of which can be 
detected by specialized detectors. Electronic amplifiers of various types are used to 
amplify the signals, which are displayed as variations in brightness on a computer 
monitor. Each pixel of computer is synchronized with the position of the beam on the 
specimen in the microscope, and the resulting image is therefore a distribution map of 
the intensity of the signal being emitted from the scanned area of the specimen.  
3.3.3	  Results	  
 
 
 
Figure 18: Cultispher G® microcarrier SEM 
The porous surface of the microcarrier bead can be seen clearly allowing expansion of the surface area 
available for cell attachment 
 
 
Figure 20 and 21 demonstrate the average size of microcarrier beads between 150-200 
µm (The range of Cultispher G® micorcarriers is 130-380 µm) 
http://www.percell.se/products.htm 
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Figure 19: Cultispher G® seeded with porcine keratinocytes day 8 SEM 
The porous surface of the microcarrier bead was obscured by the porcine keratinocytes attached to the 
surface of the microcarrier 
 
 
Figure 20: Cultispher G® surface seeded with porcine keratinocytes day 8 SEM 
A closer image of the porcine keratinocytes (spherical cells) attached to the surface of the microcarrier 
 
Cultispher G® gelatin microcarriers have a porous surface with pores range approximate 
1-10 µm, which expands the surface available for keratinocyte attachment as seen in 
figure 20. SEM images of microcarriers and porcine keratinocytes at day 8 showed a 
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confluent layer of porcine keratinocytes attached to the surface of the microcarrier 
obscuring the porous surface (figure 21). At higher magnification the microcarrier 
surface (figure 22) showed the attachment of the porcine keratinocytes to the 
microcarrier surface possibly in multi-layers.  
Although not visible by SEM, the porosity of the microcarriers could increases the 
surface area available for cellular attachment in a confined space compared to tissue 
culture flasks. Porcine keratinocytes attached to the microcarrier surface in stirred 
culture utilising the external porous surface as demonstrated using SEM images. 
Cultispher G® microcarrier beads supported porcine keratinocyte attachment and 
provided a suitable alternative to traditional tissue culture flasks. 
Many factors are essential for cells to adhere to the surface of a culture vessel; divalent 
cations and growth factors within the culture medium are two examples (Grinnell 1978). 
Foetal calf serum within the culture medium is the main source of proteins within the 
culture medium. The microcarriers were washed in the porcine keratinocyte growth 
medium prior to seeding with keratinocytes and the beads’ surface is negatively charged 
during the manufacturing process. Hence keratinocyte attachment to the microcarriers’ 
surface was possible as demonstrated by the SEM images (figure 22). 
3.4	   Comparative	   analysis	   of	   porcine	   keratinocyte	   proliferation	  
with/without	  feeder	  3T3	  cells	  in	  stirred	  culture	  
3.4.1	  Study	  objectives	  
The aim of this study was to assess porcine keratinocytes growth and expansion in 
stirred microcarrier culture with and without the use of feeder 3T3 cells. The 
comparison of data would allow planning for cell application in a porcine wound model. 
Porcine keratinocytes growth and expansion was assessed using Acridine orange 
staining, MTT staining, and Trypan blue cell count at specific time points. 
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3.4.2	   Porcine	   keratinocyte	   proliferation	   with/without	   feeder	   3T3	   cells	   in	  
stirred	  culture	  
 
Porcine keratinocytes were isolated as described in 2.2.9, cultured as described in 
2.2.10, and seeded on microcarrier beads as described in 2.2.16. A second 100 ml 
Cellspin™ magnetic stirrer flask was set up with same seeding density and 2 x 106 
freshly harvested 3T3 cells. Both flasks were maintained as described before and the 
second flask containing 3T3 cells was maintained as described in 2.2.7. 
Qualitative assessment of keratinocyte growth in the two flasks was undertaken using 
Acridine orange staining, MTT staining, and Trypan blue cell count at days 3, 6, 9, and 
12. The time points were related to the culture stirring protocol described in 2.2.16. Day 
12 was the final time point prior to discarding the cultures and terminating the study. 
3.4.3	  Results	  
Microcarriers were found to support the growth of porcine keratinocytes with or without 
3T3 feeder cells in stirred suspension culture, following initial expansion of 
keratinocytes in tissue culture flasks.  
Acridine orange staining at days 3, 6, 9, and 12 showed porcine keratinocytes cultured 
in the presence or absence of 3T3 cells populating the surface of the microcarrier beads 
(figures 23 & 24). MTT staining at days 3, 6, 9, and 12 showed porcine keratinocytes 
cultured in the presence or absence of 3T3 cells populating the surface of the 
microcarrier beads (figures 25 & 26). Both sets of qualitative assessment through 
cellular attachment to the surface of the microcarriers showed expansion of porcine 
keratinocytes with or without 3T3 cells in the culture medium in the stirred culture. 3T3 
feeder cells were used for the initial expansion of the keratinocytes in tissue culture 
flasks prior to seeding on microcarrier beads. 
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Figure 21: AO staining day 3; keratinocytes + 3T3 (upper) & keratinocytes without 3T3 (lower) 
Orange stained RNA within keratinocytes attached to the surface of microcarriers in the presence of 3T3 
cells (above) and without 3T3 (below) (x10 magnification, field width 3.6 mm) 
 
(A) Kera(nocytes/+/3T3/cells/
(B)  Kera(nocytes/without/
3T3/cells/
Day 9 
 
 
Figure 22: AO staining day 9; keratinocytes + 3T3 (upper) & keratinocytes without 3T3 (lower) 
Orange stained RNA within keratinocytes attached to the surface of microcarriers, more cells attached 
compared to day 3 (x40 (top) and x20 (lower) magnification, field width 0.9 and 1.8 mm respectively) 
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Figure 23: MTT staining day 6; keratinocytes + 3T3 (upper) & keratinocytes without 3T3 (lower) 
Dark stained keratinocytes (containing reduced formazan) attached to the surface of microcarriers in the 
presence of 3T3 cells (above) and without 3T3 (below) (x10 magnification, field width 3.6 mm) 
 
(A) Kera(nocytes/+/3T3/cells/
(B)  Kera(nocytes/without/
3T3/cells/
Day 12 
 
 
Figure 24: MTT staining day 12; keratinocytes + 3T3 (upper) & keratinocytes without 3T3 (lower) 
Dark stained keratinocytes (containing reduced formazan) attached to the surface of microcarriers (x40 
magnification (top) and x20 magnification (lower), field width 0.9 mm and 1.8 mm respectively) 
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Trypan blue was used for keratinocytes counts after dissolving microcarriers on days 3, 
6, 9, and 12 as shown in figure 27, the cell count was done 3 times and an average 
calculated. Keratinocyte cell counts in both stirrer flasks in the presence or absence of 
3T3 cells in stirred culture (figure 27) was similar with slightly more cells in the culture 
without 3T3 cells. Keratinocyte expansion was also similar with matching cell count 
increasing over the same period of time. The increase in cell counts seen in culture 
without 3T3 cells averages from < 1 x 106 at day 3 to around 3 x 106 at day 12. Both 
porcine keratinocytes cultured with and without 3T3 demonstrated expansion of the 
keratinocytes during the culture period. 
The cell counts from both groups were compared using t-test, the results demonstrated 
95% confidence interval for difference of means -49.42 to 45.17, and the power was 
0.05 (below desired power of 0.8). The difference in the mean values of the two groups 
was not great enough to reject the possibility that the difference was due to random 
sampling variability. The difference was not statistically significant with a p value of 
0.916. 
 
 
Figure 25: Comparison between KC cell count +/- 3T3 at days 3, 6, 9, and 12  
(Error bars refer to standard deviation) 
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Human keratinocytes have been cultured on microcarrier beads without 3T3 cells (Borg 
et al. 2009) following initial expansion in tissue culture flasks containing 3T3 cells. 
Porcine keratinocytes expansion occurred in stirred culture in the absence of 3T3 cells 
and cell counts were slightly higher when compared to cultures containing 3T3 cells. 
The ability to expand porcine keratinocytes in the absence of 3T3 cells would negate the 
use of 3T3 cells in cultures for in vivo animal models as it would reduce the risk of 
infection, culture contamination, and reduce culture maintenance requirements. 
3.5	   Quantitative	   assessment	   of	   porcine	   keratinocyte	   proliferation	   on	  
microcarrier	  beads	  (MTT	  assay,	  RNA	  isolation	  and	  real-­‐time	  quantitative	  
PCR)	  
3.5.1	  Study	  objectives	  
The aim of the study was to quantify porcine keratinocyte proliferation on microcarriers 
using MTT assay and K14 expression using total RNA isolation followed by real-time 
quantitative PCR. 
3.5.2	  MTT	  assay	  of	  porcine	  keratinocytes	  on	  microcarrier	  beads	  
 
Porcine keratinocytes were isolated as described in 2.2.9, cultured as described in 
2.2.10, and seeded on microcarrier beads as described in 2.2.16. 
MTT assay was performed as described in 2.2.21 on days 7, 14, and 21. A standard 
curve was used for comparison as described in 2.2.21. 
3.5.3	  RNA	  isolation	  from	  porcine	  keratinocytes	  on	  microcarrier	  beads	  
Porcine keratinocytes were isolated as described in 2.2.9, cultured as described in 
2.2.10, and seeded on microcarrier beads as described in 2.2.16. RNA isolation was 
performed as described in 2.2.22 on day 10. 
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3.5.4	  Real-­‐time	  quantitative	  PCR	  (qPCR)	  K14	  mRNA	  from	  porcine	  keratinocytes	  
on	  microcarrier	  beads	  
 
Porcine keratinocytes were isolated as described in 2.2.9, cultured as described in 
2.2.10, and seeded on microcarrier beads as described in 2.2.16. Real-time qPCR 
isolation was performed as described in 2.2.23 on day 14 and 21. 
3.5.5	  Results	  
MTT assay results: 
Initially, For MTT assay, at each time point, the samples were processed in triplicate 
wells and an average reading for each volume calculated. 
 
 
 
Figure 26: MTT assay vs. sample volumes Days 7, 14, and 21  
(Error bars refer to standard deviation) 
 
MTT assay reading plotted versus sample volume with increased assay readings from 
day 7 to day 21 demonstrating keratinocytes expansion and possibly proliferation across 
increasing sample volumes from 5 µl to 60 µl (figure 28).  
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Figure 27: Porcine keratinocyte cell count x 106 calculated using MTT assay results  
 
Using Tecan® reader software (Tecan group Ltd., Theale, Reading, UK), the assay 
reading from different sample volumes was used to calculate the total number of cells in 
culture at different time points (figure 29). Cell counts increased from 1 x 106/ml on day 
1 to 2.2 x 106/ml on day 21 (figure 29). No keratinocytes expansion was noted up to day 
7 followed by notable increase in cell count on days 14 and 21. 
 
Total RNA isolation results: 
For quantifying RNA, readings were taken at wavelength 260 nm. The readings allowed 
calculation of the concentration of nucleic acid in the sample.  
Volume (ml) Standard sample ng/µl Diluted sample ng/µl 
0.1 215 43 
0.25 130 25.9 
0.5 174 34.8 
0.75 209 41.7 
0.85 180 55.9 
0.95 483 96.6 
1 364 72.9 
1.25 487 97.5 
1.5 522 104.3 
 
Table 6: RNA isolation measurement microcarriers + porcine keratinocytes day 10 
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Figure 28: Chart representation of RNA isolation measurements in standard and diluted samples 
porcine keratinocytes + keratinocytes day 10 
 
For assessment of RNA integrity, the intensity of the RNA was analysed in diluted 
samples 1:5 for example; 20 µl from 0.1 ml (100 µl) sample. The readings from the 
diluted samples were 1:5 of the standard sample readings, with the exception of 
readings from 0.85 ml sample which was equivalent to 1:3. Since it was a single 
inconsistent reading, it was attributed to sample degradation or possible contamination 
of the standard sample. Total RNA measurement from porcine keratinocytes culture on 
microcarriers on day 10 was 255 ng/µl in 10 ml sample from 100 ml spinner flask. 
Figure 30 demonstrates the relation between the standard and diluted RNA isolation 
samples. RNA isolation measurements on day 10 were used as a baseline for RNA 
isolation on days 14 and 21, as it was used in the preliminary stages of real-time qPCR. 
Real-time quantitative PCR (qPCR) K14 results: 
K14 is a marker of basal keratinocytes, which can be used to monitor keratinocytes 
proliferation. As basal keratinocytes differentiate and migrate towards the skin surface, 
down regulation of K14 occurs (Alam et al. 2011).  
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Relative expression of K14 mRNA was calculated using the 2 ΔCT method described 
by Livak and Schmittgen (2001) where relative expression = 2-ΔCT , where ΔCT = 
CTTarget gene – CTGAPDH (GAPDH Glyceraldehyde 3-phosphate dehydrogenase).  
Relative quantification relates the PCR signal of the target transcript in a treatment 
group to that of another sample such as an untreated control. The 2 ∆CT method is a 
convenient way to analyze the relative changes in gene expression from real-time 
quantitative PCR experiments (Livak and Schmittgen 2001). Normalizing to an 
endogenous reference provides a method for correcting results for differing amounts of 
input RNA. The 2 ∆CT method uses data generated as part of the real-time PCR 
experiment to perform the normalization function. This method was chosen, as it was 
not practical to measure the amount of input RNA by other available methods.  
Real-time qPCR assay of K14 was done on days 14 and 21 since the day 14 time point 
would represent the future end point for porcine keratinocytes culture for in vivo animal 
studies. Day 21 was chosen as a comparable time point to the harvest of epithelial 
sheets from traditional keratinocytes culture in culture flasks. 
On the melt curve, one peak was observed and the PCR amplification curve and melt 
curve were saved (figure 31). The fold change in the target gene relative to the GAPDH 
endogenous control gene was calculated using Excel.  
The fold change was calculated by applying the equation 2-∆(∆CT). K14 assay was 
positive using qRT-PCR confirming porcine keratinocyte proliferation in microcarrier 
beads culture. Quantitative K14 assay showed significant increase from day 14 to day 
21, which reflected proliferation of porcine keratinocytes in stirred microcarriers 
culture. 
The results of qRT-PCR of K14 in day 14 and 21 showed increase in K14 expression 
demonstrating keratinocyte proliferation (figure 32). The results of qRT-PCR were 
different from the MTT assay, as the MTT assay demonstrated keratinocyte expansion 
in the stirred culture over the same period. 
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Figure 29: Melting curve SYBR Green 2 qRT-PCR K14  
The melting curve demonstrates K14 peaking at 80-85°C in different sample volumes versus change in 
fluorescence with temperature (dRFU/dT) confirming the detection of K14 
 
 
 
 
Figure 30: qPCR K14 mRNA expression relative to GAPDH days 14 and 21 
Increase in K14 mRNA expression from D14 to D21 demonstrating basal keratinocytes proliferation 
 
 
Combining the two sets of data together demonstrated that porcine keratinocytes expand 
and proliferate well on microcarriers in spinner flask culture in vitro. 
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3.6	   Assessment	   of	   in	   vitro	   porcine	   keratinocytes	   and	   fibroblasts	   co-­‐
culture	  on	  microcarrier	  beads	  	  
3.6.1	  Study	  objectives	  
The aim of the study was to assess qualitative and quantitative porcine keratinocyte 
growth and proliferation in co-culture with autologous fibroblasts on microcarrier 
beads. Qualitative assessment was done using fluorescent microscopy after GFP 
labelling of porcine keratinocytes. Quantitative assessment was done using MTT assay 
at days 7 and 14. 
3.6.2	  Porcine	  keratinocytes	  and	  fibroblasts	  co-­‐culture	  on	  microcarrier	  beads	  
Porcine keratinocytes were isolated as described in 2.2.9, cultured as described in 
2.2.10, GFP labelled as described in 2.2.14, and transduction frequency calculated as 
described in 2.2.15. Porcine fibroblasts were isolated as described in 2.2.11, and 
cultured as described in 2.2.12. Keratinocytes and fibroblasts were seeded on 
microcarrier beads in ratio 6:1 similar to human keratinocyte-fibroblast co-culture 
(Jubin et al. 2011) as described in 2.2.16. GFP labelled keratinocytes were inspected 
using epifluorescent microscopy (blue range) days 3,6, and 9. MTT assay was used to 
quantify porcine keratinocyte proliferation in co-culture as described in 2.2.21. 
3.6.3	  Results	  
Porcine keratinocytes expansion was demonstrated in co-culture with porcine 
fibroblasts as shown by presence of GFP positive keratinocytes on microcarriers.  
GFP positive keratinocytes were seen attached to the surface of microcarriers on day 3 
(figure 33) using contrast phase and epifluorescent microscopy (blue range). 
Qualitative assessment showed that porcine keratinocytes formed colonies in the 
presence of ﬁbroblasts on microcarriers in stirred culture.  
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Figure 31: Porcine keratinocytes (GFP labelled) + porcine fibroblasts on microcarriers day 3 
(A) Keratinocytes and fibroblasts (dark colour) attached to microcarriers (Contrast phase) 
(B) Same field using epifluorescent microscopy demonstrating GFP +ve keratinocytes (green) attached to 
microcarriers (Both x10 magnification, field width 3.6 mm) 
 
 
The fibroblast: keratinocyte ratio of 6:1 allowed controlled expansion of both types of 
cells without fibroblasts overtaking the cultures. 
Fibroblasts supported the attachment and growth of keratinocytes in similar manner to 
irradiated 3T3 cells. The attachment of porcine keratinocytes to microcarrier beads and 
proliferation in culture at days 3 and 9 was similar to keratinocyte attachment to 
microcarriers in the absence of fibroblasts. GFP labelled porcine keratinocytes attached 
to microcarriers as demonstrated at different time points and the presence of fibroblasts 
did not have a negative impact on keratinocytes attachment or proliferation. 
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Figure 32: Porcine keratinocytes (GFP labelled) + porcine fibroblasts on microcarriers day 9 
(A) Keratinocytes and fibroblasts (dark colour) attached to microcarriers (Contrast phase) 
(B) Same field using epifluorescent microscopy demonstrating GFP +ve keratinocytes (green) attached to 
microcarriers (Both x20 magnification, field width 1.8 mm). 
 
MTT assay results; 
The results were compared to the porcine keratinocytes’ assay readings from 3.5.3 on 
days 7 and 14. 
 
Figure 33: MTT assay results day 7 porcine keratinocytes and keratinocytes + fibroblasts  
(Error bars refer to standard deviation) 
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Figure 34: MTT assay results day 14 porcine keratinocytes and keratinocytes + fibroblasts  
(Error bars refer to standard deviation) 
 
 
MTT assay results comparing porcine keratinocytes (P-KC) expansion to porcine 
keratinocytes combined with fibroblasts (P-KC+FB) showed similarly comparable 
results. Comparing the results from day 7 and day 14, P-KC+FB showed higher MTT 
assay results compared to P-KC alone. The difference in MTT assay was undetectable 
in small sample volumes 5-10 µl, and became more detectable in larger sample volumes 
> 30 µl and up to 60 µl. The gap in MTT assay results increased from day 7 to day 14 in 
sample volumes between 20-40 µl. 
MTT assay results from both groups on day 7 were compared using t-test, the results 
demonstrated 95% confidence interval for difference of means -0.03 to 0.02, and the 
power was 0.05 (below desired power of 0.8). The difference in the mean values of the 
two groups was not great enough to reject the possibility that the difference was due to 
random sampling variability. The difference was not statistically significant with p 
value 0.556. MTT assay results from both groups on day 14 were compared using t-test, 
the results demonstrated 95% confidence interval for difference of means -0.04 to 0.02, 
and the power was 0.05 (below desired power of 0.8). The difference in the mean values 
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of the two groups was not great enough to reject the possibility that the difference was 
due to random sampling variability. The difference was not statistically significant with 
p value 0.357. 
These results demonstrated the expansion of porcine keratinocytes in co-culture with 
porcine fibroblasts in stirred microcarriers culture. Quantitative assessment 
demonstrated expansion of porcine keratinocytes in the presence of porcine fibroblasts 
compared to keratinocytes alone. Porcine fibroblasts co-cultured with autologous 
keratinocytes (1:6) did not expand uncontrollably to overtake the culture as 
demonstrated by the survival of the GFP positive keratinocytes in co-culture. Therefore 
co-culture of porcine keratinocytes and fibroblasts in stirred microcarrier culture 
allowed keratinocyte expansion in vitro. 
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Chapter 4: An investigation into the survival of 
retroviral GFP labelled porcine keratinocytes on 
microcarrier beads compared to sprayed keratinocytes 
in full thickness animal wound model 
4.1	  Study	  objectives	  
PTFE (Polytetrafluroethylene) wound chambers were used to isolate the full-thickness 
wounds created in pigs against epidermal cell migration from the skin edge and wound 
contraction. The design of the PTFE wound chambers allows an extension from the 
outside rim of the chamber to sit underneath the wound skin edge. Hence, the chamber 
prevents epithelial migration from the wound edges and allows assessment of wound 
healing within the chamber in isolation. 
 
Figure 35: PTFE wound chamber 
 
 
 
The PTFE chamber has an edge sitting underneath the free skin edge to prevent migration of 
keratinocytes from the skin edges 
 
The aim of this study was to assess the rate of survival of porcine keratinocytes cultured 
on microcarriers in a full thickness porcine wound model. These were compared with 
sprayed cultured keratinocytes grown in traditional culture flasks. Also, the study aims 
to investigate the migration of porcine keratinocytes off microcarriers when applied to 
the porcine wound model and the effect on formation of permanent epithelium.  
GFP retroviral labelling was used to trace the cultured keratinocytes and their possible 
contribution to newly formed epithelium. Immunohistochemical staining for K14, 
laminin, and collagen VII will be used to assess the rate of epithelial formation. 
4.2	  Study	  design	  
Two pigs were used in this study and prior to the beginning of the study; the animals as 
described in 2.3.1 were admitted to NPIMR according to 2.3.2. 
4 cm 
Skin edge 
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In the first stage of the study, the animals were anaesthetised as described in 2.3.3 in a 
fully equipped theatre for animal surgical procedures (figure 38). 
One sheet of split skin graft measuring about 8 x 8 cm was harvested from each animal 
from the posterior part of the para-spinal area as described in 2.3.4 using Zimmer® air-
driven dermatome (figure 39). The skin graft was wrapped in saline soaked gauze and 
transported back to the lab in porcine keratinocyte transport medium the same day. 
 
 
Figure 36: Operating theatre NPIMR, Northwick Park, London 
The theatre is fully equipped with a surgical operating table and an anaesthetic machine 
(monitor/ventilator) for animal surgery 
 
 
Porcine keratinocytes were isolated as described in 2.2.9, and cultured as described in 
2.2.10. The flasks from each animal were clearly labelled and kept in separate shelves in 
an incubator at 37°C. 
After keratinocyte expansion for one week, GFP labelling of porcine keratinocytes was 
undertaken as described in 2.2.14. This was repeated again in the same week and the 
frequency of transduction calculated as described in 2.2.15. 
At the end of the second week, the flasks from each animal were divided and 
keratinocytes from half the flasks were seeded on microcarriers as described in 2.2.16.  
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Figure 37: Zimmer® dermatome ready for use. 
(©http://emedicine.medscape.com/article/876290-overview#aw2aab6b6) 
The dermatome is fitted with the blade (left) and a suitable sized guard is fitted (right) and secured in 
place using screwdriver. 
 
 
The keratinocytes on microcarriers remained in stirred culture for one week until 24 
hours prior to application in the second stage of the study. The magnetic stirrer was 
stopped and the flask transferred to a tissue culture hood, where the culture medium was 
aspirated. Cells were counted using a haemocytometer after dissolving the beads using 
trypsin. Keratinocytes were also harvested from the tissue culture flasks using trypsin, 
and counted. The cells were transferred to small Falcon® tubes in a concentration of 1 x 
107 in each tube ready for spray application. The microcarriers seeded with 
keratinocytes were transferred to universal tubes, each containing 1 x 107 cells in total. 
The cells from both groups were stored in a cool bag overnight prior to application the 
next morning.  
Three weeks after harvesting the skin grafts, the animals were anaesthetised as 
described in 2.3.3. Three wounds were created on the flank of each animal and PTFE 
wound chambers inserted as described in 2.3.5 as shown in figure 40 (3 on each flank). 
Treatments were applied accordingly as shown in figure 41. 
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Figure 38: Diagrammatic representation of the site of the PTFE wound chambers on the flank of 
the animal 
(3 wound chambers were located on each flank of each animal as shown) 
 
Microcarriers and keratinocytes, and the control group (microcarriers only) were 
applied using sterile pipettes. The sprayed keratinocytes were applied evenly using a 
sterile 5 ml syringe and a disposable sterile nozzle (Syringe spray nozzle, Coster 
Aerosols Ltd, Stevenage, UK) from a distance of about 10 cm. Wounds were dressed as 
described in 2.3.5 (figure 42). 
A dressing change was done under anaesthesia one week later using the same dressings 
and photographs taken. There was no incidence of dressings being removed by the 
animals or wound infections through the period of the study. 
The animals were terminated two weeks (Day 15) following treatment as described in 
2.3.3. Photographs were taken prior to extracting the wound chambers (from standard 
distance of 30 cm using the same camera with standard settings), the wounds were 
excised along the edges, and the specimens processed as described in 2.3.6. 
Histological examination of the specimens was done using Haematoxylin and Eosin as 
described in 2.4.1, and Immunohistochemistry for K14, laminin, and collagen VII was 
done as described in 2.4.2. Analysis of images from the tissue sections was done as 
described in 2.5.2. 
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There was 12 wounds in total; divided into 3 groups (4 wounds each) as follows;  
Group 1 Microcarriers and autologous keratinocytes 
Group 2 Sprayed autologous keratinocytes 
Group 3 (Control) Microcarriers only 
 
Figure 39: Wound chamber allocation Pig 1 (Exp 1.09) 
The allocation was decided on random basis, where pig 2 had the control wounds (red) allocated to 
different sites 
 
 
(A)                 (B) 
 
Figure 40: (A) Wound chambers post insertion (B) Dressings and foam jackets applied post 
procedure 
The wound chambers are secured in place using Silk suture (left) and foam jackets were applied to protect 
the underlying dressings (right) 
 
4.3	  Results	  
This preliminary study was designed to compare the rate of survival of autologous 
keratinocytes on microcarriers (MCAK) when introduced onto full thickness wounds 
compared to autologous-sprayed keratinocytes (SAK).  
Beads +KC 
Sprayed KC 
MC only 
Wound 
chambers’ 
allocation 
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The wounds were isolated within wound chambers to prevent re-epithelialisation from 
the wound margins and wound contraction. Hence, any newly formed epithelium within 
the chambers followed the application of either MCAK or SAK. 
 
Figure 41: The 3 treatment groups Days 7 and 15 
At day 15, MC-AK showed early signs of epithelial formation noted around the edges of the central 
granulating wound (left), while the control group showed granulation tissue without any signs of 
epithelial formation (right) 
 
The biocompatibility of the gelatin microcarriers “Cultispher G®” in the wound was 
assessed in the control group, where only microcarriers were applied. Degradation of 
the microcarriers in the control group would indicate the suitability for future 
application in vivo. The three treatment groups, microcarriers did not produce any 
adverse reactions. There was no incidence of wound infection and by 15 days, therefore 
it was assumed that all microcarriers either degraded, dissolved, or were processed 
within the 3 wound groups. There were no microcarriers retrieved from any of the 
wounds indicating that no gelatin microcarriers were still present within any of the 
wounds. 
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Figure 42: Tracing of GFP labelled keratinocytes and Hx & E staining in 3 treatment groups after 
2 weeks 
(A) Sections showing GFP positive keratinocytes within section surface in MC-AK and SAK, none in 
control group (red rectangle) 
(B) Hx and E staining showing keratinocytes arranged in layers as early newly formed epidermis in MC-
AK, and less uniform epithelium in SAK and granulation tissue in control groups (black rectangle) (x10 
magnification, field width 3.6 mm) 
 
GFP positive areas within the tissue sections were observed in the MCAK and SAK 
groups (figure 44a). These areas were located mainly on the surface of the wounds as 
seen on the surface of the sections (figure 44a, within red rectangle). The GFP +ve areas 
within the epidermis were more pronounced in the MCAK group compared to SAK 
group.  
Tissue sections from all wounds were assessed for GFP content including the control 
group (MC only). MC only wounds showed very low levels of auto-ﬂuorescence (figure 
44A, lower left), whereas MCAK and SAK wounds showed signiﬁcant GFP positive 
areas (figure 44a, top and middle left).  
A macro application within Axiovision® software was used to measure the GFP positive 
areas within three random sections from each wound quadrant in the 3 groups. 
 113 
Statistical analysis of the results was done using One Way Analysis of Variance on 
ranks (Kruskal-Wallis test). There was no statistically signiﬁcant difference in GFP 
positive areas between the MCAK and SAK groups. The results indicated a comparable 
level of migration of GFP positive keratinocytes from microcarriers to wound bed 
between the two application methods. 
Intact epithelium was not observed in any of the wounds at day 15 prior to animal 
termination. The wounds in the 3 treatment groups showed presence of granulation 
tissue covering the majority of the wound area within the wound chambers (figure 43, 
red tissue seen within PTFE chambers). The observation was confirmed by the findings 
of the Haematoxylin and Eosin (Hx & E) staining of tissue sections. There was no fully 
formed epithelium in any of the three groups; keratinocytes were arranged in flat even 
layers in the MCAK group (figure 44Bb, top). Observational assessment revealed the 
layers were less uniform in the SAK group with more irregular surface and absent in the 
control group (MC only) and replaced with granulation tissue (figure 44b, lower).   
Immunohistochemical staining for K14 was positive in the MCAK and SAK groups and 
negative in the control group (figure 45a). A macro application within Axiovision® 
software was used to measure K14 positive areas (2 x 2 mm) within three random 
sections from each wound quadrant in the 3 groups selected by an independent assessor.  
The macro application was able to measure K14 positive areas within the wounds’ 
sections after uploading a template of K14 positive section from normal pig skin 
initially. Statistical analysis of the results was done using One Way Analysis of 
Variance on ranks (Kruskal-Wallis test), and the p-value was <0.001. There was a 
statistically signiﬁcant difference in K14 positive areas between the MCAK and SAK 
groups. The MCAK group had more positive K14 areas compared to the SAK group. 
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Figure 43: (A) K14 and (B) Laminin immuno-staining for 3 treatment groups 
(A) K14 staining showing K14 positive keratinocytes (black colour) overlying the sections of MCAK and 
SAK (red rectangle) 
(B) Laminin staining showing dense bundle distribution towards the surface of the section in the MCAK 
and SAK groups (right top and middle, red rectangle) compared to flat distribution within the same layer 
of the section in the control group (right lower, red rectangle) (x10 magnification, field width 3.6 mm) 
 
Immunohistochemical staining for laminin showed striated distribution of bundles 
throughout the wound sections in the MCAK, SAK, and control groups (figure 45b). 
Observational assessment of the bundles’ distribution revealed more dense distribution 
throughout the sections from the MCAK and SAK groups (figure 45b, upper and middle 
right) compared to the control group, where laminin bundles were more flat in upper 
layers of the sections (figure 45b, right lower). The bundles’ density was denser towards 
the wound surface compared to the overall distribution in the granulation tissue of the 
control group (figure 45b, right column).  No clearly formed basement membrane, 
which is characteristic of fully formed epithelium, was seen in any of the three groups. 
Collagen VII was negative in the 3 treatment groups indicating the lack of formation of 
basement membrane within mature epithelium. 
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There was no evidence of residual microcarriers within the tissue specimens by day 15 
in the 3 treatment groups. The keratinocytes as evidenced by GFP positive areas 
migrated from the microcarriers to the wound surface in the MCAK and SAK groups.  
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Chapter 5: Investigation of wound healing and 
contraction rate of autologous keratinocytes on 
microcarriers, sprayed keratinocytes and widely 
meshed skin graft 
5.1	  Study	  objectives	  
The aim of this study was to investigate whether cultured autologous keratinocytes on 
microcarrier beads could reduce wound contraction in combination with widely meshed 
(6:1) split thickness skin graft (STSG). Their effect on wound contraction was 
compared with the combination of sprayed autologous keratinocytes and widely meshed 
STSG. Widely meshed STSG alone was used as a control. Wound contraction was 
assessed using serial measurements of the wound size using Visitrak™ at set time points. 
Epithelial regeneration and wound closure were assessed macroscopically using clinical 
observation and photography. Additionally, microscopic assessment using 
Haematoxylin and Eosin staining, and immunohistochemical staining for K14, collagen 
VII, and laminin was used to assess the rate of epithelial formation at 3 weeks. 
5.2	  Study	  design	  
Three pigs were used in this study as described in 2.3.1, and were admitted to NPIMR 
according to 2.3.2. In the first stage of the study, the animals were anaesthetised as 
described in 2.3.3, and one sheet of split skin graft measuring about 8 x 8 cm was 
harvested from the flank of each animal as described in 2.3.4.  
The skin graft was wrapped in saline soaked gauze and transported back to the lab in 
porcine keratinocyte transport medium the same day. Porcine keratinocytes were 
isolated as described in 2.2.9, cultured as described in 2.2.10, and each flask was clearly 
labelled and kept in separate shelves in an incubator at 37°C. After keratinocyte 
expansion for one week, GFP labelling of porcine keratinocytes was undertaken as 
described in 2.2.14, repeated again in the same week, and the frequency of transduction 
calculated as described in 2.2.15. At the end of the second week, the flasks from each 
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animal were divided and keratinocytes from half the flasks were seeded on 
microcarriers as described in 2.2.16. The other flasks were maintained as described in 
2.2.10 until cell harvest for application. 
The keratinocytes on microcarriers remained in stirred culture for one week until 24 
hours prior to wound application. Cells were counted using a haemocytometer after 
dissolving the beads using trypsin. Keratinocytes were harvested from the tissue culture 
flasks using trypsin and counted using haemocytometer. The cells were transferred to 
small Falcon® tubes in a concentration of 1 x 107 in each tube ready for spray 
application. The microcarriers seeded with keratinocytes were transferred to universal 
tubes, each containing 1 x 107 cells in total. The cells from both groups were stored in a 
cool bag overnight prior to application the next morning. 
Three weeks after harvesting the skin grafts, (figure 46, representing wound allocations 
in one animal). There were 18 wounds in total; divided into 3 groups (6 wounds each) 
as follows;  
Group 1 Microcarriers and autologous keratinocytes + STSG (6:1) [MCAK] 
Group 2 Sprayed autologous keratinocytes + STSG (6:1) [SAK] 
Group 3  STSG (6:1) only [Control] 
 
Figure 44: Wound allocation in one animal (Exp 2.10) 
The other two animals had different wound allocations as all wounds were randomly assigned 
 
MCAK + STSG 
SAK + STSG 
Control (STSG) 
Wound allocation 
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Microcarriers and keratinocytes were applied using sterile pipettes on square wounds 
created as described in 2.3.6 covered with meshed Split thickness skin grafts (STSG) 
using Zimmer® mesher (figure 47). The sprayed keratinocytes were applied evenly 
using a sterile 5 ml syringe and a disposable sterile nozzle from a distance of about 10 
cm. Wounds were dressed using Telfa clear® and Betadine soaked gauze as previously 
described. 
 
 
 
Figure 45: Zimmer® mesher 
The mesher is hand operated using a handle attached to the left side (not shown) and skin grafts are 
processed on plastic sheets depending on meshing ratio (manufacturer specific) 
 
Dressings were changed under anaesthesia 4 days post-operative using the same 
dressings and photographs taken. The surface area of each wound was directly traced 
using Visitrak™ sheet, and the surface area measured on Visitrak™ device at each 
dressing change (figure 48) as described in 2.3.7.  
Visitrak™ is a clinically validated and widely used method of wound surface area 
measurement, and has been shown to be an accurate tool in comparison with 
photography and Image J® analysis (Chang et al. 2011). 
Further dressing changes were undertaken at day 8 and day 15 post-operatively, and the 
animals were terminated after three weeks (day 21) following treatment as described in 
2.3.3. The wounds’ surface areas were measured using Visitrak™ and photographs were 
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taken prior to wound excision. The wounds were excised full thickness and the 
specimens processed as described in 2.3.8. 
Fresh frozen sections (15 µm) were examined for the presence of GFP labelled 
keratinocytes. Histological examination of the specimens was undertaken using 
Haematoxylin and Eosin as described in 2.4.1, and Immunohistochemistry for K14, 
collagen VII, and laminin was undertaken as described in 2.4.2.  
Qualitative and quantitative assessment of wound contraction was undertaken using the 
serial photographs and the data from wound surface area assessment. Statistical analysis 
of the data was performed to compare wound contraction in the 3 treatment groups. 
 
Figure 46: (A) Visitrak™ tracing sheet (B) Visitrak™ device. 
(©http://global.smith-nephew.com/master/VISITRAK_PRODUCT_INFO_11079.htm) 
(A) The wound edges are directly traced on the animal with an assistant keeping the sheet flat on the 
wound (B) The wound is then re-traced on Visitrak™ device to calculate wound area. 
To maintain accuracy each wound was traced 3 times and an average area calculated 
 
5.3	  Results	  
5.3.1	  Macroscopic	  qualitative	  assessment	  
During the three weeks course of the study, there were no wound complications in any 
of the three treatment groups. Following the initial harvesting of a small STSG) from 
 120 
the flank of each animal for keratinocyte isolation, the donor healed two weeks later. 
Despite of the availability of the donor site for re-harvesting, the other flank was using 
for harvesting the widely meshed STSG (6:1).  
Figure 49 demonstrates the appearance of the three treatment groups in dressing 
changes on days 4, 8, 15, and 21. On day 0 (STSG harvest and keratinocyte 
application), the STSG were spread carefully to cover all the entire surface area of each 
wound. On day 4, the meshed appearance of the STSG was partly lost on some areas of 
the wound in the three groups. This was attributed to the fragile nature of the thinly 
meshed STSG 6:1, the mobility of the animals in the post-operative period and the 
wounds’ location on the animals’ flanks. The partial loss of STSG occurred in the three 
groups in similar fashion, which ruled out any correlation to the type of treatment used.  
 
 
Figure 47: The 3 treatment groups days 4 and 8 (Exp 2.10) 
From left to right; MCAK, SAK, and control (STSG) groups 
Day 4 shows widely meshed STSG applied to the 3 treatment groups, day 8 shows signs of gradual 
wound healing (filling of the interstices of the meshed STSG) in the MCAK and SAK groups 
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Figure 48: The 3 treatment groups Days 15 and 21 (Exp 2.10) 
From left to right; MCAK, SAK, and Control groups 
Day 15 shows minimal areas of granulation tissue in the MCAK and SAK groups compared to control 
group. Day 21 shows almost full wound healing (pattern of the interstices of the meshed STSG has 
disappeared). There is visible difference in the wound area seen between the 3 groups. 
 
 
On day 8, the meshing pattern of the STSG was still apparent in the SAK and control 
groups, while less apparent in the MCAK group. On day 15, MCAK group showed 
signs of re-epithelisation of the full wound surface area. The SAK group still 
demonstrated the meshed pattern of the STSG and the control group showed areas of 
unhealed granulation tissue. On day 21, the wounds in the MCAK group were healed, 
the wounds in the SAK and control groups showed small areas of unhealed granulation 
tissue around the edges. 
All the wounds were created using a template measuring 4 x 4 cm2 to provide a standard 
wound surface area. A variation was noted in the measurement of the wound surface 
area between the three groups starting from day 4 (table 7). The variation (+ 2-4 cm2) 
was noted in the three groups, the variation was attributed to the physiological wound 
edge movement prior to wound contraction. Due to the anatomical location of the 
wounds, the mobility of the skin edges probably led to retraction of the wound edges 
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prior to attachment to the underlying muscle layer during wound healing. The difference 
in mean wound surface area between the three groups on day 4 was minimal (less than 1 
cm2) (table 7). The variation was not statistically significant. 
 
 
Day 
MCAK SAK Control 
Mean 
(cm2) 
SD Mean 
(cm2) 
SD Mean 
(cm2) 
SD 
4 19.9 (1.1) 19.0 (0.9) 19.9 (0.6) 
8 16.6 (1.7) 15.7 (1.2) 16.2 (1.8) 
15 11.3 (0.5) 9.8 (0.8) 9.1 (0.6) 
21 8.5 (0.6) 7.7 (0.5) 6.3 (0.4) 
 
Table 7: Mean and Standard deviation wound surface area in the 3 groups 
 
 
 
 
 
Figure 49: Graphical representation of wound contraction in wound surface area  
(Error bars refer to standard deviation) 
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On day 8 (table 7), the mean wound surface area in the three groups was similar with 
less than 0.5 cm2 difference. Noticeably, all the 3 groups showed wound contraction of 
around 25% compared to the wound surface area on day 4. 
On day 15 (table 7), a difference of 1.5-2.2 cm2 in the mean wound surface area was 
noted between the MCAK group and the SAK and control groups. The MCAK group 
showed less wound contraction of 56.7% compared to 51.5% in the SAK group and 
45.7% in the control group. 
On day 21, the MCAK group showed wound contraction of 42.7% of the original 
wound surface area. The SAK group wound contraction was 40.5% and the control 
group wound contraction was 31.6% of the wound surface area. A difference of 11.1% 
in the wound contraction area was noted between the MCAK group and the control 
group by day 21 (figure 51). 
The wounds in the MCAK group contracted more slowly than the SAK and control 
groups. The SAK group contracted slower than the control group. Signiﬁcantly less 
wound contraction was found in wounds treated with MCAK (n = 6) than with STSG 
alone (n = 6) or SAK (n = 6) (adjusted p < 0.05; Holm-Sidak post hoc test). Generally, 
all the wounds from the three groups were healed by day 21 despite the variation in the 
contraction of the wound area.  
5.3.2	  Histological	  and	  immunohistochemical	  analysis	  
Whole wounds were excised on day 21, following the termination of the animals. 
At day 21 post-treatment, all wounds in the three groups displayed an intact epithelium. 
Fresh sections from both MCAK and SAK groups showed no GFP-positive cells despite 
full re-epithelialisation. This is due to the loss of the GFP after 2-3 weeks as previously 
discussed. Observational assessment of the Haematoxylin and Eosin staining of the 
three groups showed newly formed epithelium varying in arrangement and number of 
layers (figure 52). Both the MCAK and SAK groups showed a fully formed epithelium 
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arranged in layers resembling the architecture of normal porcine skin. The control group 
showed a thin layer of fragile epithelial cells corresponding to the nature of the thinly 
meshed STSG.  
K14, a marker of proliferating basal keratinocytes, was expressed in all wounds (figure 
53). The presence of K14 demonstrated the proliferation of keratinocytes in the MCAK 
and SAK groups to achieve epithelial closure in combination with STSG. The 
distribution of K14 in the MCAK and SAK groups was similar in pattern, with more 
pronounced multi-layered epithelium compared to the control group (figure 52). 
Immunohistochemical staining for collagen VII was clearly positive in the three groups. 
In the MCAK group, collagen VII immuno-staining was more intense compared to the 
SAK and control groups (figure 53). The MCAK group demonstrated the formation of a 
well-developed basement membrane (figure 53-middle 2nd section) compared to the 
SAK and control groups.  
The formation of basement membrane was an indication of the regeneration of intact 
epidermis in the three groups. The basement membrane appearance in the MCAK 
signified more developed epithelium compared to the SAK and control groups. 
Immunohistochemical staining for Laminin was assessed using Fluorescein 
isothiocyanate (FITC), a fluorescent stain that binds strongly to DNA (figure 54). The 
three groups showed positive staining for laminin with a variation in the laminin 
distribution. The laminin distribution in the MCAK group was more uniform across the 
sections and condensed in the basement membrane and papillary dermis region. A 
similar pattern was seen in the SAK group with more condensation in the same area 
compared to the MCAK and control groups (figure 54). 
The dense staining for laminin in the basement membrane and papillary dermis region 
could signal a more developed basement membrane in the SAK group compared to 
MCAK. The MCAK and SAK groups produced a distinctive pattern compared to the 
control group (figure 54).  
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Hx&E (x 5 & x 10) Hx&E (x 20) K14 (x 5 & x 10)  
Control  
MCAK 
SAK 
x 5 x 5 x 20 
x 10 x 20 x 10 
x 10 x 10 x 20  
Figure 50: Hx & E and K14 immuno-labelling of the 3 groups 
Hx & E staining x5 on the left, epidermis magnified x20 in the middle, and K14 staining on the right 
(positive staining dark black at the level of the epidermis) (x5 magnification-field width 7.2 mm, x10 
magnification-field width 3.6 mm, and x20 magnification-field width 1.8 mm [middle column]) 
 
MCAK Control SAK 
Hx & E  
Collagen VII  
Collagen VII immuno-labelling is seen positive in the 3 groups, the MCAK group 
(middle column) is thicker compared to the SAK and control group 
x 10 
x 10 x 10 x 10 
x 10 x 10 
 
Figure 51: Hx & E staining and Collagen VII immuno-labelling of the 3 groups 
Hx & E sections (top), with Collagen VII staining of the same sections (below). Positive staining for 
Collagen VII (Basement membrane) in the 3 groups (within the rectangle) (x10 magnification, field width 
3.6 mm) 
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 Control    MCAK    SAK 
 
Figure 52: Laminin immuno-labelling (using FITC) in the 3 groups 
Distribution of laminin in the control group (left) across the whole section compared to more uniform 
distribution within the papillary dermis in MCAK (middle) and SAK (right) [top of the section]. SAK 
showed denser distribution compared to MCAK (x10 magnification, field width 3.6 mm) 
 
 
The laminin staining in the control group was less uniform and lacked dense distribution 
in the basement membrane and papillary dermis region (figure 54, left).  
In conclusion, histological analysis of sections from the three groups demonstrated 
epithelial regeneration in all wounds examined. The quality of epithelium varied 
between the three groups with highly developed epithelium and basement membrane in 
the MCAK group. This could explain the variation in the wound contraction rate in the 
MCAK group compared to the SAK and control groups. 
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Chapter 6: Investigation of wound healing and 
contraction rate of allogeneic keratinocytes on 
microcarriers, sprayed keratinocytes and ultra-thin split 
skin graft on Integra® (Two stage dermal regeneration) 
6.1	  Study	  objectives	  
The aim of this study is to investigate whether cultured allogeneic keratinocytes on 
microcarrier beads can reduce wound contraction in combination with Integra® (dermal 
regeneration template). Their effect on wound contraction will be compared with the 
combination of sprayed allogeneic keratinocytes and Integra®. Ultra-thin split thickness 
skin graft (uSTSG) and Integra® will be used as a control, uSTSG will be used as it is 
sufficient to achieve wound closure in combination with Integra®. The area of wound 
contraction will be assessed using serial measurements of the wound size using 
Visitrak™ at set time points. Epithelial regeneration and wound closure will be assessed 
macroscopically using clinical observation and photography. Also microscopic 
assessment using Haematoxylin and Eosin staining, and immunohistochemical staining 
for K14, collagen VII, laminin, and α-SM actin will be used to assess the rate of 
epithelial formation and myofibroblast differentiation. 
6.2	  Study	  design	  
Three pigs were used in this study and prior to the beginning of the study; the animals 
as described in 2.3.1 were admitted to NPIMR according to 2.3.2. 
In the first stage of the study, the animals were anaesthetised as described in 2.3.3, and 
three square-shaped wounds were created on the flank of each animal as described in 
2.3.6. A piece of Integra® measuring 4 x 4 cm was inset in each wound using skin 
staples. One sheet of split skin graft measuring about 8-10 cm was harvested from each 
animal from the posterior part of the para-spinal area as described in 2.3.4. The wounds 
were dressed and wrapped in foam jackets as described before. The skin graft was 
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wrapped in saline soaked gauze and transported back to the lab in porcine keratinocyte 
transport medium the same day.  
Porcine keratinocytes were isolated as described in 2.2.9, and cultured as described in 
2.2.10. The flasks from each animal were clearly labelled and kept in separate shelves in 
an incubator at 37°C. After keratinocyte expansion for one week, GFP labelling of 
porcine keratinocytes was done as described in 2.2.14, repeated again in the same week 
and the frequency of transduction calculated as described in 2.2.15. 
At the end of the second week, the flasks from each animal were divided and 
keratinocytes from half the flasks were seeded on microcarriers as described in 2.2.16, 
and the remaining flasks were maintained as described in 2.2.10. The keratinocytes on 
microcarriers remained in stirred culture for one week until 24 hours prior to 
application. The magnetic stirrer was stopped and the flask transferred to a tissue culture 
hood, where the culture medium was aspirated.  
A cell count was undertaken after dissolving the beads using trypsin. Keratinocytes 
were harvested from the tissue culture flasks using trypsin, and cells counted. The cells 
were transferred to small Falcon® tubes in a concentration of 1 x 107 in each tube ready 
for spray application. The microcarriers seeded with keratinocytes were transferred to 
universal tubes, each containing 1 x 107 cells in total. The cells from both groups were 
stored in a cool bag overnight prior to application the next morning. 
During the three weeks following the creation of the wounds and harvesting the skin 
grafts, two dressing changes at days 7 and 14 were performed under general 
anaesthesia. The wounds were dressed as described before and wrapped in foam jackets. 
Three weeks after harvesting the skin grafts (Day 21), the animals were anaesthetised as 
described in (2.3.3). The silicone layer was removed from the surface of the Integra® to 
reveal a revascularised dermis and the skin staples were removed. The surface area of 
each wound was traced using Visitrak™ tracing sheet, and measured on Visitrak™ 
device as described in 2.3.7.  
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Treatments were randomised and applied to the wounds (figure 55), keratinocytes on 
microcarriers and sprayed keratinocytes were interchanged between the three pigs to 
provide allogeneic keratinocytes (Pig 1 to receive cells from Pig 2 and Pig 2 from Pig 3 
etc). uSTSG was harvested from one flank using Zimmer® air dermatome (150-200 µm 
thick). The uSTSG was applied to the control wounds and secured with skin staples. 
There were 18 wounds in total; divided into 3 groups (6 wounds each) as shown in 
(figure 55). 
Group 1 Microcarriers and allogeneic keratinocytes + Integra® [MCAlK] 
Group 2 Sprayed allogeneic keratinocytes + Integra® [SAlK] 
Group 3  uSTSG + Integra® [Control] 
 
Figure 53: Wound allocation in one animal (Exp 3.10) 
The wounds were allocated randomly and wound sites were different in the other 2 animals 
 
Microcarriers and keratinocytes were applied using sterile pipettes. The sprayed 
keratinocytes were applied evenly using a sterile 5 ml syringe and a disposable sterile 
nozzle from a distance of about 10 cm. Wounds were dressed using Biobrane®, secured 
using skin staples, and dressed with Betadine soaked gauze as described before. 
Biobrane® was used to protect the allogenic keratinocytes rather than using Telfa Clear® 
as before. A dressing change was done under anaesthesia 7 days post-operative using 
the same dressings and photographs taken. Another dressing change was done under 
MC + allo KC + Integra® 
Sprayed allo KC + 
Integra® 
uSTSG + Integra® 
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anaesthesia on day 14 post-operative. Biobrane® was adhered to the wound surface after 
the dressing change on day 14 and was left undisturbed. 
The animals were terminated three weeks (Day 21) following treatment as described in 
2.3.3, Biobrane® was poorly adhered to the wound surface and was easily removed. 
The wounds’ surface areas were measured using Visitrak™ system and photographs 
were taken prior to wound excision. The wounds were excised along the edges 
including the full thickness of the skin and subcutaneous tissue. The tissue specimens 
were transferred back to the laboratory and the specimens processed as described in 
2.3.6, and fresh sections were examined for the presence of GFP labelled keratinocytes. 
Histological examination of the specimens was done using Haematoxylin and Eosin as 
described in 2.4.1, and immunohistochemistry for K14, collagen VII, laminin, and α-
SM actin was done as described in 2.4.2.  
Qualitative and quantitative assessment of wound contraction was undertaken using the 
serial photographs and the data from wound surface area assessment. Statistical analysis 
of the data was performed to compare the overall wound contraction in the three 
treatment groups. 
6.3	  Results	  
6.3.1	  Macroscopic	  qualitative	  assessment	  
During the six weeks course of the study, there were no wound complications in any of 
the three treatment groups. Following the initial harvesting of the STSG from the flank 
of each animal for keratinocyte isolation, the donor healed in two weeks. Dressing 
changes for Integra® over three weeks showed no wound infections or tissue rejection.  
By day 21, the dermal template (Integra®) was completely vascularised and ready for 
treatment application. 
Figure 56 demonstrates the development of the appearance of the MCAlK treatment 
group during the six weeks period. On day 0 (STSG harvest and Integra® application), 
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Integra® was inset using skin staples (figure 56a), the silicone layer was not visible prior 
to dermal layer vascularisation. On day 7 (figure 56b), there is no evidence of infection 
or collections beneath the silicone layer of Integra®. On day 21 (figure 56c), Integra® 
appeared well vascularised and the silicone layer removed in readiness for treatment 
applications. Following the application of MCAlK in (figure 56d), Biobrane® was 
applied and secured using staples to protect the wounds. During the next two dressing 
changes (figure 56e and f), there were no signs of wound infection and the Biobrane® 
was well adhered to the wound surface.  
 
 
Figure 54: The MCAlK treatment group (A to C Integra® alone, D to G post treatment) [Exp 3.10] 
The silicone layer covering Integra® was clearly visible at day 7 (B), Biobrane® was applied to the 
wounds post treatment day 21 (D), and was removed on day 21 (post treatment) prior to termination of 
the experiment 
 
Between day 15 and day 21 post Integra® application during dressing changes, it was 
noted that vascularisation of Integra was complete in some wounds. Despite this 
observation, the silicone layer on all wounds was left intact. 
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On day 42 (experiment termination), following the removal of Biobrane®, all wounds in 
the three groups showed variation in epithelial closure (figure 57). MCAlK and SAlK 
groups’ wounds had residual granulation tissue (figure 57a and b) compared to full 
epithelial closure in the control group (figure 57c). The control group was the only 
group to receive autologous cells in the form of uSTSG on Integra®.  
 
 
Figure 55: Day 42 (Experiment termination) 
The difference between the 3 treatment groups is shown at experiment termination where full epithelial 
closure was achieved in the control wounds (autologous uSTSG group) 
 
 
All the wounds were created using a template measuring 4 x 4 cm2 to provide a standard 
wound surface area. As seen in the previous study (chapter 5), the variation in the 
wound surface area (+ 2-4 cm2) occurred early post operatively due to retraction of 
wound edges. This physiological stage precedes wound contraction as the wound 
surface area starts to decrease. The application of Integra® maintained the wound 
surface area at pre-contraction phase size for 3 weeks post application. 
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On day 21, the mean wound surface area in the three groups was similar with less than 1 
cm2 difference. On day 42, three weeks following treatment, a difference of less than 1 
cm2 in the mean wound surface area was noted between the MCAlK group and the 
SAlK. The control group showed the greatest contraction in wound area with a 
reduction in wound surface area from 18.88 (+/- 0.31) cm2 to 3.6 (+/- 0.23) cm2. The 
MCAlK group showed lower wound contraction with healed area of 33.7 % of the 
original wound area compared to 29.1% in the SAlK group and 19.1 % in the control 
group. 
 
 
 
Figure 56: Graph representation of wound contraction in wound surface area (Days 21 and 42) 
 
A difference of 14.6% in wound contraction area was noted between the MCAlK group 
and the control group by day 42. The MCAlK group wounds contracted less than the 
SAlK group, which contracted less than the control group (figure 58). 
The wounds in the MCAlK group contracted slower than the SAlK and control groups, 
and the SAlK group contracted slower than the control group. Signiﬁcantly less wound 
contraction was found in wounds treated with MCAlK (n = 6) than with uSTSG alone 
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(n = 6) or SAlK (n = 6) (adjusted p < 0.05; Holm-Sidak post hoc test). The control 
group wounds were healed by day 21 post treatment, the other two groups showed 
residual granulation tissue. Full epithelial closure did not occur despite the variation in 
wound area.  
6.4.2	  Histological	  and	  immunohistochemical	  analysis	  
The whole wounds were excised on day 42, following the termination of the animals. 
Fresh sections from both MCAlK and SAlK groups showed no GFP-positive cells in 
any of the wounds. 
Haematoxylin and Eosin staining of the three groups showed newly formed epithelium 
varying in quality (figure 59). Both the MCAlK and SAlK groups showed an epithelium 
comparable to the control group but with reduced epidermis thickness. Both groups 
(MCAlK and SAlK) showed a residual thin layer of granulation tissue over the 
epithelium (figure 59b and c).  
Immunohistochemical staining for collagen VII was positive in the three groups. In the 
MCAlK and SAlK groups, collagen VII immuno-staining was thicker compared to the 
control group (figure 59-middle column-Collagen VII). Both the MCAlK and SAlK 
groups demonstrated the formation of a well-developed basement membrane. The 
formation of basement membrane was an indication of the regeneration of intact 
epidermis. All wounds from the three groups showed distribution of K14, a marker of 
basal keratinocytes (figure 59-right column-K14).  
The presence of K14 demonstrated the support provided by MCAlK and SAlK groups 
to wound healing in this animal model. The distribution of K14 in the MCAlK and 
SAlK groups was similar in pattern, and comparable to the control group. 
The three groups showed positive staining for laminin with a variation in the laminin 
distribution (figure 60-left column). Immunohistochemical staining for laminin showed 
a more distinctive pattern in the SAlK group compared to MCAlK and control groups 
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(figure 60-middle). Laminin showed a more dense distribution across the sections 
compared to the more localised distribution in the basement membrane region in the 
other two groups.  
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Figure 57: Hx & E, Collagen VII and K14 immuno-labelling of the 3 groups 
(A) uSTSG, (B) SAlK, and (C) MCAlK, (D, E, and F) showing Collagen VII in the 3 groups with 
basement membrane positive staining (black rectangle). (G, H, and I) showing positive K14 staining in 
the epidermis in the 3 groups (red rectangle) (x5 magnification, field width 7.2 mm) 
 
The laminin distribution in the MCAlK and control groups was more uniform across the 
sections and condensed in the basement membrane region. The dense staining for 
laminin in the basement membrane region could signal a mature basement membrane in 
the SAlK group compared to MCAlK and control groups. 
Immunohistochemical staining for α-SMA was positive in the three groups 
demonstrating myofibroblast activity (figure 60-right column). A clear distribution 
pattern was seen in the control group where α-SMA was distributed in distinct areas 
deep within the dermo-epidermal junction (figure 60-top right within red rectangle). 
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The dermo-epidermal junction seen in more detail (x 20 magnification on the left) 
showed the difference in the distribution pattern between the 3 groups. 
The myoﬁbroblasts were arranged in ﬂat-condensed arrays parallel to the dermal–
epidermal junction compared to the other two groups. 
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Figure 58: Laminin and α SMA immuno-labelling of the 3 groups 
(A) uSTSG, (B) SAlK, and (C) MCAlK laminin staining x5 (left, field width 7.2 mm), and α-SMA x20 
(right D, E, and F, field width 1.8 mm) where myofibroblast seen within the dermo-epidermal junction  
 
In conclusion, histological analysis of sections from the three groups demonstrated 
epithelial regeneration in all the wounds examined. The quality of epithelium varied 
between the three groups as only the control group received autologous treatment 
(uSTSG). The control group demonstrated different myofibroblasts distribution through 
α-SMA immunolabelling. Both the MCAlK and SAlK groups showed re-epithelisation 
of wounds, which was comparable to the control group. This could be explained by 
epithelial migration from the wound edges to achieve closure rather than as a result of 
the allogeneic cells application. 
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Chapter 7: Investigation of wound healing and 
contraction rate of autologous keratinocytes and 
fibroblasts on microcarriers and sprayed keratinocytes 
on Integra® (Two stage dermal regeneration) 
7.1	  Study	  objectives	  
The aim of this study was to investigate whether cultured autologous keratinocytes and 
fibroblasts on microcarrier beads reduce wound contraction in combination with 
Integra® (dermal regeneration template). Their effect on wound contraction was 
compared with the combination of autologous keratinocytes on microcarriers and 
sprayed keratinocytes and Integra®. Wound contraction was assessed using serial 
measurements of the wound size using Visitrak™ at set time points. Epithelial 
regeneration and wound closure were assessed macroscopically using clinical 
observation and photography. Also microscopic assessment using Haematoxylin and 
Eosin staining, and immunohistochemical staining for K14, collagen VII, laminin, and 
α-SM actin was undertaken to assess the rate of epithelial formation and myofibroblast 
expression. 
7.2	  Study	  design	  
Three pigs were used in this study and prior to the beginning of the study; the animals 
as described in 2.3.1 were admitted to NPIMR according to 2.3.2. 
In the first stage of the study, the animals were anaesthetised as described in 2.3.3. 
Three square-shaped wounds were created on the flank of each animal as described in 
2.3.6. A piece of Integra® measuring 4 x 4 cm was inset in each wound using skin 
staples. One sheet of split skin graft measuring about 8-10 cm was harvested from each 
animal from the posterior part of the para-spinal area as described in 2.3.4.  
The wounds were dressed and wrapped in foam jackets as described before, the skin 
graft was wrapped in saline soaked gauze and transported back to the lab the same day.  
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For two weeks following the creation of the wounds and harvesting of the skin grafts, 
one dressing change at day 7 was performed under general anaesthesia. The wounds 
were dressed as described before and wrapped in foam jackets. 
Porcine keratinocytes were isolated as described in 2.2.9, and cultured as described in 
2.2.10. Porcine fibroblasts were isolated as described in 2.2.11, and cultured as 
described in 2.2.12. The flasks from each animal were clearly labelled and kept in 
separate shelves in an incubator at 37°C. After keratinocyte and fibroblast expansion for 
one week, the flasks from each animal were divided and keratinocytes were seeded with 
fibroblasts (6:1) on microcarriers as described in 2.2.16.  
Keratinocytes alone were seeded on microcarriers as described in 2.2.16 in a separate 
stirrer flask. The remaining tissue culture flasks were maintained as described in 2.2.10 
until cell harvest for wound application. 
The keratinocytes and fibroblasts, and keratinocytes alone on microcarriers remained in 
stirred culture for one week until 24 hours prior to wound application. The magnetic 
stirrer was stopped, the flasks transferred to a tissue culture hood and the culture 
medium aspirated. A cell count was undertaken after dissolving the beads using trypsin; 
keratinocytes were harvested from the tissue culture flasks using trypsin, and counted. 
The cells were transferred to small Falcon® tubes, 1 x 107 in each tube ready for cell 
spray application. The microcarriers seeded with keratinocytes and fibroblasts, and 
keratinocytes alone were transferred to universal tubes, each containing 1 x 107 cells in 
total. The count of each cell type in the keratinocyte fibroblast group was not 
undertaken. The cells from both groups were stored in a cool bag overnight prior to 
wound application the next morning. 
Two weeks after harvesting the skin grafts (Day 14), the animals were anaesthetised as 
described in 2.3.3. The silicone layer was removed from the surface of the Integra® to 
reveal a vascularised dermal layer and the skin staples were removed. The surface area 
of each wound was traced using Visitrak™ tracing sheet, and the surface area measured 
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as described in 2.3.7. Treatments were applied to the wounds accordingly (figure 61). 
There were 18 wounds in total; divided into 3 groups (6 wounds each) as shown in 
(figure 61). 
Group 1 Microcarriers and autologous keratinocytes-fibroblasts + Integra®  
[MCAK-FB] 
Group 2 Microcarriers and autologous keratinocytes + Integra®  
[MCAK] 
Group 3  Sprayed autologous keratinocytes + Integra®  
[SAK] 
 
Figure 59: Wound allocation in one animal (Exp 4.10) 
The wounds were randomly allocated and wound sites were different in the other 2 animals 
 
Microcarriers and keratinocytes plus fibroblasts and keratinocytes alone were applied 
using sterile pipettes. The sprayed keratinocytes were applied evenly using a sterile 5 ml 
syringe and a disposable sterile nozzle from a distance of about 10 cm. Wounds were 
dressed using Telfa clear®, secured using skin staples, and dressed with Betadine soaked 
gauze as described before. 
Dressing changes were performed under anaesthesia 7 and 14 days post-operatively. 
The animals were terminated three weeks (Day 21) following treatment as described in 
2.3.3. The wound surface area was measured using Visitrak™ system and photographs 
MC + KC-FB + Integra® 
MC + KC + Integra® 
SAK+ Integra® 
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were taken prior to wound excision. The wounds were excised and the tissue specimens 
were processed as described in 2.3.6.  
Histological examination of the specimens using Haematoxylin and Eosin was done as 
described in 2.4.1, and Immunohistochemistry for K14, collagen VII, laminin, and α-
SM actin was undertaken as described in 2.4.2. Qualitative and quantitative assessment 
of wound contraction was undertaken using the serial photographs and the data from 
wound surface area measurement. The measurements were statistically analysed to 
compare wound contraction in the three treatment groups. 
7.3	  Results	  
7.3.1	  Macroscopic	  qualitative	  assessment	  
During the course of the study, there was no wound infection in any of the three 
treatment groups. Following the harvesting of the STSG from the flank of each animal 
for keratinocyte and fibroblast isolation, the donor site healed in two weeks. The 
dressing changes for Integra® on day 7 showed no wound infection or tissue rejection.  
By day 14, the dermal template (Integra®) was vascularised, well adhered to the wound 
and ready for the application of the treatment groups. 
Figure 62 demonstrates the change in the appearance of the wounds from day 7, 
dressing change post application of Integra®, and day 14 pre and post treatment 
application. On day 7 (figure 62a), there was no evidence of infection or collection 
beneath the silicone layer of Integra®. On day 14 (figure 62b), Integra® was seen 
vascularised and well adhered with the silicone layer intact, (figure 62c) shows wounds 
post treatment applications with Telfa clear® applied.  
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Figure 60: Wounds following Integra® inset D7 and D14 (Pre and Post-treatment) 
(A) Day 7 following application of Integra®, the silicone layer started changing colour and was seen 
lifting off the wound by day 14 (B). (C) Wound following application of treatment (MCAK-FB) 
 
 
The vascularisation of Integra® was complete two weeks post application with no 
reported complications. At the two dressing changes post treatment day 7 & 14 (figure 
63), there was no sign of wound infection and granulation tissue was seen covering the 
wound surface.  
On day 35 (experiment termination), all wounds in the three groups showed near to 
complete epithelial closure (figure 63-day 21). MCAK-FB and MCAK group wounds 
had small areas of residual granulation tissue (figure 63-day 21). The SAK group 
showed scabbing adherent to the granulation tissue compared to the other two groups 
(figure 63-day 21, bottom right).  
On day 7, the mean wound surface area in the three groups was similar with less than 1 
cm2 difference. On day 21, three weeks following treatment, a difference of around 2 
cm2 in the mean wound surface area was noted between the MCAK-FB group and the 
MCAK and SAK groups. 
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Figure 61: Wounds in the 3 treatment groups Days 7, 14, and 21 (Exp 4.10) 
MCAK-FB (top), MCAK (middle), and SAK (lower) [left to right days 7, 14, and 21] 
The area of the wound at day 21 was different comparing the 3 groups, where MCAK-FB group showed 
reduced wound contraction compared to MCAK and SAK 
 
 
The SAK group showed the greatest wound contraction with a reduction in wound 
surface area from 19.5 (+/- 0.23) cm2 to healed area measuring 9.1 (+/- 0.39) cm2. The 
MCAK-FB group showed the lowest contraction in wound area; maintaining 56.8% 
compared to 47.6% in the MCAK group and 46.6% in the SAK group of the wound 
surface area. 
A difference of 9.2% in wound area was noted between the MCAK-FB group and the 
MCAK group by day 21. The MCAK-FB group wounds contracted less than the 
MCAK group, which contracted less than the SAK group (figure 64). 
The wounds in the MCAK-FB group contracted less than the MCAK and SAK groups, 
and the MCAK group contracted less than the SAK group. Signiﬁcantly less wound 
contraction was found in wounds treated with MCAK-FB (n = 6) than with MCAK 
alone (n = 6) or SAK (n = 6) (adjusted p < 0.05; Holm-Sidak post hoc test). The wounds 
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from the 3 treatment groups were 90% healed by day 21-post treatment. Some wounds 
showed small areas of residual granulation tissue (< 10 % of wound surface area).  
 
 
Figure 62: Graph representation of wound contraction in the 3 groups over 21 days  
(Error bars refer to standard deviation) 
 
7.3.2	  Histological	  and	  immunohistochemical	  analysis	  
The whole wounds were excised on day 21, following the termination of the animals. 
At day 21 (3 weeks post-treatment), the wounds from the 3 groups displayed an intact 
epithelium. The wounds of the MCAK-FB and MCAK groups showed granulation 
tissue less than 10% of wound surface area, but were 90% healed.  
Haematoxylin and Eosin staining of the three groups showed newly formed epithelium 
comparable in quality (figure 65). Both the MCAK-FB and SAK groups showed a well-
stratified epithelium comparable to the MCAK group (figure 65b). The thickness of the 
epidermis in the MCAK was thinner compared to the thickness of the epidermis in the 
other 2 groups. This difference was observed in about 80-90% of the sections examined 
from all the wounds in the 3 groups. No clear explanation was found for that finding 
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despite previous studies demonstrating similar epidermis thickness between MCAK and 
SAK groups.  
Immunohistochemical staining for collagen VII was positive in the three groups. The 
three groups demonstrated a well-developed basement membrane. The formation of the 
basement membrane confirmed the regeneration of an intact epidermis. 
 
(A)$MCAK(FB$
$Microcarriers$
autologous$
kera7nocytes$and$
ﬁbroblasts$
$
$
$
(B)$MCAK$
$Microcarriers$
autologous$
kera7nocytes$
$
(C)$SAK$
$Sprayed$autologous$
kera7nocytes$
Hx#&#E## Collagen#VII##
A 
B 
C 
x10 x10 
x10 x10 
x10 x10 
 
Figure 63: Hx & E and Collagen VII immuno-labelling of the 3 groups 
(A) MCAK-FB, (B) MCAK, and (C) SAK. Left column: Hx & E staining with variable thickness of 
epidermis (black rectangle). Right column: Collagen VII staining for basement membrane (positive 
within red rectangle) (x10 magnification, field width 3.6 mm) 
 
 
All wounds from the three groups showed comparable distribution of K14, a marker of 
basal keratinocytes (figure 66). The presence of K14 confirmed the regeneration of 
newly formed epithelium in the three treatment groups. The distribution of K14 in the 
MCAK-FB and SAK groups showed more intense staining possibly a thicker epithelium 
compared with the MCAK group, but similar to SAK. K14 staining findings regarding 
the thickness of epidermis were similar to findings from Haematoxylin and Eosin 
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staining previously. Both FITC and DAPI were undertaken to combine cellular staining 
(FITC) and nuclear staining (DAPI) together to illustrate clearly any variations between 
the 3 groups. 
The three groups showed positive staining for laminin with a variation in the laminin 
distribution (figure 67). Immunohistochemical staining for laminin showed a more 
distinctive pattern in the MCAK-FB group compared with the MCAK and SAK groups 
(figure 67-bottom row). 
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Figure 64: K14 immuno-labelling of the 3 groups 
From left to right: (A) MCAK-FB, (B) MCAK, and (C) SAK. DAPI (nucleus staining-top), FITC 
(positive staining for epidermis shown in red rectangle) and below merge of both stains (x10 
magnification-field width 3.6 mm, x20 magnification-field width 1.8 mm) 
 
Laminin showed a more dense distribution in the basement membrane region in the 
MCAK-FB group compared with a generalised distribution across the sections in the 
MCAK and SAK groups (figure 67-bottom row).  The laminin distribution in the 
MCAK-FB group was more uniform across the sections and condensed in the basement 
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membrane region. The dense laminin staining in the basement membrane region could 
possibly signal a mature basement membrane in the MCAK-FB group compared with 
the MCAK and SAK groups. 
Immunohistochemical staining for α-SMA was positive in the three groups 
demonstrating myofibroblasts activity (figure 68). A clear distribution pattern was seen 
in the control group (uSTSG-chapter 6) where α-SMA is distributed in distinct areas 
deep within the dermo-epidermal junction and the papillary dermis (figure 68, left). 
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Figure 65: Laminin immuno-labelling of the 3 groups 
From left to right: (A) MCAK-FB, (B) MCAK, and (C) SAK. DAPI (nucleus staining-top), Anti-laminin 
(dense distribution of laminin shown in red rectangle) and below merge of both stains (similar pattern 
within yellow rectangle) (x10 magnification, field width 3.6 mm) 
 
 
Myoﬁbroblasts were arranged in ﬂat arrays parallel to the dermal–epidermal junction 
denoting higher activity compared with the three groups included in this study (figure 
65-bottom row). The myofibroblast activity expressed in the control group (uSTSG) 
was a marker of increased wound contraction. This was reflected in the difference in 
wound surface area measurements after 21 days in the uSTSG group compared with the 
MCAK-FB, MCAK, and SAK groups included in this study. 
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Figure 66: α-SMA immuno-labelling of the 3 groups 
From left to right: (A) Control (uSTSG), (B) MCAK-FB, (C) MCAK, and (D) SAK (dermis shown) 
FITC staining (top), DAPI (nucleus staining-middle), and merge of both (below). Myofibroblasts 
distribution pattern in the 4 groups (within red rectangle) (x40 magnification, field width 0.9 mm) 
 
In conclusion, histological analysis of sections from the three groups demonstrated 
epithelial regeneration in all the wounds examined. The quality of epithelium was 
comparable between the three groups with a variation in thickness only. Wound 
contraction in the MCAK-FB group was significantly less than the MCAK and SAK 
groups. 
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Chapter 8: Discussion 
8.1	  Discussion	  of	  in	  vitro	  studies	  
Microcarrier beads have been used to support cell culture for almost four decades and 
their use to support keratinocyte cell culture provides a novel tissue engineered 
approach to cutaneous wound repair. Viable cultured keratinocytes transferred on 
microcarriers to the wound bed can be used for skin replacement therapy in various 
conditions of skin loss or breakdown (Kim et al. 2005) 
The availability of microcarriers from biodegradable materials, such as gelatin, paved 
the way for utilizing microcarriers in keratinocyte culture for skin replacement therapy. 
Recently, gelatin based microcarrier beads were used to support the growth of human 
keratinocytes in vitro without the need for 3T3 feeder cells (Borg et al. 2009). Also, 
gelatin beads were found to be degradable in 2-3 weeks when applied to chronic leg 
ulcers (Liu et al. 2004). Therefore, there are advantages for the use of gelatin 
microcarriers in keratinocyte cell culture. 
Currently, there are two types of gelatin microcarrier beads commercially available for 
cell culture Cultispher G® and Cultispher S®. Cultispher S® has different size pores and 
due to the strength of the gelatin cross-linking is more resistant to mechanical stress in 
culture conditions. Cultispher G® in comparison has more uniform sized pores and is 
more suitable for culture of anchorage dependent cells. In the first in vitro study 3.1, 
two types of gelatin-based microcarrier beads were compared for maintaining 
keratinocyte cell culture and proliferation in vitro. Two types of cultures were used, 
static and stirred cultures, with quantitative and qualitative measurement of keratinocyte 
attachment and growth. Trypan blue was used to count keratinocytes on microcarrier 
beads stirred culture at set time points. The cell count was compared with keratinocytes 
count from standard culture flasks at identical time points. 
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Trypan blue is a widely used standard dye to assess cellular viability (Du Toit and Page 
2009). The reactivity of Trypan blue is based on the fact that the chromophore is 
negatively charged and does not interact with the cell unless the cellular membrane is 
damaged. Therefore, all cells which exclude the dye are viable while cells which are 
blue in colour are non viable.  
The choice of either Cultispher G® or Cultispher S® relied on a number of important 
factors. These factors included; keratinocytes attachment to the surface, supporting cell 
expansion in culture, biodegradability of the beads, their microstructure, and 
keratinocytes proliferation. Also microcarriers need to maintain keratinocyte 
proliferation in vitro to allow for the delivery of keratinocytes for in vivo applications. 
Qualitative and quantitative assessments using MTT staining, acridine orange staining, 
Alamar Blue® assay, and Trypan blue cell count demonstrated that both Cultispher G® 
and S® microcarriers supported keratinocyte growth and expansion in rotator culture. 
Using Alamar Blue® reduction assay to assess keratinocytes proliferation, Cultispher G® 
produced marginally higher results. Results from both Cultispher S® and G® were 
compared using t-test, the results demonstrated 94% confidence interval, and the power 
was 0.04 (below the desired power of 0.8). The difference in the mean values of the two 
groups was not great enough to reject the possibility that the difference was due to 
random sampling variability. The difference was not statistically significant with a p 
value of 0.483. Therefore, the comparison of Cultispher S® and Cultispher G® found no 
significant differences, although Cultispher G® showed marginally higher rates of 
keratinocytes’ expansion seen with Alamar Blue® assay.  
In the assessment of keratinocyte cell count in microcarrier culture using Trypan blue, 
keratinocyte expansion on microcarriers was similar to conventional culture. Analysis 
of keratinocyte cell count using Trypan blue showed similar cell counts in traditional 
culture flasks and stirred microcarrier culture. The use of microcarriers did not have a 
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negative effect on keratinocyte expansion, and further studies were undertaken to 
explore potential advantages over traditional culture. 
Therefore, in the second phase of the study, the decision to use Cultispher G® was based 
on the manufacturer’s information sheet;  
http://www.sigmaaldrich.com/catalog/DataSheetPage.do?brandKey=SIGMA&symbol=
M9043 which states that the pores within the Cultispher G® microcarriers and their size 
are more uniform compared to Cultispher S®, despite Cultispher S® being more resistant 
to mechanical and thermal stress. Theoretically, the uniformity of Cultispher G® would 
be more suitable for stirred keratinocyte culture, and Cultispher G® was used in stirred 
culture. Keratinocytes cultured on microcarrier beads in agitated and stirred cultures 
produced similar results to previous in vitro studies reported in the literature (Bardouille 
et al. 2001, Abranches et al. 2007). The results from this study were similar to other 
reported studies highlighting the need for culture stirring when using microcarriers to 
maintain attachment of keratinocytes in culture. Culture stirring avoids microcarrier 
precipitation, the reduction of the surface area available for cellular attachment, and 
possibly degradation. 
Trypan blue cell count results showed keratinocytes expansion on microcarriers was 
similar to conventional culture using culture flasks. Analysis of keratinocyte cell on 
days 6, 10, and 14, produced similar expansion rates comparing the two culture 
methods. The difference in cell count across the different time points was < 0.5 x 106, 
with slightly higher count in traditional culture flasks. The results raised the question 
whether there was an advantage in using microcarriers for keratinocyte culture with no 
evidence of keratinocyte proliferation data available. 
Despite the lack of supporting evidence for keratinocyte proliferation, keratinocyte 
attachment and expansion were demonstrated. The initial findings from the qualitative 
and quantitative assessments provided a platform for further investigations.  
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Human keratinocytes were used in this initial study to set a benchmark for further in 
vitro studies where porcine keratinocytes were used. The use of porcine keratinocytes in 
further in vitro studies aimed at investigating cell behaviour on microcarriers, prior to 
establishing whether further investigation in an in vivo animal model would be 
warranted. Keratinocyte expansion in culture supported further investigations into the 
biological fate of the microcarriers following wound application.  
Since there was no sufficient data at that stage to proceed to an in vivo animal wound 
model, biodegradation of the microcarriers was investigated in a simulated 
environment. The transferral of keratinocytes and microcarriers from stirred culture to 
static culture flasks would provide an environment possibly resembling wound 
application. Porcine keratinocytes were used to assess the biodegradability of the 
microcarrier beads and keratinocytes attachment to the culture flask surface in vitro. 
Theoretically, Cultispher G® microcarriers are gelatin based and hence biodegradable 
when applied to in vivo wounds. The gelatin beads would degrade as a result of cellular 
interactions and tissue matrix remodelling during wound healing.  
With future clinical applications in mind, the gelatin microcarriers would potentially 
biodegrade in the wound environment allowing keratinocyte migration. Ideally, the 
degradation would not produce infection or inflammatory reactions in vivo. Also 
keratinocytes would remain viable to differentiate and regenerate epithelial cover.  
The use of static culture is unlikely to achieve successful outcomes using microcarriers, 
since the lack of culture agitation would not allow keratinocyte attachment to 
microcarriers. In addition, the possibility of microcarrier degradation in the static 
culture could not be excluded.  
The results from the study 3.2, demonstrated that porcine keratinocytes migrated from 
microcarriers in culture flasks following degradation of the microcarriers. Porcine 
keratinocytes on Cultispher G® when seeded in tissue culture flasks, expanded to form 
colonies and the beads biodegraded without any adverse reactions. Porcine keratinocyte 
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expansion was maintained in the absence of culture infection or complications during 
the process of the degradation of the microcarriers in vitro. Keratinocyte cell attachment 
to the porous microcarrier surface was a reversible phenomenon allowing cellular 
migration when re-seeded into culture flasks. The lack of stirring within the culture 
allowed the microcarriers to precipitate and disintegrate within the culture medium. 
Hecht et al. (1997) used collagen-coated dextran microcarriers colonized with 
keratinocytes from human foreskin using a similar spinner flask culture technique. The 
colonized microcarriers were seeded into culture flasks and keratinocyte migration and 
proliferation were assessed. Immunohistological staining showed that keratinocytes 
migrated from microcarriers onto the surface of the flasks and proliferated to form a 
layer of epithelial cells. The results from section 3.2 were similar despite the lack of 
quantitative assessment of the proliferation of porcine keratinocytes following their 
attachment to the surface of the culture flask. No further qualitative assessment of 
proliferation was attempted as this would be investigated in the next studies primarily in 
spinner culture. 
The process of microcarrier degradation in static culture in the presence of cultured 
keratinocytes could be due to either due to cellular enzymatic activity or other factors 
within the culture medium. The degradation process is difficult to fully assess and 
specify the role of different factors and cellular interactions contributing to its 
fulfilment. 
Further assessment of keratinocyte cell attachment to the surface of the microcarriers 
was undertaken. The adhesion of cells to culture surfaces is fundamental to both 
traditional culture and to microcarriers culture. Freshly isolated animal cells of many 
types, and a few stable cell lines, fail to grow when they are suspended in fluid or in an 
agar gel (Stoker et al. 1968). If such cells make contact with a solid surface such as 
suitably treated plastic, however, they attach, spread and multiply. Their growth may be 
termed anchorage dependent (Stoker et al. 1968).  
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Keratinocyte proliferation is dependant among other factors, on adhesion to a suitable 
culture surface (Grinnell 1978) and microcarriers provide a suitable surface that 
enhances keratinocyte attachment (Grinnell and Minter 1978). Culture procedures affect 
the rate at which keratinocytes attach to culture surfaces. In microcarriers culture, the 
keratinocytes and the microcarrier beads are in a stirred suspension. An initial static 
period is required to allow for keratinocyte attachment prior to initiation of stirring. 
Previous studies showed that keratinocytes attach to the surface of microcarriers when 
visualised using SEM and laser confocal microscopy (Bancel and Hu 1996, Borg et al. 
2009). In these studies, the attachment of the keratinocytes to the microcarriers’ surface 
was not complete as some pores were left empty. These studies highlighted a possible 
limitation of using Cultispher G® microcarriers for keratinocyte cell culture. The 
inability of keratinocytes to attach to all pores of the microcarriers could reduce the total 
surface area available for cell expansion within the culture. 
In the study 3.3, the aim was to assess how porcine keratinocytes attach to the surface of 
gelatin microcarrier Cultispher G® using scanning electron microscopy (SEM). This 
would allow qualitative assessment of cellular attachment and the relation between 
keratinocytes and the porous surface of the gelatin microcarriers. SEM produces a rapid, 
direct, three-dimensional view of detailed surface structure over a distance of several 
centimetres with minimal preparation of tissue sample required (Salsbury and Clarke 
1967). 
The results demonstrated keratinocyte attachment to the entire surface of the 
microcarriers and cellular population of the pores. Keratinocyte attachment utilised all 
the available surface area on the microcarriers, with some overlap of the cell layers 
being observed. Keratinocytes attached to the microcarriers’ surface and utilised the 
culture surface provided by the porous surface and total beads surface area within 
limited volume. Again, the advantage of utilising the limited space was clear when 
comparing with traditional flask cell culture. 
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The findings from this study were different from the findings of Bancel and Hu (1996) 
and Borg et al. (2009). Keratinocytes attached to the entire surface of the microcarriers 
as seen using SEM in our findings. This was difficult to explain as the seeding and 
culture protocol used in the study were according to the manufacturer’s protocol and as 
described in Borg et al. (2009). The only modification was that the culture was left 
static for 48 hours rather than just 24 hours as described by Borg et al. (2009). The 48 
hours period was chosen to allow an initial longer period for attachment of the 
keratinocytes to the microcarriers. In the early steps of keratinocytes culture on 
microcarriers, minimal attachment to the microcarriers was observed after 24 hours; 
hence the static period was changed successfully to 48 hours. This may help explain the 
difference between the findings reported here and those of Bancel and Hu (1996) and 
Borg et al. (2009). 
The suitability of Cultispher G® gelatin microcarriers to support human and porcine 
keratinocyte cell culture was established from the previous studies. The next 
investigation looked into the use of 3T3 cells within porcine keratinocyte cell culture on 
microcarriers. The use of 3T3 mouse fibroblasts in keratinocyte cell culture is critical to 
support keratinocyte proliferation in vitro. The same is not necessarily applicable to 
keratinocyte cell culture on microcarriers. 
The use of 3T3 feeder cells in keratinocyte cell culture is well established with the 
presence of murine fibroblasts within the culture supporting keratinocyte proliferation 
and colony formation (Navsaria et al. 1995). The use of microcarriers in human 
keratinocyte cell culture negates the use of 3T3 cells for keratinocyte cell culture (Borg 
et al. 2009, Bayram et al. 2005).  
Several studies demonstrated human keratinocyte cell culture without 3T3 feeder cells 
on microcarrier beads following initial expansion (Katayama et al. 1987, Gorodetsky et 
al. 2004). Porcine keratinocytes and their cell culture and attachment to microcarriers 
without 3T3 cells could be possible as demonstrated with human keratinocytes and their 
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cell culture on microcarrier beads. The absence of 3T3 cells from the porcine 
keratinocyte microcarriers’ culture has the potential to reduce infection, cost, culture 
maintenance, and produce a defined culture. However in this study, the initial expansion 
of keratinocytes included the addition of 3T3 cells to the culture, further keratinocyte 
expansion was assessed in the absence of 3T3 cells. 
In the study 3.4, porcine keratinocytes were cultured in the absence and presence of 3T3 
cells and the results compared. The results showed that microcarriers supported the 
proliferation of porcine keratinocytes in the presence or absence of 3T3 feeder cells in 
stirred culture. The primary expansion of keratinocytes was in culture flasks in the 
presence of 3T3 cells since the removal of 3T3 cells could not be negated despite 
several attempts to do so. Later, keratinocyte culture on microcarriers in stirred culture 
was achieved in the absence of 3T3 cells. Qualitative assessment using Acridine orange 
and MTT staining at various time points demonstrated porcine keratinocytes attachment 
and expansion. These findings were again similar to results reported by Borg et al. 
(2009), where initial expansion of keratinocytes was undertaken in the presence of 
murine 3T3 feeder cells.  The possibility of keratinocyte expansion in defined media or 
without 3T3 cells prior to seeding on microcarriers requires further investigation, and 
was not undertaken. However, there are no reports up to date of porcine keratinocyte 
expansion on gelatin microcarriers in stirred culture in the absence of 3T3 cells. 
The failure in the primary expansion of porcine keratinocytes in culture flasks without 
3T3 cells emphasised the important role of 3T3 fibroblasts in the attachment of 
keratinocytes and initial expansion in vitro. Quantitative assessment using Trypan blue 
for cell counts at the same time points demonstrated comparable cell counts in culture 
with or without 3T3 cells. Keratinocyte cell count was slightly higher in the absence of 
3T3 cells, averaging 1 to 3 x 106 higher than cell counts in the presence of 3T3 cells 
across 12 days. As cell count using Trypan blue included viable cells only, it was 
assumed that in culture flasks including keratinocytes and 3T3 cells, the count did not 
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include 3T3 cells. No significant differences in cell counts without 3T3 cells were noted 
from this study. Interpretation of these results needed to take into consideration the 
potential advantages of keratinocyte cell culture without 3T3 cells, even if cell counts 
were only comparable to traditional culture. Dispensing with the use of 3T3 cells in 
keratinocytes cell culture for clinical use remains a major advantage not only avoiding 
xenogenic cells presence within the culture, but also reducing infection, culture 
contamination, and maintenance requirements. The optimisation of stirred microcarrier 
culture is likely to improve keratinocyte expansion and cell population doubling in the 
future leading to culture up-scaling in a larger bio-reactor model. 
Since, porcine keratinocyte expansion was achievable in stirred culture in the absence of 
3T3 cells, subsequently porcine keratinocytes were cultured in the absence of 3T3 for 
further in vivo animal wound model studies.  
Analysis of keratin expression supports the understanding of keratinocyte proliferation 
in mono-layered culture. In human and porcine epidermis, all basal keratinocytes 
synthesize Cytokeratins K5 and K14, and sometimes K15 and K17 (Sun et al. 1983). 
K14 is an epidermal keratin, which is paired with K5 and located in the proliferating 
basal cell layer of stratiﬁed squamous epithelium (Chu and Weiss 2002, Alam et al. 
2011). K14 is a prototypic marker of dividing basal keratinocytes and helps in the 
maintenance of epidermal cell shape; it also provides resistance to mechanical stress.  
Keratins K14 and K5 are considered biochemical markers of the stratified squamous 
epithelia, including epidermis (Moll et al. 1982, Sun et al. 1983, Coulombe et al. 1989). 
K14 and K5 are transcribed at a high level in epidermal proliferation; hence K14 gene 
assay can be used for assessment of epidermis-specific transcription (Sinha et al. 2000, 
Alam et al. 2011).  
Keratin synthesis and expression in vitro is similar to in vivo expression and can be used 
to assess keratinocyte proliferation.  
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The availability of K14 antibody suitable for detection of K14 in pigs, made K14 
immunohistochemical staining achievable compared to K5 (in which a suitable antibody 
was not available) in the porcine wound model used in this study. The pairing of 
K14/K5 can be used as a proliferation marker for basal epithelium (Purkis et al. 1990). 
Hence measurement of K14 mRNA was used to assess keratinocyte proliferation in 
vitro in this study. Quantitative assessment of K14 expression by porcine keratinocytes 
in vitro was done using total RNA isolation followed by real-time qualitative PCR 
(qPCR) of K14 mRNA using GAPDH was used as housekeeping gene. 
MTT assay is a standard colorimetric assay measuring the activity of enzymes reducing 
MTT to formazan. It can be used for the assessment of cellular proliferation, including 
keratinocytes (Vistejnova et al. 2009, Peura et al. 2010, Lu et al. 2012). MTT assay was 
used to quantify cellular proliferation in the culture plotted against a standard curve of 
serial porcine keratinocyte cell counts. The MTT assay results were compared to the 
results of RNA isolation and RT-qPCR; also the results were used to calculate cell 
counts at different time points. The MTT assay results and keratinocyte cell counts 
demonstrated progressive increases in numbers along the study period, which verified 
keratinocyte expansion on microcarriers. The findings were similar to the results from 
the previous in vitro studies, which demonstrated keratinocyte expansion without clear 
evidence of cellular proliferation on microcarriers in stirred culture. 
K14 expression was positive and relative expression to GAPDH demonstrated an 
increase in K14 expression from day 14 to day 21. The expression of K14 demonstrated 
relative porcine keratinocytes proliferation with positive phenotyping of basal 
epithelium-like cells. Atiyeh and Costagliola (2007) demonstrated that cultured 
epithelial autografts suffered poor graft take i.e. adherence in clinical practice. This was 
attributed to the high proportion of differentiated cells within the cultured epithelial 
autografts. These cells are unable to further proliferate following application to wounds 
resulting in poor take.  
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Since basal keratinocytes are mainly non-differentiated keratinocytes, the findings from 
the study 3.5 provided support of the use of stirred microcarrier culture for keratinocyte 
expansion and culture. The use of microcarriers stirred in culture provides an alternative 
source of expanded, non-differentiated keratinocytes for wound application, compared 
with traditional culture techniques. This assumes that the microcarriers delivered this 
way would degrade within the wound environment and have no adverse effect on the 
subsequent keratinocyte migration and proliferation. 
In comparing the MTT assay and K14 expression results carried out in study 3.5, the 
MTT assay demonstrated cell expansion without keratinocyte proliferation; K14 
expression on the other hand demonstrated relative keratinocyte proliferation. As K14 
expression is mainly seen in basal epithelium, the proliferation was of basal-like 
keratinocytes phenotype within the stirred culture. This phenotype specific proliferation 
was not translated as a general keratinocyte population proliferation as shown by the 
MTT assay. 
Human keratinocytes have been cultured in co-culture with autologous fibroblasts 
replacing feeder 3T3 cells (Jubin et al. 2011). The authors demonstrated that autologous 
porcine keratinocytes formed colonies and proliferated in the presence of autologous 
ﬁbroblasts in two types of media. The ratio of keratinocytes to fibroblasts was 6:1, and 
ﬁbroblasts did not overgrow the cultures, compared to ratios less than 6:1. This was in a 
similar manner to culture in the presence of lethally irradiated 3T3 cells. 
The presence of autologous fibroblasts in culture may have a role in epithelial 
regeneration in vivo. Assessment of porcine keratinocyte proliferation in co-culture with 
autologous fibroblasts was essential prior to use in an animal model. Green Fluorescent 
Protein (GFP) labelling of porcine keratinocytes prior to seeding on microcarriers 
enabled their detection later using fluorescent microscopy.  
In the study 3.6, lethally irradiated murine 3T3 feeder cells were replaced with 
autologous non-irradiated ﬁbroblasts. Based on the results of Jubin et al. (2011), the 
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same ratio of 6:1 keratinocytes to fibroblasts was used in the study. Porcine 
keratinocytes were GFP labelled to allow qualitative assessment of their expansion 
within the co-culture with fibroblasts. The MTT assay was used for quantitative 
assessment comparing porcine keratinocytes culture and porcine keratinocytes 
fibroblasts co-culture. 
The results demonstrated porcine keratinocyte expansion and attachment to 
microcarriers in the presence of autologous fibroblasts in stirred culture. The MTT 
assay results were slightly increased in keratinocytes fibroblasts co-culture compared to 
keratinocytes culture alone. The difference was not statistically significant with p value 
0.357. The variation in the MTT assay results could be attributed to the presence of 
autologous fibroblasts, which were not irradiated compared to 3T3 cells. The results did 
not provide evidence of keratinocyte proliferation. 
The fact remains that the use of microcarriers to support keratinocytes culture is a 
developing culture technique, which would require further optimisation to ensure 
keratinocytes proliferation in vitro. The use of microcarriers could provide an improved 
handling and delivery method for keratinocytes culture in the future with optimisation. 
With similar keratinocytes expansion rates, the advantages of microcarriers culture 
would favour its use over conventional culture flask culture. The advantages include the 
large surface area to volume ratio offered by microcarriers and improved control of 
culture parameters (van Hemert et al. 1969). Reduced requirements for culture medium, 
labour, and less risk of contamination (since less handling of the cells in culture is 
usually required) are among other potential advantages. 
The application of proliferating keratinocytes within cultured autografts would provide 
cells that are able to re-epithelialise skin defects. Therefore, further assessment of 
proliferation of keratinocytes within stirred culture is required to evaluate the efficiency 
of the culture method. Since keratinocyte proliferation is an important parameter when 
comparing keratinocyte culture on microcarriers with traditional culture methods. 
 160 
The results from the previous in vitro studies demonstrated successful expansion and 
attachment of human and porcine keratinocytes on gelatin microcarriers in stirred 
culture. Keratinocytes attached easily to the porous surface of the microcarriers and 
expanded in the absence of 3T3 feeder cells. The limitations of the outcomes were clear, 
as the results did not provide clear evidence of keratinocytes proliferation on 
microcarriers in vitro. The limited evidence of keratinocytes proliferation was provided 
by K14 expression in study 3.5 demonstrating proliferation of basal-epithelium of non-
differentiated keratinocytes. 
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8.2	  Discussion	  of	  in	  vivo	  studies	  
Using traditional keratinocyte culture in culture flasks, cultured epithelial autografts 
(CEA) are harvested using dispase from the flasks and applied on wounds. Proliferating 
keratinocytes within the CEA continue to proliferate in the wound environment and re-
epithelialise the wound bed. Cultured keratinocytes could be applied to the wound in a 
pre-confluent state, which improves survival and re-epithelialisation rates (Harris et al. 
1998). Several methods have been described for the delivery of cultured keratinocytes 
to the wound bed for clinical application. Keratinocytes can be applied on a delivery 
membrane or in the form of cell suspension. The delivery membrane can be made of 
either synthetic or biological material, and the cell suspension can be delivered as a 
spray or droplet (Andree et al. 2001).  
Chester, Balderson and Papini (2004) reported that the delivery of cultured 
keratinocytes as cell spray was more efficient in epithelial regeneration when compared 
to membrane delivery. In vitro comparisons of keratinocyte delivery methods have 
shown cell spray as more efficient when compared with other methods (Fredriksson et 
al. 2008). Keratinocyte cell delivery as cell spray provides higher cellular viability, 
adherence, and proliferation (Fredriksson et al. 2008). Application of cultured 
keratinocytes in a cell suspension or spray can accelerate epithelial formation 
(Magnusson et al. 2007, Wood et al. 2006). Based on these studies, cultured 
keratinocyte cell delivery as cell spray was chosen as the standard delivery method to 
compare with microcarriers in the in vivo animal studies.  
In order to assess the rate of survival of keratinocytes on microcarriers and their 
possible role in wound re-epithelialisation, an animal wound model is required. An 
animal model should provide a similar wound environment mimicking clinical 
application in patients.  
Montagna and Yun (1964) analysed pig skin sections from multiple anatomical sites to 
find an animal model similar to human skin. Their findings showed that the anatomy of 
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porcine skin was the most similar to humans. The choice of the porcine wound model 
was based on previous studies, which reported using the same model (Bevan et al. 1997, 
Ng et al. 1997, Grant et al. 2001). These studies showed good correlation between the 
porcine wound model and human wound healing. The findings indicated the suitability 
of this animal model for pre-clinical investigations of treatments for full-thickness 
wounds in humans, hence the pig wound model was chosen as the in vivo model.  
The early efforts for creating an isolated wound chamber in vivo within an animal model 
included the use of intra-peritoneal diffusion chambers (Algire 1957, Algire et al. 
1958). Later efforts included granuloma air pouches to study the effect of steroids on 
local tissue (Selye 1953). Cutaneous silicone implants were used to study wound 
healing following application of cultured keratinocytes (Worst et al. 1974). Kangesu et 
al. (1993b) further developed the silicone implants to produce polytetrafluoroethylene 
(PTFE) wound chambers for use in a pig wound model. PTFE is a per-fluorocarbon 
polymer compound commonly used as an alloplastic implant material. It is inert and 
non-adhesive when interacting with various tissues and it has been shown to be non-
toxic to keratinocytes in vitro (Kangesu et al. 1993b). Kangesu et al. (1993a) later 
reported using the PTFE wound chambers successfully to assess keratinocyte growth 
following application of cultured keratinocytes on dermal defects. 
From the above evidence, the decision to use the PTFE wound chambers in the pig 
wound model for assessment of keratinocyte growth and migration was taken. Porcine 
keratinocyte grown on Cultispher G® gelatin microcarrier beads were applied to full 
thickness wounds with PTFE chambers. This was compared with application of sprayed 
cultured keratinocytes using a standard spray nozzle. The fate and survival rate of the 
cultured keratinocytes were assessed to understand whether the cells would continue 
proliferation in the wound environment or not. 
As the cultured keratinocytes migrate and become part of the newly formed epithelium, 
a cellular marker is required to identify the cells post transplantation. Ideally, the marker 
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should be stable and remain unchanged during cellular proliferation, and also resistant 
to the histological preparation of tissue samples. Retroviral labelling has been 
previously used in a porcine wound model to identify cultured keratinocytes (Ng et al. 
1997, Bevan et al. 1997, Grant et al. 2001). In these studies, the lac Z gene was used as 
a cell marker, the main disadvantage was the gene required tissue processing to identify 
and as a result further histological staining was compromised. Green fluorescent protein 
(GFP) does not require tissue processing prior to cell identification hence is ideal to use 
as an initial assessment tool. Further histological staining is not affected and allows 
tissue processing to assess epithelium regeneration and wound healing. GFP retroviral 
labelling of porcine keratinocytes was chosen in this experiment as a marker for 
keratinocytes post wound application.  
In addition to GFP tracing in tissue sections to investigate the survival rate of cultured 
keratinocytes, immunohistochemical staining for K14, laminin and collagen VII were 
used. K14, laminin, and collagen VII were used to assess the rate of epithelial formation 
and quality of the newly formed epithelium following cultured keratinocyte application. 
The results from this study demonstrated that the application of keratinocytes on gelatin 
microcarriers in full thickness wound chambers led to keratinocyte migration and 
survival in a wound environment.  
The choice of Cultispher G® microcarriers aimed to avoid complications such as foreign 
body reaction or granuloma formation as the microcarriers were biodegradable in 
comparison with non-biodegradable microcarriers. Other types of microcarrier beads 
such as PLGA [polylactic-co-glycolic acid] have been shown to remain with the tissues 
and resist resorption (Kim et al. 2005).  
In the study in section 4, 3 treatment groups with 12 wounds in total, no wound 
infections or adverse reactions from the microcarriers’ application were noted. The 
termination of this study was chosen at day 15 to trace the GFP labelling of the 
keratinocytes post application. Ng et al. (1997) showed that in a porcine wound model 
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with de-epithelialised dermis, cultured keratinocytes labelled with Lac Z gene were 
identified 3 weeks post application. Grant et al. (2001) and Svensjo et al. (2001) 
reported similar transduction rates at 8 days with the transduced cells in the 
differentiated layers of the epithelium and not the basal layer. The loss of Lac Z gene 
expression was noted to increase after day 8 with no identification of transduced cells 
(Svensjo et al. 2001). Also expression of GFP has been shown in retro-virally labelled 
cultured keratinocytes in an immuno-compromised nude mouse model (Spandau et al. 
2000, Del Rio et al. 2002).  
The porcine wound model used in this study was immuno-competent, and in this 
porcine model a loss of GFP expression was noted by 4 weeks despite a high 
transduction rate (Pfutzner et al. 2006). The loss of GFP expression could be related to 
the host immune response against the transgene expression (Lu and Ghazizadeh 2007). 
Therefore, 2 weeks represented an appropriate time point to trace GFP labelled 
keratinocytes within the wounds before the decline in GFP expression in 3-4 weeks. 
GFP positive areas were found at the surface of wounds in the MCAK and SAK groups 
confirming the survival of keratinocytes in the 2 groups. Statistical analysis of the 
intensity of GFP expression within 3 random sections in 2 x 2 mm area within the 
epidermis using macro application on Axiovision® software showed no difference 
between the 2 groups. There was no advantage to microcarrier delivery of keratinocytes 
over cell spray in regards to GFP expression. Collectively, Keratinocytes’ application 
using microcarriers as a delivery method provided similar results to application using 
cell spray.  
At day 15 when the study was terminated, no full epithelial coverage was noted 
macroscopically in any of the 3 groups. This can be attributed to the short study period 
and possibly the lack of dermal support to the cultured keratinocytes in a full thickness 
wound model. In this study, the lack of dermal support within the wound represented a 
challenge to the survival of the keratinocytes post wound application. The end target of 
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full wound re-epithelialisation was not the aim of this study, and was assessed in further 
studies utilising the same wound model. 
The two groups microcarriers autologous keratinocytes and sprayed autologous 
keratinocytes (MCAK & SAK) showed positive immuno-staining for K14 and laminin. 
Collagen VII immuno-staining was negative in the two groups, and all immuno-staining 
for K14, laminin, and collagen VII was negative in the control group. Interpreting these 
results, statistical analysis of K14 staining in the MCAK and SAK groups showed more 
K14 positive areas in the MCAK group. The number of cells applied to each wound 
chamber in the 2 groups was 1 x 107 as confirmed by cell count following harvesting 
from tissue culture flasks.  
Therefore, the keratinocytes in the MCAK group expressed a higher number of basal-
like phenotype keratinocytes in the wound post application compared to the SAK group. 
This assumption relied on the statistical difference in K14 staining when comparing the 
two groups; understandably, the reliability of this method is limited. If available, retro-
viral labelling of keratinocytes using a traceable vector in vivo would provide a more 
reliable method. The different cell handling methods in the 2 groups prior to wound 
application could possibly explain this finding. In the MCAK group, microcarriers 
seeded with keratinocytes were simply pipetted from the stirred culture to universals 
prior to pipetting on to the wound. In the SAK group, trypsin was used to harvest the 
cells from the culture flasks into a cell suspension prior to spray on the wound. The 
effect of trypsin use on keratinocyte migration or proliferation in vivo is unclear, but it 
could have produced a negative effect.  
The positive expression of laminin as an early marker of basement membrane in the 
MCAK and SAK groups was interesting. In both groups, laminin expression showed a 
different pattern to the overall distribution in granulation tissue in the control group. 
Laminin expression in the form of a dense pattern concentrated towards the wound 
surface in the MCAK and SAK groups, demonstrated the potential to regenerate mature 
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epithelium on full thickness wounds. Whether this could ultimately be achieved 
remained unclear due to the lack of dermal support and the termination of the study at 
15 days. Regeneration of epithelium in combination with various types of dermal 
replacement therapies was investigated in further studies. 
Currie et al. (2003) compared the application of SAK and AK in ﬁbrin glue to full 
thickness wounds in a porcine wound chamber model. The authors reported only 
approximately 25% of the wounds showed epithelial cover after 3 weeks of treatment. 
The findings from the study described in chapter 4 were similar, as wound healing was 
not achieved in the 2 weeks period. 
Immuno-staining for collagen VII was negative in the 3 treatment groups, indicating the 
lack of a fully formed basement membrane within a mature epithelium. The findings 
confirmed the need for dermal replacement therapies to achieve full epithelial closure. 
This study provided a proof of concept that gelatin microcarriers could be used to 
transfer autologous cultured keratinocytes to full thickness wounds in vivo. Keratinocyte 
cell culture on microcarriers in stirred culture had no negative effects on cell survival or 
expansion in vivo. Further studies were required to assess whether full epithelial closure 
is achievable using microcarriers for autologous keratinocyte culture and delivery. 
Generally, cutaneous wounds heal through a process that combines migration of 
keratinocytes from the wound edges and wound contraction. Wound contraction 
develops through the differentiation of dermal fibroblasts to myofibroblasts and their 
contractile action on the extracellular matrix through expression of α SMA (Wipff et al. 
2007). The differentiation of fibroblasts toward a myofibroblast phenotype is dependent 
on; mechanical tension, adhesion to extracellular matrix via integrin receptors, and 
stimulation by transforming growth factor beta (TGF-β) (Sharpe and Martin 2013). 
Wound contraction is an integral part of the process of wound healing; contraction of 
the wound edges provides wound closure and assists re-epithelialisation of the wound 
surface. Wound contraction in anatomical areas such as skin overlying joints leads to 
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the formation of “contractures” resulting in limitation of range of movement 
(Billingham and Medawar 1955, Parry et al. 2010). Scars resulting in contractures 
represent a major problem following skin loss after burn injuries or trauma. 
Contractures produce a functional deficit affecting patients’ rehabilitation and return to 
pre-morbid levels of activity. Contractures are usually associated with decreased 
physical function, physical role limitation, bodily pain, and decreased vitality 
(Schneider et al. 2006). Scar contracture by definition is an impairment caused by 
replacement of skin with scar tissue of insufficient extensibility and length (Boyce et al. 
2006b, Richard et al. 2009). Subsequently, contractures result in a loss of motion or 
tissue alignment of an associated joint or anatomical structure (Richard et al. 2009). 
Different studies investigated the use of nonsurgical methods to prevent the 
development of scar contractures. The use of various physiotherapy protocols 
(Okhovatian and Zoubine 2007) or splinting techniques (Wust 2006, Obaidullah et al. 
2005) have been described. Surgical techniques have also been described for the release 
of contractures, including the use of various flaps (Xie et al. 2012, Kim et al. 2012, 
Feng et al. 2010). Other techniques have also been described such as scar release (Kung 
et al. 2012, Grishkevich 2012, Daya 2008). 
In utilising various flaps whether fascio-cutaneous or musculo-cutaneous, the aim is to 
replace the scarred tissue with more pliable tissue offering less restriction of movement. 
In case of scar release, different techniques are used to either lengthen the scar or reduce 
the tightness, to provide more skin mobility over the affected anatomical site. 
It is understood that a wound left open will contract in a faster rate compared to another 
wound treated with a skin graft (Bertolami and Donoff 1979). Application of meshed 
skin grafts leads to poor quality scarring and formation of contractures when compared 
to split or full thickness skin grafts. Secondary contraction of skin grafts is more 
pronounced in split skin grafts due to the lack of dermis when compared to full 
thickness grafts. Another alternative is the use of dermal replacement therapies in 
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addition to skin grafting to reduce the formation of scar contractures. Alloderm®, 
dermal replacement product, was found to reduce post burn contractures over joints in 
combination with split skin grafts (Yim et al. 2010). 
The process of wound contraction is produced through the contractile forces exerted by 
myoﬁbroblasts during the normal process of wound healing (Gabbiani 1996). 
Myofibroblasts are a phenotype of differentiated ﬁbroblasts developing in the 
maturation phase of wound healing (Hinz et al. 2007). The differentiation of fibroblasts 
occurs in response to mechanical stimuli and the release of transforming growth factor 
beta 1 (TGF-β1) (Gabbiani 2003, Hinz 2007). During the process of granulation tissue 
evolution, fibroblasts acquire smooth muscle (SM) cell features (Gabbiani et al. 1971). 
These features include the presence of cytoplasmic microfilament bundles, which are 
the source of the force producing wound contraction (Gabbiani 1981).  This similarity 
with SM cells was confirmed when strips of granulation tissue were isolated and placed 
in a pharmacological bath. The granulation tissue contracted and relaxed under the 
influence of epinephrine, norepinephrine, and 5 hydroxy tryptamine producing 
contraction and relaxation similar to SM cells (Majno et al. 1971). The name 
myofibroblast was suggested to describe the modified and possibly contractile fibroblast 
(Gabbiani et al. 1972). Myofibroblasts have been shown to contain higher amounts of 
polymerized actin compared to normal fibroblasts in vivo.  
Wound healing is signiﬁcantly impaired in mouse models with an ablated myoﬁbroblast 
differentiation pathway (Blumbach et al. 2010, Liu et al. 2010). Therefore, wound 
contraction is a part of the process of wound healing, but excessive contraction is an 
undesirable effect. Excessive myoﬁbroblast activity within granulation tissue can lead to 
excessive scarring and contracture formation. The mechanism of wound contraction is 
not fully understood, but reducing the contraction rate can lead to improving the quality 
of scarring. It can also lead to preventing the development of contractures and their 
implications. Influencing the rate of wound contraction could lead to reducing the 
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formation of contractures across joint areas in particular leading to restoration of full 
range of motion. 
Other models have been described to investigate wound contraction, Elsdale and Bard 
(1972) introduced a ﬁbroblast-impregnated collagen gel model to study the behaviour of 
ﬁbroblasts and myoﬁbroblasts in vitro. This model has been extensively used to study 
wound contraction in vitro (Harrison et al. 2005) . The model used three-dimensional 
gels to induce morphological changes in ﬁbroblast similar to in vivo changes (Elsdale 
and Bard 1972).  
Harrison et al. (2006b) and Harrison and MacNeil (2008) reviewed the mechanisms 
behind wound contraction. Several theories were suggested to explain the process of 
wound contraction. Theories suggest that myofibroblasts either exert a pulling force or 
traction on collagen fibrils or extracellular matrix fibrils producing wound contraction. 
The pulling or traction force generates inward movement of the wound edges producing 
wound contraction and subsequent closure.  
The widely accepted theory for wound contraction is that contraction is brought about 
by the differentiation of ﬁbroblasts to myoﬁbroblasts (Majno et al. 1971, Gabbiani et al. 
1971). Fibroblast differentiation is accompanied by intrinsic expression of α-actin 
ﬁlament bundles (Welch et al. 1990). Myoﬁbroblasts have contractile properties similar 
to smooth muscle cells and the sliding movement of the actin filaments results in cell 
adherence (Montandon et al. 1977). As a result of cell adherence, a compact cell mass 
develops producing contraction of granulation tissue followed by inward movement of 
the wound edges. 
The need to provide better quality epidermal regeneration following application of 
cultured autologous keratinocytes resulted in a major shift. The use of undifferentiated 
single-cell suspensions and static carriers is currently recommended compared to 
differentiated cell sheets (Huss et al. 2007, Levine et al. 1977). As a result, a larger 
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proportion of the transplanted keratinocytes can contribute to epidermis regeneration 
compared to differentiated cells (Seland et al. 2011). 
Biodegradable porous microcarriers ‘Cultispher S®’ provided an optimal matrix for the 
adhesion, migration and proliferation of epithelial cells (Gustafson et al. 2007, Huss et 
al. 2010). Seland et al. (2011) reported that grafting of ‘Cultispher S®’ microcarriers 
coated with cultured keratinocytes into full thickness wounds in athymic rats resulted in 
a thick epithelium. The regenerated epithelium was thicker and also substantial soft-
tissue regeneration was noted compared to grafting with sheet-cultured keratinocytes. 
Application of skin grafts on full thickness wounds reduces wound contraction and 
hypertrophic scarring (Walden et al. 2000). However, skin grafts undergo primary 
contraction following harvesting and secondary contraction following application on the 
wound bed. Secondary contraction results in contracture formation and poor cosmetic 
outcome (Walden et al. 2000). Combination therapies using skin grafting and cultured 
keratinocytes may have a role in reducing wound contraction.  Other factors influencing 
wound contraction include; the wound bed and the skin graft thickness. Skin grafting on 
muscle fascia and full thickness skin grafts reduce wound contraction compared to 
mobile tissue and STSG (Corps 1969a, Corps 1969b).  
A complex relationship exists between keratinocytes and fibroblasts during the process 
of wound contraction. Myofibroblast differentiation is influenced by keratinocyte 
differentiation during wound healing (Boyce et al. 1991). Full thickness skin grafts 
reduce myoﬁbroblast differentiation and wound contraction compared to STSG (Corps 
1969a). The use of keratinocytes on microcarriers or as cell spray could add more 
keratinocyte cell volume to STSG resulting in reduced wound contraction. 
The measurement of the reduction in wound area over a period of time can quantify 
wound contraction in vivo (Lammers et al. 2011). This can be achieved through 
accurate measurements of wound area at different time points following the creation of 
a wound (Lammers et al. 2011). In the second in vivo study in chapter 5, the treatment 
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with MCAK and SAK, in conjunction with widely meshed STSG (6:1) was compared. 
Epithelial repair and wound contraction in both groups were compared with control 
using widely meshed STSG (6:1) alone. The use of the widely meshed STSG (6:1) was 
chosen, as it was unlikely to produce full epithelial wound closure due to the wide 
meshing pattern. 
Understanding the role of wound contraction in wound healing and the factors 
influencing the process is important. The primary mechanism for full thickness wound 
healing in mammals is wound contraction (Billingham and Medawar 1955). The 
mechanical movement of the wound edges towards the centre of the wound along with 
keratinocyte migration achieves wound closure (Billingham and Medawar 1955).  
Wound contraction may be prevented by covering the wound with a skin graft, thicker 
skin grafts reduce wound contraction more than thinner grafts (Billingham and Russell 
1956). The use of full thickness skin graft to cover a granulating full thickness 
cutaneous defect inhibits contraction (Billingham and Russell 1956). Full thickness 
wounds treated with STSG have been shown to contract less than wounds left to heal by 
secondary intention (Sawhney and Monga 1970). The epidermal and dermal 
components within the STSG allow wound closure via keratinocytes migrating from the 
skin graft. In addition, keratinocyte migration from the wound edges and wound 
contraction help achieve epithelial closure. The use of keratinocytes on microcarriers 
could possibly replace the epidermal component of the STSG, while the widely meshed 
STSG could replace the dermal component. 
In this study, the ability of MCAK or SAK to re-epithelialise the wound bed in 
conjunction with widely meshed STSG was investigated. This situation closely 
resembles clinical treatment regimes, where the lack of donor sites for STSG harvesting 
warrants wide skin graft meshing in combination with other treatments. In this study, 
the meshing procedure increased the surface area of the graft 6 times (6:1) and provided 
a thin STSG. The STSG alone was used as the control group in the study and the effect 
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on wound contraction following the application of MCAK and SAK on square full 
thickness wounds was assessed. The use of square wounds was to allow the natural 
process of wound edges’ contraction, which would not be possible with the use of PTFE 
wound chambers. Inward migration of keratinocytes from the wound edges in 
combination with wound contraction through fibroblasts and myofibroblasts lead to 
wound healing. The two processes occur in tandem and none alone would achieve 
wound healing.  
The use of keratinocytes cell suspensions in combination with STSG has been 
investigated previously. Keratinocytes cell suspensions provided the epidermal 
component, while the STSG provided the dermal component. Navarro et al. (2000) 
investigated the combination of cell suspensions and meshed skin grafts in a porcine 
wound model. More epithelial thickness and new vessel formation were noted in 
between the interstices of STSG in combination with cell suspensions compared to 
STSG alone (Navarro et al. 2000). Sprayed keratinocytes alone applied to full thickness 
wounds produced similar histological findings (Fraulin et al. 1998). 
The results from the second in vivo study demonstrated the use of autologous 
keratinocytes on microcarriers in combination with thin meshed STSG produced a 
reduction in wound contraction. The MCAK group showed wound contraction of 42.7% 
compared to 40.5% in the SAK group and 31.6% in the control group after 21 days. The 
values represented percentage reduction in the wound surface over the study period. A 
difference of 11.1% in wound contraction was noted between the MCAK group and the 
control group by day 21. Therefore, the wounds in the MCAK group contracted less 
than the SAK and control groups. Signiﬁcantly less wound contraction was noted in 
wounds treated with MCAK (p < 0.05; Holm-Sidak post hoc test).  
All the wounds from the three treatment groups were healed by day 21 despite the 
variation in wound area contraction. Full epithelial closure was achieved in all three 
groups; the difference in the epithelial structure in the three groups was shown in 
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histological analysis. The epithelial structure was fully developed in the MCAK and 
SAK groups compared to the control group. Basement membrane formation was 
positive in the three treatment groups confirming epithelial closure. Basement 
membrane staining was more intense in the MCAK group compared to the SAK and 
control groups. The variation in the histological findings could be explained by the 
fragility of the thin STSG alone in the control group compared to the combination 
therapy with autologous keratinocytes in the other two groups. Application of 
keratinocytes on microcarriers produced a structured epithelium, basement membrane, 
and a reduction in wound contraction. Also application of keratinocytes on 
microcarriers improved epithelium quality compared with SAK. It is unclear whether 
this effect was a result of the difference in the culture and application methods of the 
two treatments or due to a different factor.  
Noticeably animals possess a subcutaneous muscle layer “panniculus carnosus” 
enabling the skin to glide over deeper structures (Billingham and Medawar 1955). In 
humans, this muscular layer is absent and skin is attached to deeper structures. This 
difference in skin attachment between animals and humans allows extensive wound 
contraction in animals. In this study, wound closure was achieved in the three groups, 
despite the control group receiving widely meshed (6:1) STSG only. This can be 
attributed to the greater wound contraction ability in pigs compared to humans. It also 
highlighted the limitations of animal models for assessment of wound contraction 
compared to humans. 
GFP positive cells were not seen in any of the sections from the three groups after 3 
weeks. In similar studies, GFP labelled keratinocytes were not detectable after 3-4 
weeks despite evidence that transplanted cells survived (Pfutzner et al. 2006, Lu and 
Ghazizadeh 2007). 
From this study, it was possible to consider that the reduction in wound contraction was 
due to a change in the behaviour of fibroblasts or myofibroblasts. Their contraction 
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within the wound was reduced, although it is unclear how this effect was achieved. The 
reduction in wound contraction is considered a favourable outcome factor in a clinical 
setting where the limitation of skin mobility produces contractures and disability. 
Nillesen et al. (2011) reported the use of acellular composite skin replacement 
consisting of porous dermal layer of collagen type I, elastin, dermatan sulphate, heparin, 
Fibroblast growth factor (FGF) 2, and vascular endothelial growth factor. The dermal 
scaffold had a thin epidermal layer of collagen type I, heparin and FGF7. This skin 
replacement therapy produced a delay in wound contraction when compared to Integra® 
and control wounds left to heal by secondary intention in a rat model up to 14 days. By 
day 28, there was significant wound contraction in all the treatment groups with no 
statistical difference in the wound area (Nillesen et al. 2011). FGF2 and 7, and vascular 
endothelial growth factor may have a role in reducing early wound contraction in a rat 
excisional wound model (Nillesen et al. 2011). The role of similar paracrine factors in 
the pig wound model remains a possibility requiring further investigation to understand 
their role and effect on wound contraction. 
The interactions between keratinocytes and fibroblasts during the process of wound 
healing are complex (El Ghalbzouri et al. 2004, Le Poole and Boyce 1999). Andree et 
al. (2001) showed higher concentrations of transforming growth factor-β (TGF-β) in 
porcine wounds treated with sub-confluent keratinocyte suspensions compared to SAK 
and controls. Based on these results, there may be beneﬁts from the combination of cell-
based therapy with the application of STSG. The results from this study are consistent 
with our previous results comparing STSG and SAK treatments at Blond McIndoe 
Research Foundation (Reid et al. 2007). 
In the second in vivo study, widely meshed STSG was used to support autologous 
keratinocytes in achieving epithelial closure. The treatment in combination with MCAK 
produced reduction in wound contraction. The presence of a different type of dermal 
support could possibly alter wound contraction. The use of dermal regeneration 
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template in combination with MCAK and its effect on wound contraction was 
investigated in the next study.  
Allogeneic skin grafts showed signs of rejection in the porcine wound model 12 days 
following application (Richters et al. 2005). Allogeneic graft rejection in an immuno-
competent host is usually mediated through activation of T lymphocyte cells as 
previously explained. Achauer et al. (1986) reported the use of cyclosporin for 2 years 
in a case with extensive burns to stop allograft rejection. No graft rejection was noted 
during the 2 years or following the gradual withdrawal of cyclosporin.  Krupp et al. 
(1994) also reported the use of allografts in combination with Cyclosporin in a case 
report. Following the withdrawal of Cyclosporin, allografts were replaced with cultured 
autologous keratinocytes on allogeneic dermis. From these reports it is clear that the 
clinical role of allografts is limited to temporary wound cover, longer survival of 
allografts requires the use of immuno-suppressants.  
However, in case of extensive burn injuries, this temporary cover is sometimes vital to 
patient survival. The use of allogeneic keratinocytes on microcarriers can possibly 
replace the use of cadaveric allografts, which is the current clinical standard. The 
disadvantages of cadaveric allograft use such as limited availability, transport, and 
storage could be avoided with the application of cultured allogeneic keratinocytes on 
microcarriers.  
Integra®, dermal regeneration template (DRT) is composed of two layers; a bovine 
collagen-based dermal layer, and a temporary epidermal silicone sheet, which is 
removed following vascularisation of the dermal layer (Hansen et al. 2001). The dermal 
layer is composed of bovine type I collagen and shark chondroitin-6-sulphate, covered 
with a protective layer of nonporous silicone (Burke et al. 1981). The dermal layer is 
revascularised in 2-3 weeks providing a suitable wound bed for either ultra-thin skin 
grafting (150 µm) or cultured keratinocytes epidermal sheets. 
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Integra® was introduced as a treatment in burns surgery almost 30 years ago (Burke et 
al. 1981). In 1996, Integra® received U.S. Food and Drug Administration (FDA) 
approval for use as dermal regeneration template (Moiemen et al. 2006) and has been 
widely used since then. The role of Integra® in the treatment of major burns is to 
provide a temporary cover following the excision of burns. This provides valuable time 
for the next stage of epidermal cover during the vascularisation of the dermal 
component. In the meantime, physiological wound closure with minimising fluid loss 
helps to stabilise a critically ill patient. The use of Integra® has also been shown to 
reduce wound contraction in full thickness skin wounds (Reid et al. 2007). 
The main disadvantages of the use of Integra® are its high cost and the possibility of 
wound infection (Nguyen et al. 2010). Due to the fact that the dermal component 
requires 2-3 weeks for vascularisation, Integra® is susceptible to bacterial infection 
during that period. General factors such as the immuno-compromised status of burns’ 
patients and local wound conditions despite antibiotic cover play a major role. 
Heimbach et al. (1988) in a multi-centre randomised controlled trial compared Integra®, 
autografts, allografts and xenografts. They reported Integra® as superior in wound 
healing time compared to other types of skin grafting. In two major studies by 
(Heimbach et al. 1988, Peck et al. 2002) no major complications or safety issues were 
reported following the use of Integra®. Both studies reported patient mortality, which 
was related to extensive burn injuries especially inhalational injuries. No patient 
mortality was attributed to the use of Integra® in either of the two studies. 
In cases of extensive burn injuries and the lack of availability of skin graft donor sites, 
allografts can be used. Deceased donor allograft skin provides temporary cover of the 
burn wound in both partial thickness and full thickness skin loss. Allograft skin can also 
be used as a protective covering layer for widely meshed skin grafts (Alexander et al. 
1981). The use of allografts improves wound healing, reduces heat and ﬂuid loss, and 
improves scarring by restoring temporarily the protective role of the skin (Brychta et al. 
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2002). Allografts can also be applied as cultured epithelial sheets in the treatment of 
deep dermal burns (Brychta et al. 2002).  
The disadvantages of allograft use include graft rejection and limited availability. Host 
rejection occurs after patients recover from the immuno-compromised status of the burn 
injury.  The availability of allografts relies on tissue banks, and there is low risk of 
disease transmission. Ethical and cultural implications for donors and recipients also 
need to be considered (Burd and Chiu 2005). 
The combination therapy of Integra® and allogeneic cultured keratinocytes has potential 
applications in severe cases of burn injuries or skin loss. The lack of available skin graft 
donor sites warrants exploring alternatives to autografts. The use of Integra® produces a 
vascularised bed supporting the application of cultured epithelial allografts and could 
prolong their survival. 
Biobrane® is a biosynthetic dressing composed of a knitted nylon mesh that is bonded to 
a thin, silicone membrane and coated with porcine polypeptides (Hansen et al. 2001). 
Biobrane® has a variety of applications; it can be used as a temporary dressing for 
partial thickness burns or graft donor sites. It can be also used as a protective dressing 
over widely meshed split skin grafts initially to protect the fragile grafts from shearing. 
The design of Biobrane® allows its adherence to wounds and it can be trimmed away as 
wound healing progresses (Hansen et al. 2001). Biobrane® is considered an alternative 
to the use cadaveric allografts as it has similar properties to skin. Several studies 
established the safety and efficiency of Biobrane® as a temporary burn dressing 
(Gerding et al. 1990, Barret et al. 2000, Lal et al. 2000).  
Biobrane® was also found to reduce wound contraction in full thickness wounds in rat 
animal model (Frank 1984, Frank et al. 1984). The reduction in wound contraction was 
a result of mechanical splinting rather than influencing myofibroblast activity (Frank et 
al. 1984). Therefore, the use of Biobrane® could provide a protective layer to either 
keratinocytes on microcarriers or as cell spray post wound application.  
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Alpha smooth muscle (α-SM) actin is important for myofibroblast contraction taking 
into consideration that α-SM actin is widely expressed in contractile cells such as 
myoepithelial or vascular SM cells. The main role of these cells is contraction, hence it 
likely myofibroblasts have a similar contractile role in wound healing. 
 α-SM actin has been suggested as the most significant marker of myofibroblasts 
(Sappino et al. 1990). The presence of myofibroblasts correlates with wound 
remodelling phase including wound contraction. Therefore, α-SM actin is the cell 
marker generally present in the myofibroblasts of normally healing granulation tissue 
(Gabbiani 2003). During the progression of the process of wound healing, fibroblasts 
acquire SM cell features; in the form of myofibroblasts capable of contraction 
(Desmouliere et al. 1993). Myofibroblasts appear temporarily in normal wound healing 
and more permanently in excessive fibrosis such as hypertrophic and keloid scarring 
(Desmouliere et al. 1995). The role of myofibroblasts in wound contraction was 
highlighted through research into foetal wound healing. In foetal wound healing, 
regeneration is the dominating process over scarring, and there is no appearance of 
myofibroblasts in fetal scar-less wound healing (Adzick and Lorenz 1994). 
Wound scarring can be significantly reduced if epithelial closure is achieved within 
three weeks (Deitch et al. 1983, Deitch 1985, Cubison et al. 2006). Therefore achieving 
epithelial closure is a priority, and if it cannot be permanent, then temporary closure 
using allografts or cultured epithelial allografts is recommended. It could be possible for 
cultured allogeneic keratinocytes to survive longer following wound application in 
combination with dermal regeneration template. The potential for using microcarriers as 
a delivery method could also be explored along with possible effects on wound 
contraction.  
In full thickness wound reconstruction, different types of dermal substitutes serve as a 
scaffold to support cellular migration and wound healing (Truong et al. 2005). Dermal 
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substitutes support re-epithelisation activity, which is achieved via a wide variety of 
additional treatments.  
Some disadvantages to the use of Integra® in both clinical and experimental settings 
have been reported. Stern, McPherson and Longaker (1990) reported that 14.4% of 
human patients who received Integra® developed foreign body granuloma cells and 
eosinophil infiltration. Truong et al. (2005) demonstrated numerous foreign body 
granuloma cells in Integra®  treated wounds in a nude mouse model. They attributed the 
findings to a reaction to the constituents of Integra®, which could delay the 
vascularisation process.  
Overall as discussed before, the safety of Integra® and its effect in reducing wound 
healing time has been established (Heimbach et al. 1988). Also in previous work by our 
research group, Integra® was shown to reduce wound contraction (Reid et al. 2007). 
The combination therapy of Integra® and delivery of allogeneic cultured keratinocytes 
could have a future potential. As in the use of allografts, the concept of allogeneic cells 
could possibly postpone the need for immediate definitive treatment. Commercial 
products currently available include Cryoskin® (Altrika, Sheffield, United Kingdom), 
which can be provided on patient-by-patient basis in the UK. This is crucial, in cases of 
lack of available autografts or cultured autologous keratinocytes, to stabilise a critically 
ill patient temporarily. Several studies reported successfully the use of allogeneic 
cultured keratinocytes for treatment of chronic wound (Bayram et al. 2005, Martin et al. 
2005) and recently a phase 2 randomised placebo-controlled multi-centre trial involving 
205 patients (Kirsner et al. 2012). Allogeneic keratinocytes delivered to diabetic foot 
ulcers on Cytoline1™ microcarriers (polyethylene & silica) achieved wound healing in 
three weeks (Bayram et al. 2005). 
The use of Biobrane® in the study in section 6 in combination with Integra® and 
allogeneic keratinocytes treatment was aimed at providing a protective and supportive 
layer to the cells. The concept of combining allogeneic keratinocytes with Biobrane® 
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has been previously reported in a rabbit wound model (Lin et al. 1993). Allogeneic 
keratinocytes irradiated prior to wound application on Biobrane® sheets completely 
resurfaced the wounds with by day 21 (Lin et al. 1993). This study showed that the use 
of allogeneic keratinocytes could generate epithelium leading to wound closure. 
In this study, the use of allogeneic keratinocytes on microcarriers and as cell spray on 
Integra® was compared to a clinically standard treatment. The Integra® application 
followed by ultra-thin split thickness skin graft (uSTSG) application in 2-3 weeks is 
widely used in the treatment of full thickness burns’ (Pham et al. 2007). No Biobrane® 
was applied to the control wounds, as there is no indication for Biobrane® use in 
combination with uSTSG. 
Integra® was used as dermal replacement and to provide support to MCAlK and SAlK 
following wound application. As expected, the application of Integra® maintained the 
wound surface area up to day 21, when treatment was applied. It was noted from 
previous studies and discussed in chapter 5 that control wounds treated with widely 
meshed STSG alone were healed by day 21. Hence, the role of Integra® in reducing 
wound contraction and maintaining wound surface area can be assumed.  
Notably the vascularisation of Integra® was complete around the second week post 
wound application. This finding is different from the manufacturer’s recommendation 
for clinical application, which recommends 3 weeks for vascularisation: 
(http://integralife.com/products/pdfs/634199956311907893_IDRT_Treatment_Guidelin
es_ER3341.pdf)  
It is possible that the rate of vascularisation of Integra® is different in the porcine wound 
model compared to humans. The use of Integra® with non-cultured cell suspension has 
been reported as a single stage procedure resulting in re-epithelisation (Wood et al. 
2007). The rapid rate of vascularisation of the template in the porcine model contributed 
to the one stage wound closure (Wood et al. 2007). 
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Transplanted allogeneic skin to a healthy recipient would undergo a rejection process 
leading eventually to the destruction of the graft in around 14 days (Richters et al. 
2005). The allograft rejection is mediated by activation of T cells, which can 
specifically destroy major histocompatibility complex–incompatible cells (Richters et 
al. 2005). Epidermal Langerhans cells initiate the rejection process, where they migrate 
from the skin graft to the recipient’s draining lymph node of where activation of the T 
cells occur (Larsen et al. 1990). Dendritic cells within the dermis behave similarly 
producing further activation of the T cells (Richters et al. 1999). The use of cultured 
allogeneic keratinocytes lacking in Langerhans and dendritic cells has been reported 
(Phillips 1991). The use of allogeneic keratinocytes still does not produce permanent 
epithelium as graft rejection still occurs (Phillips 1991, Benichou et al. 2011). 
Following transplantation, the recipient T cells infiltrated the allogeneic graft or 
cultured epidermal sheets eventually causing rejection (Aubock et al. 1988). For 
definitive wound coverage, allogeneic cultured keratinocytes or grafts should be 
followed or combined with autologous cells or grafts. 
The results from the third in vivo study showed the two groups MCAlK and SAlK 
wounds demonstrated epithelial closure 21 days following treatment application. 
Despite the presence of some residual granulation tissue, a satisfactory wound closure 
of more than 90% was achieved. These results were similar to the results reported by 
Lin et al. (1993) in a rabbit wound model using irradiated allogeneic keratinocytes on 
Biobrane®. The results regarding full epithelial closure unfortunately cannot be 
replicated in humans, unless the host is immuno-suppressed. The combination of 
Integra®, allogeneic keratinocytes, and Biobrane® could be considered an option in 
severe injuries where temporary coverage is required until permanent coverage is 
available. 
The lack of GFP positive cells hinders the assessment of the origin of the newly formed 
epithelium in the MCAlK and SAlK groups. It is likely that wound healing in the two 
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groups was a result of epithelial migration from the wound edges rather than the 
allogeneic keratinocytes. The source of the keratinocytes contributing to wound healing 
in the MCAlK and SAlK groups was not clear. Keratinocytes migration from the wound 
edges was the likely explanation of how wound healing was achieved. Histological 
examination of the epithelium in the MCAlK and SAlK groups revealed similar quality 
to the control group. The combination treatments in the two groups played a role in 
promoting satisfactory wound closure comparable to autologous uSTSG use. 
The application of Integra® maintained the wound surface area up to day 21, when 
treatment was applied. From the previous study in section 5, control wounds treated 
with widely meshed STSG were healed by day 21, demonstrating the role of Integra® in 
reducing wound contraction. In this study, the vascularisation of Integra was complete 
around the second week post application. In further studies, the application of 
treatments 2 weeks following Integra® was considered to reduce the possibility of 
wound infections. 
The MCAlK group wounds’ area contracted 14.6% of the original wound area less than 
the wounds in the control group by day 42. The MCAlK group wounds’ area contracted 
4.6% of the original wound area less than the wounds in the SAlK group. The variation 
in wound contraction could be possibly related to the use of microcarriers for allogeneic 
keratinocyte delivery. Signiﬁcantly less wound contraction was found in wounds treated 
with MCAlK when compared with SAlK or uSTSG alone (adjusted p < 0.05; Holm-
Sidak post hoc test). 
In conclusion, there is a role for using allogeneic keratinocytes delivered on 
microcarriers in improving wound healing. The application of allogeneic keratinocytes 
on microcarriers in combination with Integra® and Biobrane® reduced wound 
contraction. The epithelial closure achieved in the MCAlK and SAlK groups is unlikely 
to be replicated in a clinical situation due to host rejection. The effect of autologous 
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keratinocytes with or without autologous fibroblasts delivered on microcarriers on 
wound contraction was assessed in the next study. 
The interactions between keratinocytes and fibroblasts in vivo during the process of 
wound healing are fundamental for the maintenance of keratinocyte cell culture in vitro. 
Rheinwald and Green (1975b) demonstrated that keratinocyte growth in culture is 
dependent on interaction with fibroblasts. The use of murine 3T3 fibroblasts in 
keratinocyte cell culture was originally described by Rheinwald and Green (1975a). As 
an alternative, the use of human fibroblasts in keratinocyte cell culture was also reported 
(Limat et al. 1990). The expression of growth factors such as Transforming growth 
factor-beta 1 (TGF-β1) and Interleukin-6 (IL-6) is up-regulated during wound healing 
(Werner et al. 2007). TGF-β1 production by keratinocytes stimulates fibroblasts 
proliferation resulting in IL-6 up-regulation (Desmouliere et al. 1993). IL-6 in return 
stimulates keratinocyte proliferation and the keratinocyte-fibroblast interaction 
continues during wound healing (Grossman et al. 1989). The differentiation of 
fibroblasts to myofibroblasts is modulated by cytokines such as platelet-derived growth 
factor (PDGF) (Tingstrom et al. 1992). Skin substitutes containing ﬁbroblasts 
demonstrated enhanced neovascularisation as fibroblasts expressed cytokines following 
application on wounds (Erdag and Sheridan 2004). Skin substitutes containing 
ﬁbroblasts showed better graft take, less contraction and enhanced vascularisation 
(Erdag and Sheridan 2004, Demarchez et al. 1992).  
Therefore, fibroblasts play an important role interacting with keratinocytes in vitro and 
in vivo. The interactions in vivo promote wound healing and result in optimum 
outcomes. Hence, the treatment of full thickness skin injuries with keratinocytes in the 
form of epidermal sheet grafts or cell spray could be improved by adding fibroblasts.  
During the wound healing process, ﬁbroblasts undergo migration from adjacent intact 
dermis to the ﬁbrin clot at the site of skin injury (Yang et al. 2012). In response to 
growth factors such as TGF-β1, extracellular matrix (ECM), and mechanical wound 
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tension, fibroblasts differentiate into myofibroblasts (Webber et al. 2009). As 
previously discussed, myofibroblast expression of α-SMA plays an important role in 
wound contraction. 
The co-culture of keratinocytes and fibroblasts demonstrated up-regulation of TGF-β1 
expression, increased ECM deposition, and induced α-SMA expression in ﬁbroblasts 
(Shephard et al. 2004b). Other studies have shown that keratinocytes suppressed the 
proliferation of co-cultured fibroblasts (Harrison et al. 2006a). The investigation of the 
interactions between keratinocytes and fibroblasts using monolayer culture in vitro may 
not be sufficient to study in vivo behaviour (Yang et al. 2012). The interactions between 
keratinocytes and fibroblasts are particularly evident in the late phase of wound healing 
during wound contraction and scar formation (Yang et al. 2012).              
As discussed in the previous study, the use of Integra® dermal regeneration template 
reduced wound contraction in combination with allogeneic cultured keratinocytes. The 
use of full thickness skin grafts (FTSG) to cover wounds is known to reduce contraction 
(Rudolph 1980). Further studies using Electron microscopy demonstrated that FTSG did 
not influence myoﬁbroblast populations or differentiation (Rudolph 1980, Vande Berg 
and Rudolph 1985). The application of FTSG led to myofibroblasts disappearing from 
the wound earlier than wounds without FTSG (Rudolph 1979, Vande Berg and Rudolph 
1985). Artificial dermal substitutes and biomaterials aiming at restoring the dermis 
should ideally be enriched with keratinocytes and fibroblasts to resemble FTSG.  
The possibility of application of ﬁbroblasts in combination with dermal substitutes 
could have the potential to improve dermal regeneration. This in turn would lead to the 
reduction of wound contraction and improving the functional and aesthetic outcomes of 
skin replacement therapy compared with current available treatments. Worth noting that 
fibroblasts differentiation into myofibroblast is a part of the normal process of wound 
healing. Up to date, there are no available methods to control the number of fibroblasts 
differentiating into myofibroblasts. 
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The differentiation of fibroblasts to myofibroblasts in vivo is marked by an increase in 
the intracellular contractile capability of myofibroblasts (Rudolph and Woodward 
1978). The effect of dermal substitutes on fibroblast differentiation and wound 
contraction requires further investigation. The combination of autologous keratinocytes 
and fibroblasts with Integra® could lead to epithelial closure and possibly influence 
wound contraction. 
The in vitro replacement of murine 3T3 cells with human allogeneic fibroblasts (Sun et 
al. 2004) or irradiated human fibroblasts (Mujaj et al. 2010) has been described. Recent 
work by the Blond McIndoe Research Foundation demonstrated a ratio of 6:1 
keratinocytes to fibroblasts produced the maximum cumulative population doubling 
(Jubin et al. 2011). The effect of fibroblasts on wound re-epithelisation has been shown 
in a porcine wound model (Peura et al. 2012). The results showed that fibroblast 
aggregate-derived paracrine mediators stimulated epidermal regeneration in vivo (Peura 
et al. 2012).  
An important function of any potential skin substitute is to support the formation of an 
epidermal barrier restoring the physiological function of skin (Kempf et al. 2011). The 
need to restore the epidermal barrier remains a clinical priority, but the restoration of 
dermal architecture is also important (Klingenberg et al. 2010). Incorporating 
autologous cultured keratinocytes and fibroblasts within skin substitutes could 
potentially restore the epidermal and dermal skin architecture. Skin replacement therapy 
should ideally be able to reconstruct all layers of the skin including the epidermis and 
the dermis. The loss of the skin barrier function leads to a clinical challenge where 
restoration of the epidermal cover is a priority. Cultured epidermal sheet grafts provide 
an adequate treatment to restore the epidermis, but have many disadvantages. The 
fragility of the epidermal sheet grafts is mainly due to the lack of a dermal support 
within the grafts. Hence, combination therapy using cultured epidermal grafts and 
dermal replacements is recognised as an alternative approach (Heimbach et al. 1988).  
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Therefore, microcarriers could be used as a delivery method for autologous 
keratinocytes and fibroblasts in combination with Integra®. Other dermal replacements 
are available, but the use of Integra® has been shown to reduce wound contraction 
compared to STSG (Reid et al. 2007). In the assessment of in vitro porcine 
keratinocytes and fibroblasts co-culture in study 3.6, microcarriers supported 
keratinocytes fibroblasts co-culture in vitro. The effect of their application on the wound 
with regard to epithelial closure and wound contraction was assessed in the study in 
section 7. 
In the study in section 6, allogeneic keratinocytes on microcarriers and cell spray were 
compared to the standard therapy of uSTSG and Integra®. Since the results from this 
control group on the same animal model were available, 3 treatment groups were 
allocated in this study. The results from the 3 treatment groups were compared to the 
control group from the previous study in section 6. 
Dermal substitutes have been developed over the last 30 years (Burke et al. 1981). 
Integra® has been for many years the most widely used dermal substitute, but recently 
several new artiﬁcial dermal substitutes have been developed (Nguyen and Dickson 
2006).  Truong et al. (2005) compared different dermal substitutes in skin wound 
healing in a mouse model. All dermal substitutes were incorporated into the wound bed 
and wound contraction was decreased (Truong et al. 2005). A study comparing Integra® 
and Matriderm® in a rat model revealed no major differences in graft take rates or 
vascularisation (Schneider et al. 2009). Recently, five dermal substitutes including 
Integra® and Matriderm® were compared in a porcine wound model (Philandrianos et 
al. 2012). No major differences in wound healing or scar formation was found between 
the different dermal substitutes over a period of 6 months (Philandrianos et al. 2012).  
The use of microcarriers to deliver cultured autologous keratinocytes and fibroblasts in 
combination with Integra® is a novel concept. Dermal substitutes such as Integra® 
provide a scaffold onto which keratinocytes can migrate and repair the injury (Truong et 
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al. 2005). The results of this study showed the application of autologous keratinocytes 
and fibroblasts on microcarriers produced epithelial closure. Histological analysis 
showed a developed epithelium and basement membrane as demonstrated by immuno-
labelling of K14, Collagen VII and laminin. 
The mechanism of differentiation of fibroblasts into myofibroblasts in vitro was 
reported to be cell density dependent (Masur et al. 1996) . Fibroblasts seeded at low 
density produced a cell culture population consisting of 70-80% myofibroblasts. In 
contrast, fibroblasts seeded at high density produced cultures with only 5-10% 
myofibroblasts (Masur et al. 1996). The challenge of keratinocyte fibroblast co-culture 
is that fibroblasts have the potential to expand at rates higher than keratinocytes. 
Fibroblasts rapid expansion in co-culture in vitro can lead to overtaking the culture and 
suppressing keratinocyte activity. The ratio of 6:1 as reported by Jubin et al. (2011) was 
used in this study for keratinocytes and fibroblasts culture on microcarriers. The low 
seeding density of fibroblasts could have contributed to less myofibroblast proliferation 
in vivo. It is worth noting that this was a purely theoretical assumption as no 
keratinocyte to fibroblast cell count in the MCAK-FB group was undertaken prior to 
wound application. 
Kempf et al. (2011) reported the use of a denatured collagen microfiber scaffold seeded 
with human fibroblasts and keratinocytes for skin grafting. The scaffold was 
biocompatible, biodegradable, and delivered human fibroblasts and keratinocytes in an 
in vivo mouse model. The combined delivery of keratinocytes and fibroblasts in skin 
substitutes is more preferable than the delivery of keratinocytes alone. Theoretically, the 
combination of keratinocytes and fibroblasts can allow the regeneration of the epidermis 
and the dermis hence restoring the skin architecture. 
During the late phase of wound healing, cellular interactions are dominated by 
keratinocyte-fibroblast interactions (Werner et al. 2007). The wound-healing 
environment changes from an inflammatory phase to the formation of granulation 
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tissue. The formation of a new basement membrane zone in the neo-epithelium is a 
result of the interactions between keratinocytes and fibroblasts (El Ghalbzouri et al. 
2004). The composition of the basement membrane and its formation can also influence 
keratinocytes phenotype (El Ghalbzouri et al. 2004). Shephard et al. (2004a) analysed 
fibroblast responses to keratinocyte-derived stimuli in a comparative study. The authors 
compared mRNA expression of fibroblasts in monoculture with the fibroblasts co-
cultured with keratinocytes. Fibroblasts differentiated into myofibroblasts as shown by a 
time-dependent increase of α-SMA-positive mesenchymal cells (Shephard et al. 2004a). 
The expression data showed that several genes characteristic of TGF-β1 signalling were 
upregulated. Physical factors such as mechanical tension exerted by the wound edges 
play an important role in fibroblast differentiation. Shephard et al. (2004b) reported that 
fibroblasts differentiate into myofibroblasts after 1-2 days in co-culture with 
keratinocytes compared to control cultures of fibroblasts alone. 
Ideally, the interactions between keratinocytes and fibroblasts during wound healing 
should be replicated following the application of skin replacements. Therefore, skin 
substitutes should comprise keratinocytes and fibroblasts applied together in an attempt 
to replicate physiological wound healing.  
Several studies assessed wound healing using artificial dermal substitutes in vivo using 
a porcine model (Butler et al. 1999, Myers et al. 2007, Haslik et al. 2010). The studies 
assessed different modalities of dermal substitutes in combination with epidermal 
substitutes such as keratinocyte seeding, cultured epithelial autografts, and skin grafts. 
In a recent study, Philandrianos et al. (2012) compared five different dermal substitutes 
in a porcine wound model. The authors used 4 x 4 cm2 square wounds in a porcine 
animal model identical to the wound model in this body of work. The authors argued 
that all of the five dermal substitutes (Integra®, Renoskin®, Matriderm®, Proderm®, and 
Hyalomatrix®) had long term scar quality as good as a skin graft alone. Hence, the 
authors questioned the rationale behind using artificial dermal substitutes if the resulting 
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scarring and wound healing is comparable with skin grafts alone. Taking into 
consideration the findings from this study, there are real advantages for the use of 
artificial dermal substitutes. Artificial dermal substitutes are used clinically when there 
is no available donor site for skin grafting or in anatomical areas where dermal support 
is required in addition to skin grafting.  
In extensive cases of skin loss, the first stage application of dermal substitutes 
temporarily restores the physiological barrier functions of the skin. Integra® has a 
silicone layer that prevents fluid and tissue fluid loss from the wounds while 
vascularisation takes place. This allows time for cultured keratinocytes delivered on 
microcarriers or as epithelial autografts or cell spray to be ready. Therefore, artificial 
dermal substitutes continue to have an important role in the treatment of trauma and 
burns patients. 
In this study, a difference of 9.2 % in wound contraction area was noted between the 
MCAK-FB group and the MCAK group by day 21-post treatment. The reduction in 
wound contraction in MCAK-FB group could be partly explained by the presence of 
fibroblasts compared to MCAK and SAK groups. The three groups (MCAK-FB, 
MCAK, and SAK) had reduced myofibroblast activity demonstrated by a reduction in 
α-SMA expression compared with uSTSG and Integra® (used as control). The reduction 
in myofibroblast activity was not related to the use of microcarriers for cell delivery as 
SAK showed similar picture. The difference in wound contraction could be explained 
by the difference in laminin and α SMA distribution in the MCAK-FB and the other 3 
groups including the standard treatment combination of uSTSG and Integra®. 
The reduction in wound contraction in the MCAK-FB and MCAK groups compared to 
SAK provided evidence of an advantage to using microcarriers as delivery method. 
Using microcarriers to deliver keratinocytes and fibroblasts facilitated efficient cellular 
integration into the wound, hence enhancing wound healing and reducing contraction. 
Lamme et al. (2000) reported that the use of autologous ﬁbroblasts in conjunction with 
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acellular dermis reduced contraction in porcine full-thickness wounds. The reduction in 
wound contraction was accompanied by a reduction in αSMA-positive myoﬁbroblasts 
(Lamme et al. 2000). The results from the study in chapter 7 showed a reduction in 
αSMA-positive cells in wounds treated with keratinocytes alone or keratinocytes with 
ﬁbroblasts. Interpreting these results, it can be assumed that the addition of a cellular 
component in the form of autologous keratinocytes with or without fibroblasts led to a 
reduction in the contraction of healing wounds.  
The number of cells transplanted to the wound bed has a direct effect on wound 
contraction (Lamme et al. 2000). Further studies using variable cell counts on 
microcarriers are needed to establish whether the same effect can be replicated using 
microcarriers. The reduction in wound contraction discussed in chapter 7 could be a 
result of the combination of keratinocytes and fibroblasts or simply the effect of 
increased cell populations within the wound. 
A significant reduction in wound contraction occurred using microcarriers to deliver 
keratinocytes or keratinocytes with ﬁbroblasts in combination with Integra®. Similar to 
the findings reported by Lamme et al. (2000), the presence of additional cells in the 
granulation tissue possibly reduced the need for cells to migrate from the wound 
margins. This is a process that would normally bring them into contact with the signals 
necessary for myoﬁbroblast differentiation. It is also conceivable that keratinocytes or 
keratinocytes with ﬁbroblasts delivered on microcarriers can reduce wound contraction 
more than cells delivered in suspension. This could potentially be due to keratinocytes 
being damaged during process of harvesting from tissue culture flasks. The results from 
the study in chapter 7 support this assumption since wounds treated with cells on 
microcarriers contracted approximately 10% less than those treated with sprayed cells.  
The reduction in wound contraction area is a significant outcome following the 
application of keratinocytes and fibroblasts on microcarriers. Reducing wound 
contraction can clinically reduce the incidence of development of contractures.  
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In conclusion, the possibility of application of a skin replacement therapy capable of 
reducing wound contraction is promising. Further studies are required to assess 
keratinocytes and fibroblasts interactions on microcarriers in combination with or 
without different dermal replacements in vivo. 
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8.3	  Conclusion	  
The studies described in this body of work assessed the culture of human and porcine 
keratinocytes on gelatin microcarriers in vitro and in vivo. The studies also assessed the 
effect of application of porcine keratinocytes on microcarriers on wound contraction in 
vivo. This work presented the results of experiments to test the effects of microcarriers 
in culture and delivery of keratinocytes using a porcine model for full-thickness 
wounds. 
The traditional culture of human keratinocytes in culture flasks remains time consuming 
and expensive. Modifications to the standard keratinocyte cell culture in vitro can be 
introduced to reduce time and costs. Also the application of cultured epithelial 
autografts (CEA) in vivo is known to have disadvantages such as fragility and poor take. 
Hernon et al. (2006) reported the primary take of CEA at 45% in one burns unit over 
ten-year period. Other problems highlighted included the delay in treatment delivery 
and poor handling in vivo due to fragility. In comparison, keratinocytes seeded on 
microcarriers can be applied directly on the wound bed, as gelatin microcarriers are 
biodegradable hence improving the handling of cultured keratinocytes. Fragility and 
wound breakdown in the long-term require further assessment in a clinical model. 
In the in vitro investigations, results showed the ability of gelatin microcarriers 
‘Cultispher G®’ to support keratinocyte expansion in vitro in static and stirred culture. 
Analysis of microcarriers seeded with keratinocytes using SEM demonstrated that the 
cells attached to the entire surface of the microcarriers.  
Liu et al. (2006) demonstrated successfully the use of porcine gelatin microcarrier beads 
for human fibroblast culture for mass production of autologous living dermal 
equivalents. Borg et al. (2009) demonstrated that the use of  microcarriers for 
keratinocyte cell culture eliminated the need for feeder cells. The use of microcarriers 
also facilitated the development of an improved keratinocyte cell culture compared with 
traditional flask culture. In our in vitro studies, the results from comparing two types of 
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microcarriers showed similar findings, where 3T3 feeder cells were initially used in the 
microcarrier keratinocyte cell culture. In later in vitro studies, porcine keratinocyte 
expansion on microcarriers was achieved in the absence of 3T3 feeder cells. Dispensing 
with the use of 3T3 cells for the initial expansion of porcine keratinocytes was not 
achieved and remains a challenge. 
When seeded in static culture, porcine keratinocytes migrated from the surface of the 
microcarriers to tissue culture flasks and reached confluence. Cultispher G® 
microcarriers biodegraded within the culture medium without affecting keratinocyte 
expansion and subsequently confluence. This finding was similar to previous work by 
Malda et al. (2003), Chun et al. (2004), and Chung et al. (2008), which demonstrated 
the biodegradability of microcarriers for chondrocyte cell culture. Kim et al. (2005) and 
Gustafson et al. (2007) demonstrated the biodegradability of microcarriers for 
keratinocyte cell culture.  
Further studies were undertaken since the initial in vitro studies did not demonstrate 
keratinocytes proliferation on microcarriers. Quantitative assessment of porcine 
keratinocyte proliferation on microcarrier beads was performed using MTT assay, RNA 
isolation and real-time quantitative PCR. K14 was used as a marker for porcine 
keratinocyte proliferation. MTT assay results showed a progressive increase in cell 
count demonstrating porcine keratinocyte expansion. K14 assay results showed an 
increase in K14 expression demonstrating keratinocyte proliferation. 
The results from this study demonstrated keratinocyte-specific proliferation on 
microcarriers, which was not shown in the earlier in vitro studies. The earlier in vitro 
studies demonstrated keratinocytes attachment and expansion in microcarriers static and 
stirred culture without clear evidence of proliferation. 
Further assessment of in vitro porcine keratinocytes and fibroblasts co-culture on 
microcarrier beads was performed with future clinical application in mind. The results 
demonstrated porcine keratinocytes expansion in the presence of autologous ﬁbroblasts. 
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Autologous fibroblasts optimised growth and expansion conditions within the 
microcarriers stirred culture in a similar form to 3T3 feeder cells. The use of the 
autologous fibroblasts dispensed the use of 3T3 feeder cells within the microcarrier 
stirred culture. 
The initial expansion of keratinocytes in static culture in the presence of 3T3 feeder 
cells continued to be necessary due to problems with the initial attachment in culture 
following isolation. Replicating the results reported by Jubin et al. (2011) for human 
keratinocytes microcarriers culture using porcine keratinocytes would require further 
investigations to negate the use of 3T3 cells. 
Further studies investigating the secretion and availability of growth factors, matrix 
proteins, and the interaction between keratinocytes and fibroblasts are required. Also, 
further studies are required to dispense with the use of 3T3 feeder cells for the primary 
expansion of keratinocytes. The in vitro results despite their limitations signalled the 
possibility of investigating the use of microcarriers in an in vivo animal model. 
In conclusion, the in vitro results demonstrated that microcarrier keratinocytes culture is 
likely to have some beneﬁts over traditional culture methods. The results highlighted the 
future possibility of in vivo application of autologous keratinocytes and autologous 
ﬁbroblasts following successful co-culture. The utilisation of the keratinocyte 
microcarrier culture in clinical use requires further investigation in an in vivo animal 
wound model. The application of autologous ﬁbroblasts and keratinocytes could 
potentially have signiﬁcant beneﬁts in the treatment of skin loss providing an alternative 
to the fragile cultured epidermal grafts. 
Another area where microcarriers keratinocyte culture might have an impact is wound 
contraction. A signiﬁcant amount of wound contraction occurs during the process of 
wound healing and excessive wound contraction may result in the development of 
contractures. The role of keratinocytes and keratinocytes-fibroblasts co-culture on 
microcarriers in reducing wound contraction was investigated in the in vivo studies.  
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Several methods have been described for the delivery of cultured keratinocytes to the 
wound bed for clinical application. In vitro comparisons of keratinocyte delivery 
methods have shown cell spray as more efficient when compared with other methods 
(Fredriksson et al. 2008). Based on these studies, cultured keratinocyte cell delivery as 
cell spray was chosen as the standard delivery method to compare with microcarriers in 
the in vivo animal model. Previous studies showed good correlation between the porcine 
wound model and human wound healing. Hence the pig wound model was chosen as 
the in vivo wound model in further studies.  
Excessive wound contraction beyond the physiological process of wound healing leads 
to the development of wound contractures. A very close relationship exists between the 
time required for achieving wound healing and wound contracture formation. Wound 
healing within 3 weeks produces less scarring and contracture formation (Deitch et al. 
1983, Cubison et al. 2006). Therefore, early clinical identification of full thickness skin 
injuries requiring either skin grafting or skin replacement therapy is important. Also 
providing the treatment within the ﬁrst 3 weeks following the injury and achieving 
wound healing is critical. Hence, the availability of cultured keratinocytes for cell-based 
therapy as early as possible within this limited time frame is essential to provide the 
necessary treatment. The utilisation of microcarriers for keratinocyte cell culture can 
provide keratinocytes for wound application within the time frame of 3 weeks, hence 
reducing scarring and contracture formation. 
Currently, standard keratinocyte cell culture for clinical use involves cell culture in 
tissue culture ﬂasks and repeated cell passages. Keratinocytes are passaged several 
times to maintain the cells in a sub-conﬂuent state until clinical application. Sub-
conﬂuent keratinocytes have been shown to facilitate better epithelial repair than cells 
grown to conﬂuent sheets (Desai et al. 1991). Keratinocytes within confluent sheets 
demonstrate change from a proliferative to a differentiated phenotype with reduced 
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quality of wound repair (Desai et al. 1991). In comparison the use of microcarrier 
culture showed sufficient amounts of proliferative sub-conﬂuent cells at low passage.  
In the first in vivo experiment, the survival of GFP labelled keratinocytes following 
application on full thickness wounds was investigated. The study was terminated at two 
weeks to investigate the fate of the GFP transduced cells. As expected, epithelial closure 
was not achieved in the 2 weeks period, as a minimal period of 3 weeks is required to 
achieve full epithelial healing. Histological analysis of wound sections showed GFP-
positive cells primarily in the superﬁcial wound regions after 2 week. These results 
were consistent with previous work done at the Blond McIndoe Research Foundation 
(Ng et al. 1997), and results reported by (Vogt et al. 1994). Histological analysis of the 
wounds showed mainly dense granulation tissue, which was consistent with previous 
work (Currie et al. 2003). The use of PTFE wound chambers prevented keratinocyte 
migration from the wound edges, which in turn prevented epidermal regeneration by 
keratinocytes migration. Any epidermal cover, if any, would have been a result of either 
MCAK or SAK applied within the wound chamber.  
The lack of epidermal cover could be related to the absence of dermal replacement 
therapy in combination with cultured keratinocytes application or simply due to the 
two-week study period. Both MCAK and SAK groups showed early signs of basement 
membrane regeneration and recreation of multi-layer architecture compared to lack of 
these features in the control group. These results also demonstrated the biocompatibility 
of the gelatin ‘Cultispher G®’ microcarriers in the porcine model, as no adverse 
reactions to the beads or wound infections were noted.  
The initial in vitro studies showed the migration of keratinocytes from the surface of 
microcarriers to culture flasks, the first in vivo study demonstrated the same effect in 
vivo. The hypothesis was keratinocytes migration and proliferation in vivo would 
replicate the in vitro behaviour with microcarriers presence and subsequent degradation 
having no influence on the process. Keratinocyte cell culture on microcarriers in stirred 
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culture had no negative effects on cell survival or proliferation in vivo. The comparison 
between using microcarriers for keratinocyte culture and application, and sprayed 
keratinocytes showed comparable results. Despite not achieving full epithelial closure in 
the two groups, the advantages of the microcarrier culture were further explored in the 
next studies. Further in vivo studies were undertaken to assess achieving full epithelial 
closure using microcarrier delivered autologous keratinocyte. 
In further in vivo studies, full epithelial closure and the effect on wound contraction, 
using MCAK in combination with STSG (Split thickness skin graft) was investigated. 
The use of keratinocytes cell suspensions in combination with STSG has been 
investigated previously. Keratinocytes cell suspensions provided the epidermal 
component, while the STSG provided the dermal component. Fraulin et al. (1998) and  
Navarro et al. (2000) reported no difference in wound contraction rate following the use 
of cell suspension in combination with meshed STSG. Based on these studies, epithelial 
closure can be achieved using SAK and meshed STSG. Hence, in chapter 5, MCAK and 
SAK were compared in combination with widely meshed STSG (6:1), while using 
widely meshed STSG as control in square wounds without chambers. 
It is worth noting that both these studies used non-cultured keratinocytes for wound 
application. The application of cultured keratinocytes has been reported to produce 
significant wound re-epithelialisation when compared with non cultured keratinocytes 
(Svensjo et al. 2001). The results from chapter 5 showed similar findings to the afore- 
mentioned study. The results showed that the addition of keratinocytes, as MCAK or 
SAK, had a clear effect on wound healing, particularly in relation to wound contraction.  
Wound contraction was signiﬁcantly less after treatment with MCAK or SAK compared 
to wounds treated with STSG alone. This lower wound contraction could be due to the 
keratinocytes themselves or their expression of paracrine factors. The results from this 
study are consistent with our previous results comparing STSG and SAK treatments at 
Blond McIndoe Research Foundation (Reid et al. 2007). The presence of paracrine 
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factors may reduce myoﬁbroblast differentiation and therefore reduce wound 
contraction. Identifying these factors and quantifying their effect on wound contraction 
would require an in vivo model replicating the wound environment. 
In the study described in chapter 5, there was no evidence of GFP-labelled cells 
persisting at 21 days in wounds treated with GFP-labelled MCAK or SAK. These 
results are again consistent with previous studies that have shown that GFP expression 
does not persist beyond two weeks (Kirsch et al. 2003, Pfutzner et al. 2006, Lu and 
Ghazizadeh 2007). Previous studies have shown that expression of transfected marker 
genes in the porcine in vivo model is lost in keratinocytes integrating in more basal 
layers of the neo-epithelium (Vogt et al. 1994). The results from chapter 5 are similar 
and support the above-mentioned findings from these previous studies as no GFP 
expression by keratinocytes was detected after 3 weeks. 
Histological analysis showed the quality of epithelial repair was consistent between the 
MCAK and SAK groups. It is difficult to define the contribution of exogenous cells to 
wound re-epithelialisation due to the inability to trace GFP-labelled keratinocytes. It is 
still a possibility that keratinocytes within either MCAK or SAK did not survive within 
the wound environment. The fact that wounds within both the MCAK and SAK groups 
showed mature epithelium and less contraction compared to STSG alone makes this less 
likely. Also even in the presence of the widely meshed STSG, epithelial closure was 
unlikely within the 3-week period relying on endogenous keratinocyte migration alone.  
However, due to the lack of supporting evidence about long-term survival, the reduction 
in wound contraction could be an effect of keratinocytes application method or the cells 
themselves. The use of microcarriers as a delivery method for keratinocytes or simply 
the addition of the exogenous keratinocytes could have produced the reduction in 
wound contraction.  
In the third in vivo animal study in chapter 6, the use of the dermal substitute Integra® in 
combination with allogeneic keratinocytes on microcarriers or as cell spray was 
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investigated. Both groups were compared to the standard clinical application of Integra® 
and ultra-thin STSG; treatments in the 3 groups were done as two-stage procedures. The 
decision to use allogenic keratinocytes was a replication of the clinical use of allografts 
particularly in the management of extensive burn injuries.  
In this study, the use of allogeneic cells facilitated epithelial wound closure of 
comparable quality to that of wounds treated with autologous cells or uSTSG. No GFP 
positive cells were found in any of the wounds from the MCAlK or SAlK groups. 
Epithelial closure was achieved in a comparable fashion to the control group where 
autologous keratinocytes were applied as ultra-thin STSG. Certainly, the inability to 
trace the keratinocytes post wound application hinders the assessment of the origin of 
the newly formed epithelium. 
Hammond et al. (1987) demonstrated that cultured allogeneic sheet grafts survived 
longer than non-cultured allogeneic grafts in a mouse model. Their ﬁndings were 
mainly attributed to the loss of Langerhans cells in culture, which are involved in the 
graft rejection process as previously discussed. LaFrance and Armstrong (1999) 
reported that allogeneic ﬁbroblasts delivered to partial-thickness porcine wounds on 
poly-(L-lactide) microcarriers were well tolerated. Also, allogeneic cells were beneﬁcial 
in the treatment of chronic wounds, such as recalcitrant leg ulcers, when combined with 
the commercial product Apligraf® (Falanga and Sabolinski 1999). 
It is likely that wound healing in the two groups (MCAlK and SAlK) was a result of 
epithelial migration from the wound edges rather than the allogeneic keratinocytes. 
Histological examination of the epithelium in the MCAlK and SAlK groups revealed 
similar quality epithelium to the control group. The combination treatments in the two 
groups played a role in promoting satisfactory wound closure comparable to autologous 
uSTSG use. 
The “take” of cultured epithelial autografts is improved by the presence of a dermal 
layer (Chester et al. 2004, Cuono et al. 1986). In the study described in chapter 6, 
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Integra® was used as dermal replacement and to provide support to MCAlK and SAlK 
following wound application. As expected, the application of Integra® maintained the 
wound surface area up to day 21, when treatment was applied. It was noted from 
previous studies and discussed in chapter 5 that control wounds treated with widely 
meshed STSG alone were healed by day 21. Hence, the role of Integra® in reducing 
wound contraction and maintaining wound surface area can be assumed. It was difficult 
to accurately assess whether the reduction of wound contraction was a result of 
microcarriers use as a delivery vehicle or other variables within the wound environment.  
There is possibly a role for using allogeneic keratinocytes delivered on microcarriers for 
the improvement of wound healing. The application of allogeneic keratinocytes on 
microcarriers in combination with Integra® and Biobrane® reduced wound contraction, 
even though the mechanism is unclear. The epithelial closure achieved in the MCAlK 
and SAlK groups is unlikely to be replicated in a clinical situation due to graft rejection 
in immuno-competent humans. 
The effect of autologous keratinocytes and fibroblasts delivered on microcarriers on 
wound contraction was assessed in chapter 7. Integra® is usually used as dermal 
replacement reference treatment in comparing new artificial dermal products (Druecke 
et al. 2004). Therefore in the study described in chapter 7, the effect of autologous 
keratinocytes and fibroblasts on microcarriers in combination with Integra® on wound 
contraction was investigated. As the results from the control group on the same animal 
model were available, 3 treatment groups were allocated in this study, MCAK-FB, 
MCAK, and SAK. The results from the 3 treatment groups were compared to the 
control group from the study in chapter 6 (Integra® and ultra-thin STSG). 
A reduction in αSMA-positive cells in wounds treated with keratinocytes alone or 
keratinocytes with ﬁbroblasts was demonstrated. Interpreting these results, it can be 
assumed that the addition of a cellular component in the form of autologous 
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keratinocytes with or without fibroblasts led to a reduction in the contraction of healing 
wounds.  
The number of cells transplanted to the wound bed has a direct effect on wound 
contraction (Lamme et al. 2000). Further studies using variable cell counts on 
microcarriers are needed to establish whether the same effect can be replicated using 
microcarriers. The reduction in wound contraction observed in chapter 7 could be a 
result of the combination of keratinocytes and fibroblasts or simply the effect of 
increased cell populations within the wound. 
A significant reduction in wound contraction occurred using microcarriers to deliver 
keratinocytes or keratinocytes with ﬁbroblasts in combination with Integra®. Similar to 
the findings reported by Lamme et al. (2000), the presence of additional cells in the 
granulation tissue possibly reduced the need for cells to migrate from the wound 
margins. This is a process that would normally bring them into contact with the signals 
necessary for myoﬁbroblast differentiation. It is also conceivable that keratinocytes or 
keratinocytes with ﬁbroblasts delivered on microcarriers can reduce wound contraction 
more than cells delivered in suspension. This could potentially be due to keratinocytes 
being damaged during process of harvesting from tissue culture flasks. The results from 
the study in chapter 7 support this assumption since wounds treated with cells on 
microcarriers contracted approximately 10% less than those treated with sprayed cells.  
The reduction in wound contraction may represent a small percentage, but the clinical 
signiﬁcance of the change in wound contraction is valuable. A small reduction in wound 
contraction can possibly prevent contracture formation. The formation of skin 
contractures can lead to impairment of function and limitations of ranges of movement.  
Significant improvements in function, particularly over joints, can be achieved when 
contracture formation is avoided. 
It is arguable that microcarriers could offer a better method of delivery for keratinocytes 
and ﬁbroblasts when compared with cell spray despite the lack of strong evidence, the 
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advantages of microcarriers culture over the traditional culture in tissue culture flasks 
required for cell spray were discussed in the in vitro studies. 
In conclusion, both the in vitro and in vivo studies collectively demonstrated that the use 
of microcarriers in culture and delivery of keratinocytes and/or fibroblasts had many 
advantages. The use of microcarriers allowed the transfer of cells to the wound bed 
without the use of trypsin for cell harvest. Avoiding the use of trypsin could enhance the 
ability of the cultured keratinocytes to re-epithelialise the wound and generate neo-
epithelium. The handling and application of microcarriers and keratinocytes or 
fibroblasts was similar to sprayed cell application. There were no major technical 
difficulties associated with the application of microcarriers and cultured cells on porcine 
wound model. The inert characteristics of the microcarriers achieved the delivery of 
cultured cells to the wound bed with minimal impact on the keratinocytes or the wound 
environment. The reduction in contraction achieved using microcarriers for culture and 
delivery of keratinocytes represented a highly desirable outcome in the treatment of full-
thickness wounds.  
The ﬁndings from this work were signiﬁcant as they highlighted a real potential for 
clinical beneﬁt to patients sustaining large full-thickness wounds. Microcarrier-
keratinocyte culture could be used to reconstruct and restore the function of the 
epidermis in combination with dermal replacement therapies. Potentially, the use of 
microcarriers could be modulated to reduce wound contraction, guide the regeneration 
of epidermis, and the interactions between cells responsible for wound contraction. The 
early provision of viable keratinocytes supported by a dermal component is likely to be 
conducive to a less contractile myofibroblast phenotype resulting in reduced wound 
contraction. 
Finally, microcarriers clearly have great potential in skin tissue engineering 
applications. Microcarriers can be used in expansion of keratinocytes and fibroblasts 
and investigation of cellular differentiation in culture. This can be achieved in an 
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efficient culture method that saves cost and space needed for culture. Therefore, 
microcarriers could be considered a very useful tool for skin regeneration research and 
future clinical application. In the near future, microcarriers could play an important role 
in clinical restoration of skin barrier following burn injuries and trauma. 
Through a better understanding of the mechanisms behind wound contraction, new 
treatment modalities to reduce wound contraction can be developed. Any minimal 
reduction in wound contraction resulting in avoiding contracture formation could have a 
significant improvement in patients’ lives following extensive skin loss injuries. 
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8.4	  Assessment	  of	  hypotheses	  
 
8.2.1 Human and pig keratinocytes will attach to microcarrier beads in vitro and 
proliferate under in vitro culture conditions 
This hypothesis is supported 
 
8.2.2 Cultured autologous pig keratinocytes on microcarrier beads will migrate 
from the microcarrier beads and integrate into neo-epithelium when applied to 
porcine full thickness wounds 
This hypothesis is partly supported 
 
8.2.3 Green fluorescent protein is a long-term retroviral genetic marker in 
cultured pig keratinocytes on microcarrier beads when applied to full thickness 
wounds 
This hypothesis is rejected 
 
8.2.4 Cultured autologous pig keratinocytes on microcarrier beads will form 
permanent epithelium when applied to full thickness wounds 
This hypothesis is partly supported 
 
8.2.5 Cultured autologous pig keratinocytes on microcarrier beads will reduce 
wound contracture when applied to full thickness wounds in combination with 
widely meshed split skin graft  
This hypothesis is supported 
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8.2.6 Cultured allogeneic pig keratinocytes on microcarrier beads in combination 
with two-stage artificial dermal regeneration template and artificial skin 
replacement will produce epithelial closure when applied to full thickness wounds 
This hypothesis is partly supported 
 
8.2.7 Cultured allogeneic pig keratinocytes on microcarrier beads in combination 
with two-stage artificial dermal regeneration template and artificial skin 
replacement will reduce wound contracture when applied to full thickness wounds  
This hypothesis is supported 
 
8.2.8 Cultured autologous pig keratinocytes and fibroblasts on microcarrier beads 
in combination with two-stage artificial dermal regeneration template will form a 
permanent functional epithelium when applied to full thickness wounds 
This hypothesis is partly supported 
 
8.2.9 Cultured autologous pig keratinocytes and fibroblasts on microcarrier beads 
in combination with two-stage artificial dermal regeneration template will reduce 
wound contraction in full thickness wounds 
This hypothesis is supported 
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8.5	  Future	  research	  
Continuous development of the methods used for keratinocyte culture is needed to 
improve their availability for clinical application. Efficient cell culture techniques, 
higher productivity and media free from animal products are all areas for future 
development.  
The number of cells produced should increase for the same cost and in a similar space 
improving cost efficiency, along with more robust culture methods. If possible the 
number of patient interventions in term of cell applications should be minimised 
reducing labour hours and infection rates. 
Future research in the field of keratinocyte cell culture continues to be challenging and 
more in vivo wound models are required. The aspects for improvement include for 
example, culture productivity, co-culture of keratinocytes and fibroblasts, and delivery 
methods to the wound.  
Further research may look at different types of materials for microcarrier beads such as 
cellulose or poly D, L-lactic-co-glycolic acid (PLGA), or possibly growing cells without 
pre-expansion. The newly developed materials ideally should be biodegradable and 
biologically inert. Improvements such as the usage of defined mediums and robust 
application techniques could be achieved in the future. 
The interactions between keratinocytes on microcarriers and dermal replacement 
template “Integra®” shown in the previous studies are interesting. There are different 
types of artificial dermis available commercially, and further research is now required to 
explore the benefits of their use with MCAK in various in vivo wound models. These 
studies comparing the various types of artificial dermis would explore epithelial 
regeneration and the effect on wound contraction. 
There is evidence suggesting that myofibroblast differentiation is controlled by 
keratinocytes through paracrine growth factors (Shephard et al. 2004b). Further studies 
are required to investigate their mechanism of action and possibly the development of 
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similar molecules in vitro. The balance between keratinocytes and fibroblasts during 
wound healing needs to be explored in vivo. The main aim would be to produce stable 
neo-epithelium without wound contracture formation. 
There have been several attempts to combine autologous cultured keratinocytes and 
dermal substitutes (Boyce et al. 2006b). Despite these attempts, there is no true 
replacement for skin including sweat glands, hair follicles, and nerve endings. The 
development of such off the shelf product may be still years away, but the possibility of 
combining keratinocytes, fibroblasts, and dermal replacement may be a first step. 
Another area of future research is the modification of allogeneic keratinocytes during 
culture prior to wound application. This modification could be in the form of inhibition 
of the allogeneic keratinocytes from inducing a host immune response, and possibly 
reducing time required for keratinocytes in culture. This achievement could open the 
horizon for scaling-up in vitro keratinocyte cell culture without relying on conventional 
culture methods. 
Another area of potential development is targeting the complex interactions between 
various growth factors and cytokines in wound healing using biological therapies. The 
majority of the biological therapies primarily aim to reduce hypertrophic or keloid 
scarring such as TGF-β antagonists, basic fibroblast growth factor, and Rho-associated 
kinase inhibitors (Sharpe and Martin 2013).  
The use of microcarrier beads for keratinocyte cell culture and delivery is a relatively 
new area of research, which is rapidly expanding. The results from the studies in this 
thesis may pave the way for a randomised controlled clinical trial in the near future. 
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